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Chapter
1
General introduction to a novel approach
to characterize developmental changes 
in pharmacokinetics across the human 
lifespan: application to the prediction of 
clearance in children




Medicine is both an art and a science. In the beginning of Cecil’s Textbook of 
Medicine, it says, “Medicine is a profession that incorporates science and the 
scientific method with the art of being a physician. The art of tending to the sick 
is as old as humanity itself. Compared with its long and generally distinguished 
history of caring and comforting, the scientific basis of medicine is remarkably 
recent.” [1]. Individualized medicine or personalized medicine comprises up-
to-date scientific methods that aim to match the right drug to the right patient 
according to individual characteristics. Dose selection is one of the important 
issues in individualized treatment, as it determines the efficacy and the safety 
in the patients who receive the drug.
In paediatrics, selection of the optimal dose is even more crucial, since children 
are more vulnerable and less tolerant than adults to the drug treatment. 
However, the knowledge on the variation in the two major determinants of 
the drug effect, pharmacokinetics (PK) and pharmacodynamics (PD), is limited 
in paediatrics. Such reality makes that in paediatric clinical practice the dose 
selection is still empirical and based on mg/kg, despite profound differences in 
response between children and adults, and between children of different ages, 
that may or may not be scaling with bodyweight in a linear manner [2].
Pharmacokinetics (PK), which includes the processes of drug absorption, 
distribution, and elimination, may be referred to as the action of the body 
on drugs. Pharmacokinetic processes determine the time course of the drug 
concentration in the circulation, in tissues, and eventually at the target site. 
Obviously, the knowledge of the variation in pharmacokinetics in children is 
essential in determining the optimal dose to reach a certain target concentration 
or exposure.
In addition, the drug concentration-effect relationship, characterizing the 
pharmacodynamics (PD), determines the intensity of the pharmacological 
response resulting from the drug treatment. In paediatrics, the concentration-
effect or the exposure-response relationship may differ from that in adults. 
Therefore knowledge of the pharmacodynamics in children is equally important 
in selecting the optimal dose.





It is not surprising that the PK-PD characteristics of a drug in paediatrics are 
not the same as in adults, due to physiological differences between adults and 
children. For example, the gastric pH is neutral (6 to 8) at birth and is acidic 
(2 to 3) in adults [3]; the total body water content is 80-90% of the bodyweight 
at birth and is 55-60% in adults [3]; the activity of CYP3A4 is extremely weak 
or absent in the fetus and begins to rise after birth to reach 30-40% of the 
adult activity after one month [3]. The differences in PK-PD between adults 
and children are not straightforward but rather unpredictable because of 
the complexity of the underlying physiological changes during growth and 
development. In order to describe how PK-PD characteristics change during 
the ontogeny process and ideally across the human age-span from birth to 
adults, mathematical and statistical modeling is needed.
Mathematical modeling must have been used in pharmacology for a long 
time, although it is hard to tell when the exact start was. The nature of the 
human learning process, from the observational learning towards the abstract 
reasoning, makes the application of mathematical modeling in pharmacology 
inevitable. After a thorough understanding of the mechanism of the underlying 
process, mathematical models constitute a scientific basis for quantifying and 
parameterizing the real biological, physiological and pathological processes, 
which enables the prediction and comparison of the drug effect and 
individualization of the drug treatment.
Legislation in the United States [4, 5] and in Europe [6] requires that clinical 
investigations be conducted in paediatric populations. Due to the ethical and 
practical limitations in paediatric clinical trials, the conduction of the clinical 
investigation is facing the challenge of evaluating drug efficacy and safety in 
the paediatric population on the basis of very limited information. Modeling 
and simulation was soon recognized by drug developers and regulators as the 
most optimal way to efficiently analyze data and to design clinical trials [4, 6-9]. 
A paradigm with scenarios for the use of modeling and simulation in paediatric 
medicines development was proposed, where modeling and simulation was 
identified as a tool to navigate in the paediatric decision tree and as a study 
optimization and data analysis tool [8].
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Generally, there are two modeling approaches to investigate the changes of the 
pharmacokinetic characteristics of a drug in human. The first modeling approach 
is based on observed drug concentrations in blood samples taken in a clinical 
study and is referred to as the descriptive method or top-down method. The 
other approach is based on massive physiological and biochemical information, 
such as enzyme abundance, gastric pH, permeability, blood flow etc. and is 
referred to as the physiologically based (PB) method or the bottom-up method.
Although discussion and exploration of modeling and simulation (M&S) in 
paediatric drug development is still ongoing, there is no doubt about the 
necessity of M&S according to a vote in FDA’s Pharmaceutical Science and 
Clinical Pharmacology Advisory Committee meeting in March 2012, where all 
voters supported the viewpoint that M&S should be considered in all paediatric 
drug development programs. As to the modeling and simulation in paediatric 
drug development, both “top-down” and “bottom-up” modeling approaches 
are used.
1.2. Top down approach
The top down approach is fitting observations. In pharmacokinetics, observations 
are the concentrations of the drug. Compartmental pharmacokinetic analysis 
is the most common top down modeling approach, which simplifies the 
description of the drug distribution in the human body as a distribution in 
a number of hypothetical compartments, each with different values of the 
equilibrium rate constants. This compartmental modeling approach has distinct 
advantages in predicting or simulating the time course of drug concentrations, 
since it describes the concentration versus time profile with parameterized 
differential equations.
Based on the assumption of compartments, two data analysis approaches 
can be applied: the standard two-stage (STS) approach and the population 
approach. With the STS approach, PK parameters are, in the first stage, 
estimated in each individual based on individual concentration time profiles. 
In the second stage, these parameters are summarized by calculating the mean 
or median of the parameters and the variability between subjects. A major 





drawback of this methodology is that it requires a relatively large number of 
samples in each individual, while each individual has to contribute roughly 
the same number of samples. With the STS approach, it is very difficult to 
distinguish between inter-individual (variability between subjects) and intra-
individual or residual variability (variability within one subject, measurement 
error and model misspecification) and as a result inter-individual variability is 
often overestimated [10].
In the second approach, the population approach, statistical random variables 
are added on its structural pharmacokinetic parameters, to account for 
the inter-individual variability within a population. With the help of these 
population pharmacokinetic (POPPK) models, we can attribute the variability 
between individuals in the observed drug concentrations to the variability 
between individuals in the values of different pharmacokinetic parameters, 
such as clearance, volume of distribution, absorption rate constant etc. Finally, 
the inter-individual variability of the pharmacokinetic parameters may be 
explained by some variables that are related to physiological volumes and 
functions, e.g. weight or age, in a so-called covariate analysis. In this population 
approach, the human body system is regarded as a whole in the beginning and 
is gradually unfolded searching for the physiological cause of the variation in 
the observed drug concentrations. The uppermost feature of this approach is 
that it describes or fits the facts, which are drug concentrations.
In paediatrics, clinical studies are more difficult to conduct than they are in 
adults. Due to ethical and practical issues [11], typically fewer PK samples per 
individual can be collected during paediatric trials, which results in sparse 
data for modeling. The population approach is usually preferred for analyzing 
paediatric PK data because of its capability in dealing with sparse data and 
in identifying inter-individual variability in paediatric population. Moreover, 
the population pharmacokinetic approach has been proposed in aiding dose 
selection in early paediatric development [12]. Besides, Clinical Trial Simulation 
(CTS) based on available population pharmacokinetic models has been 
used in the development of an adaptive paediatric clinical trial design [13]. 
Furthermore, sampling schemes were optimized according to the non-linear 
mixed effects model based simulation [14] and maximization of the Fisher 
Information Matrix (FIM) [15] tilde.
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One of the most important applications of the top down modeling approach 
in paediatrics is scaling drug pharmacokinetic parameters (e.g. clearance 
and volume of distribution etc.) from adults to children. In general, there 
are three methods for scaling drug pharmacokinetic parameters: allometric 
scaling, ¾ allometric scaling with maturation function, and systematic 
covariate analysis.
1.2.1. Allometric scaling
Scaling is a term borrowed from engineering, which refers to adaptation 
of a functional system to operate at different production scales [16]. Similar 
adaptations of biological function between species and within the human 
lifespan are needed in pharmacokinetics. Allometry is the study of size and its 
consequences. The scaling of biological functional systems can be studied and 
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In the allometric equation, P is the physiological parameter of interest, BW is the bodyweight. 
The parameters a and b are the allometric constant and the allometric exponent, respectively. 
This simple equation has been found to be a robust and powerful basis of scientific theory 
when applied to the analysis of the ecological implications of body size [17]. This theory was 
thought to be realistic as allometric equations are built empirically using actual observations 
[18]. Even though there are some biological explanations on this allometric phenomenon [19-
21], it is important to realize that the constant b, which is referred to as the allometric 
exponent, has no physiological meaning by itself [16]. This allometric function has been 
studied widely in inter-species metabolic rate scaling [22-25] and has been brought into the 
area of pharmacokinetic modeling for the scaling drug clearance and volume of distribution 
[26]. In the population pharmacokinetic modeling, the allometric equation is adapted as 
follows [18] 
   (2)    
in which Pi is the individual PK parameter in a subject with a bodyweight of BWi and Pstd is the 
PK parameter of a standardized individual with a bodyweight of BWstd. The adapted allometric 
equation (equation 2) is the most frequently used covariate model structure in population 
pharmacokinetic modeling for describing changes in PK parameters between adults and 
children.   
For paediatric studies, it has been proposed that the allometric exponent b should be fixed to 
the value of 0.75 for the scaling of drug clearance and to the value of 1 for volume of 
distribution to account for differences in size, no matter whether it is applied to adults or 
children [18]. This view is based on the allegedly substantial experimental evidence for these 
values of the allometric exponent in biology. Indeed many studies have reported values of the 
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used covariate model structure in population pharmacokinetic modeling for 
describing changes in PK parameters between adults and children.
For paediatric studies, it has been proposed that the allometric exponent b 
should be fixed to the value of 0.75 for the scaling of drug clearance and to 
the value of 1 for volume of distribution to account for differences in size, no 
matter whether it is applied to adults or children [18]. This view is based on the 
allegedly substantial experimental evidence for these values of the allometric 
exponent in biology. Indeed many studies have reported values of the 
estimated allometric exponent for clearance that are close to 0.75. However, 
the allometric equation with the fixed value of 0.75 for clearance, referred to as 
¾ allometric equation, has been challenged by different researchers [27, 28]. 
The challenges are mostly on the basis of the argument that the value of 0.75 
should be the universal allometric exponent for clearance, while many studies 
have shown that use of the ¾ allometric equation yields discrepancies between 
observed versus predicted concentrations in very young children [29-31].
In this respect, Mahmood systematically investigated the predictive performance 
of scaling methods with different allometric exponent values (0.75, 0.8, 0.85 and 
1) across the whole paediatric age-span for 41 drugs [27]. Clearances reported 
from literature were compared with allometric model predicted clearances with 
different exponent values. He found that all methods exhibited uncertainty in 
the prediction of the drug clearance in children and that no single method was 
suitable for all drugs for all age groups. The study also indicates that a single 
exponent may not be suitable for the prediction of drug clearance in children of 
all ages from adult data; therefore, a combination of methods is recommended in 
order to improve the prediction. It appears that for children ≤1 year old, a better 
approach is to use no exponent (exponent =1) on the ratio of children and adult 
body weight. Specifically, allometric exponent values close to or above 1 were 
estimated for scaling clearances in young children [27]. After age 5, one can use 
any of the three exponents (0.75, 0.80 and 0.85) to achieve a reasonably good 
prediction of clearance in children [27].
1.2.2. ¾ Allometric scaling with maturation functions
In paediatric POPPK modeling, age may also have an influence on the inter-
individual variability of drug clearance, especially in young children, infants and 
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neonates. This influence can be explained as the reflection of changes during 
the ontogeny in the physiological mechanism related with maturation instead 
of size. However the distinction between age and bodyweight as the basis for 
the scaling is complicated by the fact that age and bodyweight are correlated 
in a highly nonlinear manner. Consequently, in the covariate analysis of POPPK 
modeling, the apparent influence of age on the value of clearance may be 
contaminated by the influence from bodyweight and vice versa. Therefore, it 
has been proposed to separate the influence of bodyweight and age effect 
by using the ¾ allometric equation in the covariate analysis for clearance to 
account for size [26]. To account for the influence of maturation, an asymptotic 
exponential maturation function for clearance, incorporating postnatal age, 
has been proposed, which is incorporated as a multiplicative factor in the ¾ 
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In this equation β is the parameter reflecting fractional difference from the 
CL
std
 at birth. The parameter t is the parameter describing half-times of age-
related changes in clearance. It is worthy to note that parameter β should be 
constrained between -1 and 0 so that the maturation factor (MF) will start from 
1+ β, which is less than 1, at birth and gradually approach to 1 with adult age.
A modified version of equation 3 was used to describe acetaminophen 
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on a hyperbolic function has been proposed as the maturation function in the ¾ allometric 
scaling model [35].   
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Maturation functions on the basis of age as covariate seem to help to account for the 
discrepancy from the ¾ allometric equation in young children and can be used to describe the 
changes in clearance across a large age-span. However, it was also reported to have a poor 
predictive power of clearance in preterm and term neonates, infants and very young children 
[36, 37]. In addition, incorporating the combination of two correlated covariates in the 
nonlinear mixed effect model may result in bias in parameter estimates [38]. Recently, it has 
been shown that when one of two correlated covariates that contain information about a 
model parameter is pre-selected over the other, the predictive performance of the resulting 
model may be diminished, unless the pre-selected covariate relationship reflects the true 
biological relationship [39]. Although there are examples of the successful use of the ¾ 
allometric equation in the adult population, it has been shown to be unreliable in young 
children [27-31]. The colinearity between the bodyweight and age covariates and its 
consequences, therefore, become a concern when it is used as a descriptive reference model 
for clearance. 
1.2.3. Systematic covariate analysis 
In population pharmacokinetic modeling, a covariate analysis does not only comprise the 
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for the discrepancy from the ¾ allometric equation in young children and can be 
used to describe the changes in clearance across a large age-span. However, it was 
also reported to have a poor predictive power of clearance in preterm and term 
neonates, infants and very young children [36, 37]. In addition, incorporating the 
combinati  of two correlated covariates in the n nlinear mixed effect model 
may result in bias in parameter es imates [38]. Recen ly, it has b en shown that 
when one of two correlated covariates that contain information about a model 
parameter is pre-selected over the other, the predictive performance of the 
resulting model may be diminished, unless the pre-selected covariate relationship 
reflects the true biological relationship [39]. Although there are examples of 
the successful use of the ¾ allometric equation in the adult population, it has 
been shown to be unreliable in young children [27-31]. The colinearity between 
the bodyweight and ge covariates and its conseque ces, therefo e, become a 
concern w n it is used as a descriptive reference model for clearance.
1.2.3. Systematic covariate analysis
In population pharmacokinetic modeling, a covariate analysis does not 
only comprise the identification of covariates that significantly influence 
the PK parameters but also includes the shape of the relationships between 
covariates and parameters. In the ¾ allometric scaling approach with 
maturation functions, the shape of the relationship between bodyweight and 
clearance is not determined by the data but is fixed a priori. In contrast to this 
approach, a data-driven systematic covariate analysis approach without any a 
priori assumption was proposed in paediatric modeling [40]. In the systematic 
covariate analysis, covariates are plotted independently against the empirical 
Bayesian estimates (EBE) of PK parameters, which provides graphical aids in 
identifying the most appropriate covariate equation. Covariate equations can 
be tested from the simplest linear function to complicated nonlinear functions 
such as Generalized Additive Model (GAM). Potential covariates are separately 
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tested and are considered statistically significant if the objective function 
decreased 7.9 points [40]. When more than one significant covariate for the 
simple model is found, the covariate-adjusted model with the largest decrease 
in objective function is chosen as a basis to subsequently explore the influence 
of additional covariates by means of the same criteria [40]. Covariates can be 
stepwise included into or excluded from the model depending on the model 
building strategy and the number of the candidate covariates. However, the 
final covariate model should be confirmed by the absence of unexplained inter-
individual variability from covariates, which can be illustrated by the absence 
of a trend in the plot of EBE inter-individual (η) against the covariate [41].
An example of such a systematic covariate analysis approach was reported in 
a study of morphine glucuronidation clearance in preterm neonates, infants 
and children younger than 3 years [40]. The final model was reported to be the 
best model for describing the changes in morphine glucuronidation clearance 
within the study age-span [42]. Later on, this model was externally validated [43] 
and proved to be applicable across drugs that share same metabolism pathway 
mediated by UGT2B7 enzymes [44]. Paci et al. also applied such systematic 
covariate analysis in a research for busulfan in 205 children from 10 days to 15 
years [45]. After testing different covariate models for clearance, they found that 
the allometric scaling model with the exponent value of 1.25 for bodyweight 
less than 9 kg and 0.76 for greater than 9 kg was the best covariate model [45].
1.3. Bottom up approach
In contrast with the top-down approach, the physiologically based approach 
looks at the pharmacokinetics from the underlying mechanism. The 
general concept of PBPK modeling is to mathematically describe relevant 
physiological, physicochemical, and biochemical processes that determine the 
pharmacokinetic behavior of a compound in as much detail as is appropriate 
or needed [46]. In paediatrics, unlike top-down approaches that require the 
availability of age-appropriate observed data, bottom-up approaches are 
used at a stage when these data have yet to be generated. Knowledge-driven 
or bottom-up approaches are based on the integration of various types of 
information (e.g. in vitro data, physiological and anthropometric information, 





and drug physicochemical properties) with a model that structurally mimics 
the functioning of the biological system including relevant organ system(s) 
[47]. Chen and Gross [48] and Himmelstein and Lutz [49] discuss the rationale 
and history behind the development of PBPK models and report examples 
of the first PBPK models. Khalil and Läer provided a general overview of the 
structure of PBPK models as well as their applications and weaknesses [46]. 
Most recently, Barrett et al. gave a review of the PBPK modeling specialized on 
its application in paediatric drug research [50].
Physiologically Based Pharmacokinetic (PBPK) models have been applied for 
the selection of the first-in-children dose in paediatric drug development. 
Edginton reviewed the knowledge-driven PBPK approaches for the guidance 
of first-in-children dosing [47] and proposed a workflow of the application of 
PBPK in paediatric drug development together with Maharaj and Barrett [51]. 
Additionally, Johnson and Rostami-Hodjegan pointed out other potential 
applications of the PBPK model, where the conduct of studies is not feasible 
(e.g. drug-drug interactions in paediatric populations, particularly those with 
varying genotypes or renal function compared to average individuals) [52].
Interest in PBPK modeling in the field of paediatric drug development has been 
increasing recently. However, there are still skepticisms about the predictive 
performance of the PBPK models in paediatric drug development. The main 
concerns about the PBPK models are on the reliability of the resources to build 
PBPK models and the knowledge gap between in vitro and in vivo, between 
adults and children. Specifically, the PBPK model prediction in young children 
is less confident as some physiological information, such as enzyme activity, 
in those populations is not available. Leong et al. reviewed data relating to 
PBPK modeling and simulation in submissions to FDA made during the years 
2009 - 2011 with respect to four paediatric drugs, as well as research on the use 
of PBPK tools with respect to several model agents used across varying age 
groups [53]. They found that PBPK models could not accurately predict weight 
normalized clearance values (CLBWnorm) for all paediatric groups [53]. They urged 
that there is a critical need to refine paediatric PBPK models [53]. The request of 
the refinement of PBPK models not only comes from regulators but also arose 
from clinicians, who reminded us not to get PBPK modeling too disconnected 
from the “in vivo” world of paediatric developmental pharmacology [54].
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1.4.  Descriptive and predictive performance of 
paediatric models
For all pharmacokinetics models, either descriptive or mechanistic, the 
performance in describing observations should be demonstrated. In nonlinear 
mixed effect models, a large number of methods have been proposed 
for diagnosing, evaluating and validating various aspects of the model 
performance. Where possible all these methods should be considered in 
building a descriptive model. Generally, the more validations a model goes 
through, the more reliable the model is. External validation, incorporating data 
that have not been used to build the model, is preferred over internal validation. 
However, we should be aware that a model is always developed based on data 
collected in distinct study settings, which are determined by factors such as 
the inclusion criteria of patients, the design of the study and the distribution 
of covariates. For the external data these settings may be different, leading to 
models that differ from the original. One can never make sure that a model is 
valid in the next new dataset even if the model has been validated internally 
and externally before. Model validation results are always reliable within certain 
constraints. Having noticed the limitation of the model validation, we should 
always be aware of the importance of the necessary model validations as they 
are helping us to determine whether the model is appropriate for the data it is 
built on.
In paediatrics, evaluation of pharmacokinetic models are especially important 
due to the heterogeneity in paediatric populations and the fact that paediatric 
datasets are typically sparse [11]. However, paediatric models were seldom 
evaluated adequately in the past [55]. Amongst all model validation methods, 
some aspects are especially important. This concerns in particular the model 
for scaling of the PK parameters over a large age-span. Krekels et al. have 
proposed a scheme of systematic model evaluation approaches for paediatric 
pharmacokinetic modeling, which covers all the important aspects [42].
The fit of the model to the drug concentration is always the first aspect to be 
evaluated in pharmacokinetic modeling, since good concentration prediction 
is the basic requirement for a PK model. Usually, the goodness-of-fit is evaluated 
through the visual inspection of graphs [56] including i) observed (OBS) versus 





individual predicted (IPRED) concentrations, ii) OBS versus population predicted 
(PRED) concentrations, iii) conditional weighted residual error (CWRES) versus 
time, and iv) CWRES versus PRED. The OBS versus PRED plot is specifically 
important as it reflects whether the whole population model (comprising 
structure model and covariate model) is adequate. In a model covering a large 
age-span, the OBS versus PRED plot needs to be stratified between age groups 
for further examination of whether the adequacy is the same for individuals 
in different age ranges. However, the stratified OBS versus PRED plot cannot 
help in identifying the cause of the bias in itself, as it reflects sum effects of 
all pharmacokinetic parameters. In population pharmacokinetic modeling 
with the First Order approximation Conditional Estimation (FOCE) algorithm, 
empirical Bayesian estimates (EBE) provide post hoc individual parameters of 
pharmacokinetic parameters (clearance or volume of distribution). This EBE 
is not only useful for predicting individual concentrations but is also helpful 
in covariate model building and diagnosis. Specifically, plots of post hoc 
inter-individual variability of a PK parameter versus covariates may be used 
to check whether there is a covariate relationship. Moreover, plots of post 
hoc estimates of a PK parameter versus covariates facilitate the identification 
the shape of the covariate relation. Eventually, an adequate covariate model 
should be confirmed by the absence of correlation between covariates and 
inter-individual variability of the concerned PK parameters [41]. However, the 
evaluation based on the EBE should be done with caution if there is a high 
shrinkage of the EBE inter-individual random effect, defined as η-shrinkage 
[57]. High η-shrinkage usually occurs when few data are available from an 
individual [41] and may mislead the covariate relationships finding [58]. This 
is particularly important in paediatric investigations, as they may typically 
contain sparse data.
Simulation based model validations or evaluations play an important role 
in POPPK modeling. A visual predictive check (VPC) is a commonly used for 
model validation in adults [59], which illustrates lines for the median values 
and their 90% prediction interval based on 100 to 1,000 times simulation of 
concentration-time profiles. The observed values in the internal or external 
dataset are subsequently plotted on top of this. It can then be visually checked 
whether 90% of the observations are within the indicated prediction interval 
and whether there is no bias in the observations compared with the prediction 
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interval. The VPC is a simulation-based diagnostic that can be used when the 
PK or PD profiles for all individuals in the dataset are similar and it allows for 
easy interpretation of the result. For this diagnostic tool, there are no statistical 
tests and all evaluations are based on visual assessment.
Although the VPC can also be used for the evaluation of paediatric models, when 
data are obtained during routine clinical practice and variability in individual 
dosing and sampling schemes are high, a (normalized prediction distribution 
error) NPDE methodology [60] is often easier to perform and interpret. This 
method yields information on how accurate the model predicts the median 
value of the observations and the variability within them. The interpretation 
of this diagnostic is less straightforward than for the VPC, but the advantage 
of this method is that it can be used when the variability in dosing regimen 
(both in time, amounts and rates) is high or when there is a large number of 
covariates in the model. This can for instance be the case for data obtained 
during routine paediatric clinical practice.
Model predictive performance usually refers to the capability of a model in 
predicting true measurements [61]. In paediatric pharmacokinetic models, 
true measurements are concentration profiles. Therefore, the goodness-of-
fit plot is an evaluation method of the predictive performance of the whole 
pharmacokinetic model, which comprises the structure model, statistical 
models and covariate models. Besides, another predictive performance may 
be evaluated if the empirical Bayesian estimates (EBE) of pharmacokinetic 
parameters are regarded as the true individual measurements predicted by 
covariates. Actually, the predictive performance of the covariate models can 
be visually inspected by the plot of individual post hoc parameters against 
covariates superimposed with covariate model predicted curves. However, two 
numerical quantities of this predictive performance, mean squared prediction 
error (MSE) and root mean squared prediction error (RMSE), are more preferable 
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The definitions of those two quantities are expressed in equation 7 and equation 8. The root 
mean squared prediction error (RMSE) can be expressed as percent of mean true 
measurements (%RMSE) using equation 9 as follows [37] . 
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1.5. Discussion and conclusion 
Drug prescription in the paediatric population is still very empirical while there is an urgent 
need for evidence based dosing in children. In pharmacokinetics, both population 
pharmacokinetics (POPPK) models and physiologically based pharmacokinetics (PBPK) 
models can describe and/or predict drug concentration time profiles and facilitate drug 
development and clinical practice.  
The population pharmacokinetic approach is aiming to fit clinical observations. Paediatric 
POPPK model is usually based on a relatively large clinical dataset from a large number of 
different individuals, while the paediatric physiologically based model (PBPK) is based on 
relatively limited physiological data coming from published or unpublished in vitro studies. 
Although clinical samples are difficult to collect in paediatric populations because of the 
ethical and practical reasons, POPPK model can still utilize these sparse data efficiently and 
derive reliable results. Not only can POPK model estimate the mean values of 
pharmacokinetic parameters over a population, it can also provide the distribution of those 
parameters, which is useful for clinical trial simulations. However, due to the absence of 
physiological mechanisms, POPPK model results are restricted to specific drugs or 
populations and can not be extrapolated to other drugs. A combination of the POPPK 
approach and PBPK approach is naturally the best solution. Krekels et al. elaborated on 
combining PBPK and POPPK approaches in order to identify the influence of changes in the 
system- and drug- specific parameters on the net maturation of in vivo UGT2B7-mediated 
glucuronidation [62]. In the end, they suggested that the maturation profile for UGT2B7 
ontogeny in a PBPK model can be improved based on information obtained from a covariate 
model of a paediatric population model derived for a specific substrate for UGT2B7 on the 
basis of a systematic covariate analysis [62].  
Such a combination of POPPK and PBPK approaches may be important particularly for 
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Drug prescription in the paediatric population is still very empirical while there 
is an urgent need for evidence based dosing in children. In pharmacokinetics, 
both population pharmacokinetics (POPPK) models and physiologically based 
pharmacokinetics (PBPK) models can describe and/or predict drug concentration 
time profiles and facilitate drug development and clinical practice.
The population pharmacokinetic approach is aiming to fit clinical observations. 
Paediatric POPPK model is usually based on a relatively large clinical 
dataset from a large number of different individuals, while the paediatric 
physiologically based model (PBPK) is based on relatively limited physiological 
data coming from published or unpublished in vitro studies. Although clinical 
samples are difficult to collect in paediatric populations because of the 
ethical and practical reasons, POPPK model can still utilize these sparse data 
efficiently and derive reliable results. Not only can POPK model estimate the 
me  values of pharmacokinetic parameters over a population, it can also 
provide the distribution of those para eters, which is useful for clinical trial 
simulations. However, due to the absence of physiological mechanisms, POPPK 
model results are restricted to specific drugs or populations and can not be 
extrapolated to other drugs. A combination of the POPPK approach and PBPK 
approach is naturally the best solution. Krekels et al. elaborated on combining 
PBPK and POPPK approaches in order to identify the influence of changes in 
the system- and drug- specific parameters on the net maturation of in vivo 
UGT2B7-medi ted glucuronidation [62]. In the en , the suggest d that t e 
maturation profile for UGT2B7 ontogeny in a PBPK model can be improved 
based on information obtained from a covariate model of a paediatric 
population model derived for a specific substrate for UGT2B7 on the basis of a 
systematic covariate analysis [62].
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Such a combination of POPPK and PBPK approaches may be important 
particularly for paediatric drug development, where dose selection may 
be determined based on PBPK model simulation. The PBPK model for dose 
selection in the development of a new drug can be refined by the results of 
covariate functions from POPPK models of probe drugs sharing the same 
physiological mechanism as the new drug. Moreover, with the help of POPPK 
model, physiological parameters in PBPK models can be scaled to certain 
paediatric populations where no in vitro information is available. Therefore, 
developing a POPPK model covering the age-span from birth to adult with good 
descriptive performance all across is of great value. For this, a novel approach 
is proposed given the described limitations of the ¾ allometric scaling model 
and its derivative maturation model.
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2.1. Background and introduction
In pharmacokinetics, drug clearance is an important parameter that 
characterizes the rate of elimination from the circulation. The value of clearance 
constitutes the basis for dose selection in clinical practice. During growth and 
development of a human being, there are many physiological and anatomic 
changes resulting in varying drug clearance in the paediatric population, 
with values typically differing substantially from drug clearance in the adult 
population. The need to optimize the dose in children warrants detailed 
investigations into the variation in drug clearance in the paediatric population.
Population modeling and simulation constitutes a scientific basis to characterize 
inter-individual variation in pharmacokinetics. An important feature of population 
modeling is the possibility to attribute the variability between individuals in 
the observed drug concentrations to the variability in the values of different 
pharmacokinetic parameters. The latter variability may in its turn be explained 
by variables that are related to physiological volumes and functions, e.g. weight 
or age, in a so-called covariate analysis. This data-driven modeling approach 
provides us pertinent information on the variation in clearances over the whole 
paediatric age-span based on clinical observations. A limitation of population 
pharmacokinetic analysis is that it does not enable predictions on the variation in 
clearance beyond the drugs and the conditions that have actually been studied.
At present, there is great interest in the use of physiologically based 
pharmacokinetic (PBPK) for the prediction of variation in drug clearance paediatric 
populations [1-3]. An important feature of PBPK models is their physiological 
basis. As a result they enable prediction of the variation in pharmacokinetics of 
drugs that have not been studied, based on known information on changes in 
physiological function. However, due to the difficulty of collecting in vitro data 
in children, e.g. enzyme activity in neonates, the knowledge of physiological 
processes is missing for some paediatric populations, making the PBPK model 
less reliable in simulating PK profiles in those populations.
Ideally, the best paediatric pharmacokinetic model should be able to not only 
fit the clinical observations but also explain the physiological mechanism. A 
combination of the POPPK and PBPK is naturally the best solution. It is proposed 
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that PBPK models are refined by the results of covariate functions from POPPK 
models of probe drugs sharing the same physiological mechanism. Moreover, 
with the help of POPPK model, physiological parameters in PBPK models can 
be scaled to certain paediatric populations where no in vitro information 
available. Therefore, developing a POPPK model covering the age-span from 
birth to adult with good descriptive performance all across is of great value.
Amongst currently used top-down population pharmacokinetic models, 
neither the ¾ allometric scaling model nor its derivative maturation model 
can describe the developmental changes in drug clearances with adequate 
statistical stability and predictive performance overall across the entire age-
span. In this thesis we present a novel approach to describe the developmental 
changes in pharmacokinetic parameter estimates across the entire human 
lifespan, specifically focusing on drug clearances.
2.2. Outlines of the thesis
In Chapter 3, we studied the developmental changes in the clearance of 
propofol in various age groups, ranging from preterm neonates to adults. The 
emphasis was on estimation of the value of the allometric exponent in distinct 
age ranges. To this end, a large database was established comprising data 
obtained in neonates, infants, toddlers, children, adolescents and adults. Next, 
the allometric exponent was estimated when scaling clearance between two 
different paediatric subgroups or between one paediatric group and one adult 
group. With the pre-specified allometric equation, the values of the exponent 
were found to vary depending on the combination of the selected paediatric 
subgroups. Interestingly, the values of the allometric scaling exponent were 
larger than 1 when the subgroup with neonates was included in the analysis. 
From this analysis, it is concluded that there is no single value of the allometric 
exponent that describes variation in clearance across the entire human lifespan.
In Chapter 4, we introduced a novel approach to describe developmental 
changes in clearance across the human lifespan from preterm neonates 
to adults, based on the concept that “the allometric exponent varies with 
bodyweight”. To this end data on the clearance of propofol were analyzed with 
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different covariate models to describe developmental changes in clearance. 
The covariate models that were considered were: i) a mixture model, ii) a cut-
point model and iii) a bodyweight dependent exponent (BDE) model. In this 
analysis the BDE model was found to yield the best description of the changes 
in clearance across the whole paediatric age-span.
In Chapter 5 the BDE model was applied for the scaling of the total clearance 
of morphine, clearance to M3G and clearance of M3G across preterm neonates, 
children, adolescents and adults. It succeeded in describing those clearances 
without including additional age covariates, which were found to be necessary 
in model developed before. In this study, we also demonstrated the BDE model 
can be used not only for parent drug but also for its metabolites.
In Chapter 6, we further tested the BDE model in describing paracetamol clearance 
across whole paediatric age-span, which had been modeled with different 
covariates in the past. Again, it was clearly proved that for data across the human 
lifespan, the BDE model is able to describe the age-related changes in clearance 
very well without the need for additional age variables. Visual comparison among 
model predicted clearances from different models showed the BDE model had 
adequate descriptive performance of clearance throughout the whole paediatric 
age-span, whereas other models could only perform well in part. Based on the 
final model, simulations were performed to derive optimized dosing guidelines for 
paracetamol across the entire paediatric age range including preterm neonates.
In the meantime, a simplified version of the BDE model was successfully 
implemented for three other drugs: busulfan, midazolam and antibiotics. The 
results of these analyses are presented in the appendices I - II. The simplified 
BDE model is still based on the concept of using a monotonous continuously 
decreasing function of bodyweight to express age related changes in allometric 
exponent with bodyweight. The simplified BDE model may be better suited 
than the full BDE model in cases where preterm or term neonates are not 
included, or when the drug is metabolized by the CYP450 3A iso-enzymes or 
renally cleared by the kidney.
In Chapter 7, general conclusions and future perspectives of the work 
presented in this thesis were discussed.
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Aim: For scaling clearance between adults and children, allometric scaling 
with a fixed exponent of 0.75 is often applied. In this analysis, we performed 
a systematic study on the allometric exponent for scaling propofol clearance 
between two subpopulations selected from neonates, infants, toddlers, 
children, adolescents and adults.
Methods: Seven propofol studies were included in the analysis (neonates, infants, 
toddlers, children, adolescents, adults1, and adults2). In a systematic manner, 
two out of the six study populations were selected resulting in 15 combined 
datasets. In addition, the data of the seven studies were regrouped into five 
age-groups (FDA Guidance 1998), from which four combined datasets were 
prepared consisting of one paediatric age-group and the adult group. In each 
of these 19 combined datasets, the allometric scaling exponent for clearance 
was estimated using population pharmacokinetic modelling (NONMEM 7.2).
Results: The allometric exponent for propofol clearance varied between 1.11 
and 2.01 in case the neonate dataset was included. When two paediatric 
datasets were analysed, the exponent varied between 0.2 and 2.01, while it 
varied between 0.56 and 0.81 when the adult population and a paediatric 
dataset except for neonates were selected. Scaling from adults to adolescents, 
children, infants and neonates resulted in exponents of 0.74, 0.70, 0.60 and 1.11 
respectively.
Conclusions: For scaling clearance, ¾ allometric scaling may be of value for 
scaling between adults and adolescents or children, while it can neither be 
used for neonates nor for two paediatric populations. For scaling to neonates 
an exponent between 1 and 2 was identified.
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In paediatric pharmacokinetic (PK) modeling, scaling of pharmacokinetic 
parameters and in particular of clearance is a major issue, as it provides the 
rationale for tailoring suitable doses in children [1-3]. Scaling is required both 
in paediatric drug development for dose finding and selection of new drugs 
and in clinical practice where dose optimization and individualization is being 
performed when treating children. Accordingly, in paediatric drug development 
scaling of PK parameters between adults and the target paediatric population 
is highly relevant, while in clinical practice it may be relevant to scale within the 
paediatric population, i.e. a dose from children to neonates. For both purposes, 
currently the ¾ allometric scaling approach is nowadays propagated.
Allometric scaling was originally brought up to describe metabolic rates 
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particular of clearance is a major issue, as it provides the rationale for tailoring suitable doses 
in children [1-3]. Scaling is required both in paediatric drug development for dose finding and 
selection of new drugs and in clinical practice where dose optimization and individualization is 
being rf r   tr ti  il r . A cordingly, in paediatric drug development scaling 
of PK parameters between adults and the target paediatric population is highly relevant, while 
in clinical practice it may be relevant to scale within the paediatric population, i.e. a dose from 
children to neonates. For both purposes, currently the ¾ allometric scaling approach is 
nowadays propagated.  
Allometric scaling was originally brought up to describe metabolic rates between different 
species [4]. The allometric scaling function for clearance can be described as  
   (1) 
where CLi represents clearance for an individual with bodyweight BWi, CLstd represents 
clearance for a standard individual with bodyweight BWstd, and expCL is the allometric scaling 
exponent which was proposed to be ¾ for metabolic rate [4]. Later on, for the purpose of 
scaling clearance from adults to children, this allometric exponent was also proposed to be 
fixed to a value of 0.75 [5], which leads to an over-prediction of clearance values for young 
children [6, 7]. In order to account for this discrepancy, a maturation function on the basis of 
age was proposed and applied in many studies [5]. More recently, a bodyweight-dependent 
exponent model was reported to cope with over-prediction of clearance at youngest age 
ranges by allowing the exponent value to vary with bodyweight [8]. Without the need for an 
age-based function, this approach was reported to capture changes in clearance from 
preterm neonates to adults for propofol [8] and from 1 month infants to adults for busulfan [9]. 
Even though the exact value for the exponents slightly varied between these drugs, typically 
higher values for the exponent were identified at younger age ranges, representing higher 
maturation rates at lower bodyweights. 
In absence of specific information on the age-based maturation function required for the 
application of the allometric scaling theory [5] or on specific values of the bodyweight 
dependent exponent function [8, 9], allometric scaling based on bodyweight alone may be 
applied during paediatric drug development or when analysing data from clinical practice. In 
literature, both a fixed value of 0.75 [10-12] and an estimated value [13-15] for the allometric 
exponent have been reported for scaling clearance in children.  
In this study, we did a series of hypothetical analyses by applying the allometric scaling 
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In absence of specific information on the age-based maturation function 
required for the application of the allometric scaling theory [5] or on specific 
values of the bodyweight dependent exponent function [8, 9], allometric 
scaling based on bodyweight alone may be applied during paediatric drug 
development or when analysing data from clinical practice. In literature, both 
a fixed value of 0.75 [10-12] and an estimated value [13-15] for the allometric 
exponent have been reported for scaling clearance in children.
In this study, we did a series of hypothetical analyses by applying the 
allometric scaling function for clearance on two types of combined datasets 
from seven previously published propofol studies consisting of neonates, 
infants, toddlers, children, adolescents and adults. Combined datasets could 
consist of two study populations (type I models) or two age groups according 
to FDA Guidance 1998 [16] (type II models). In these combined datasets, the 
allometric exponents for clearance were estimated and the performances of 
the scaling function were evaluated in order to investigate the feasibility and 
boundary of the allometric scaling method without an age-based maturation 
function in both clinical practice situation and paediatric drug development 
situation.
3.2. Methods
3.2.1. Subjects of the original studies
A total of 174 subjects from seven previously published studies on propofol PK 
were included in the current study, including neonates (1-25 days) [17], infants 
(3.8-17.3 months) [18], toddlers (12-31 months) [19], children (3-11 years) [20], 
adolescents (9.8-20.1 years) [21], adults I (33-57 years) [22], adults II (26-81 
years) [23]. Detailed information on the studies is summarized below.
Neonates [17]
Twenty-five cardiovascularly and respiratory stable neonates with a median of 
bodyweight of 2.82 (range 0.68-4.03) kilograms, postnatal age of 8 (1-25) days 
and gestational age of 37 (26-40) weeks were given an intravenous bolus dose 
of propofol (3 mg×kg-1) for the elective removal of chest tubes, (semi)elective 
chest tube placement or endotracheal intubation.
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Twenty-two non-ventilated infants after major craniofacial surgery with a 
median bodyweight of 8.9 (4.8-12.5) kilograms, aged 10 (3.8-17.3) months 
received 2-4 mg×kg-1·h-1 propofol during a median of 12.5 (6.0-18.1) hours.
Toddlers [19]
Twelve toddlers with minor burns, who had a median bodyweight of 11.2 (8.7-
18.9) kilograms and age of 17.8 (12-31) months, were administered 4 mg×kg-1 
propofol just before bathing.
Children [20]
Fifty-three healthy unpremedicated children with a median bodyweight of 23.3 
(15-60.5) kilograms and median age of 7 (3-11) years participated in this study. 
Twenty children received an intravenous loading dose of 3 mg×kg-1 propofol. 
In the remaining 33 children, an intravenous loading dose of 3.5 mg×kg-1 was 
followed by a maintenance infusion. In 18 of the 33 children, a single infusion 
rate of 0.15 mg×kg-1×min-1 was administered, while 15 children received an 
infusion of 0.20 mg×kg-1×min-1 for 30 minutes, followed by an infusion of 0.125 
mg×kg-1×min-1 until the end of the procedure.
Adolescents [21]
Fourteen adolescents with a median bodyweight of 51 (36.6-82) kilograms 
and median age of 14.7 (9.8-20.1) years were anaesthetized with propofol-
remifentanil (2-10 mg×kg-1·h-1) for scoliosis surgery during 6.8 (3.3-7.7) hours 
with an intra-operative wake-up test followed by re-induction of anesthesia.
Adults I [22]
Twenty-four women undergoing gynaecological surgery, with a median 
bodyweight of 68.5 (55-80) kilograms and a median age of 45.5 (33-57) years, 
received 2.5 mg×kg-1 propofol over 60 seconds for induction of anesthesia.
Adults II [23]
Twenty-four healthy volunteers with a median bodyweight of 79.4 (44.4-122.7) 
kilograms and median age of 53 (26-81) years were administered a bolus dose 
of propofol, followed 1 hour later by a 60 minutes infusion with an infusion rate 
of 25, 50, 100, or 200 mg×kg-1·min-1 in a study which investigated the influence 
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of the method of administration, infusion rate, patient covariates, and EDTA 
(ethylenediaminetetraacetic acid) on the pharmacokinetics of propofol.
3.2.2. Combined datasets that were analysed
Two types of combined datasets were prepared from the data of the seven 
previously published propofol studies [17-23]:
Type I models: For the type I models, six study populations, i.e. neonates [17], 
infants [18], toddlers [19], children [20], adolescents [21] and adults [22, 23], 
were identified from the data of the seven original studies by merging datasets 
Adults I [22] and Adults II [23] into one adult population. In a systematic manner, 
two out of these six study populations were selected resulting 15 combined 
datasets.
Type II models: For the type II models, the data of the seven propofol studies 
[17-23] were regrouped into five age groups as defined by FDA Guidance for 
industry of 1998 [16]:
1) neonates (birth to 1 month)
2) infants (1 month to 2 years)
3) children (2 to 12 years)
4) adolescents (12 years to 16 years)
5) adults (above 16 years)
Four combined datasets were then prepared consisting of one of the four 
paediatric age groups and the adult group.
In total, 19 models were built on those 19 datasets, each of which either 
comprised two study populations (type I models) or two FDA age groups (type 
II models).
3.2.3. Pharmacokinetic modelling
The population pharmacokinetic analysis was performed with the non-linear 
mixed effects modelling software NONMEM version 7.2. (ICON Development 
Solutions, Ellicott City, MD, USA) using the first-order conditional estimation 
method with the interaction option (FOCEI). Tools like S-PLUS interface for 
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NONMEM (LAP&P Consultants BV, Leiden, NL), S-Plus (version 8.1, Insightful 
Software, Seattle, WA, USA), XPose and R (version 2.10.0) were used to visualize 
the output and evaluate the models.
Model Building & Assessment
Propofol concentrations were logarithmically transformed and fitted 
simultaneously, since the range in concentrations was more than 1000 fold. 
Model building was performed in three steps: (1) selection of structural model, (2) 
selection of statistical sub-model, (3) covariate analysis. A difference in objective 
function (OFV) between models of more than 3.8 points was considered as 
statistically significant (p<0.05 assuming a Chi-square distribution). Furthermore, 
the goodness-of-fit plots (observed versus individual predicted concentrations 
and versus population predicted concentrations, and conditional weighted 
residuals versus time and versus population prediction concentrations) were 
evaluated [24]. In addition, improvement of the individual concentration-
time profiles, the confidence intervals of the parameter estimates, and the 
correlation matrix were assessed. Besides, stratified observed versus population 
predicted goodness-of-fit plot and post hoc clearance versus bodyweight plots 
were considered, as in each of the 19 analyses two populations with a different 
human age range were analysed [24]. According to Karlsson et al., a high value 
for shrinkage of the inter-individual variability (η), named as η-shrinkage, may 
distort the true relationship between the parameters and covariates when 
empirical Bayes Estimates (EBE), sometimes referred as post hoc estimates of 
parameters, are used [25]. As the post hoc clearances were used in our study in 
the covariate analysis, we evaluated the η-shrinkage for clearance, for which a 
maximum percentage of 20% was considered acceptable.
Structural Model
Based on previous reports [26-28], the time-course of propofol concentrations 
in most combined datasets were modelled with a three-compartment model, 
which was parameterized in terms of total clearance (CL), volume of distribution 
of the central compartment (V1), volume of distribution of the rapid-
equilibrating peripheral compartment (V2) and slow-equilibrating peripheral 
compartment (V3), and inter-compartmental clearances between central 
compartment and two peripheral compartments (Q2,Q3). In two models that 
were built on the datasets that included individuals from the infant study [18], 
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a two compartment model was the most suitable structural model because, 
due to the lack of samples in that period, the very fast distribution process 
could not be identified.
Statistical Model
Inter-individual variability in the pharmacokinetic parameters was tested in the 




(V2) and slow-equilibrating peripheral compartment (V3), and inter-compartmental clearances 
between central compartment and two peripheral compartments (Q2,Q3). In two models that 
were built on the datasets that included individuals from the infant study[18], a two 
compartment model was the most suitable structural model because, due to the lack of 
samples in that peri d, the v ry fast distribution process could not be identified. 
Statistical Model 
Inter-indivi ual v riability in the pharmacokinetic parameters was tested in the model 
assuming log-normal distributions, expressed as 
    ,                     (2) 
where  is the individual pharmacokinetic parameter value for the ith individual,  is the 
population pharmacokinetic parameter value or typical value, and  is a random variable for 
the ith individual from a normal distribution with mean zero and variance . While the 
inclusion of inter-individual variability on the different PK parameters was tested, model 
improvement by inclusion of covariance between these variability parameters was tested as 
well.  
For the residual error, an additive model for log-transformed concentrations was used which 
corresponds to proportional error on untransformed data, expressed as: 
    ,           (3) 
where  is the value of the observed propofol concentration of ith individual at time j,  
is the value of the predicted propofol concentration of the ith individual at time j, and  is a 
random variable for this observation from a normal distribution with mean zero and variance 
. 
Covariate Model 
In all 19 combined datasets, post hoc propofol clearances were described by bodyweight 
using the allometric scaling function of equation (1). For the other pharmacokinetic 
parameters, bodyweight was also incorporated in an allometric manner (equation 4) if this 
would decrease the OFV significantly (p<0.005). 
    (4) 
In this equation,  is the individual parameter;  is the population parameter;  and 
 are corresponding to the individual and median bodyweight;  is the allometric 
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Covariate Model 
In all 19 combined datasets, post hoc propofol clearances were described by bodyweight 
using the allometric scaling function of equation (1). For the other pharmacokinetic 
parameters, bodyweight was also incorporated in an allometric manner (equation 4) if this 
would decrease the OFV significantly (p<0.005). 
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(V2) and slow-equilibrating peripheral compartment (V3), and inter-compartmental clearances 
between central compartment and two peripheral compartments (Q2,Q3). In two models that 
were built on the datasets that included individuals from the infant study[18], a two 
compartment model was the most suitable structural model because, due to the lack of 
samples in that period, the very fast distribution process could not be identified. 
Statistical Model 
Inter-individual variability in the pharmacokinetic parameters was tested in the model 
assuming log-normal distributions, expressed as 
    ,                     (2) 
where  is the individual pharmacokinetic parameter value for the ith individual,  is the 
population pharmacokinetic parameter value or typical value, and  is a random variable for 
the ith individual from  normal distribution with mean zero and variance . While the 
inclusion of inter-indi idu l variability on the different PK para eters was tested, model 
improvement by inclusion of covariance between these variability parameters was tested as 
well.  
For the residual error, an additive model for log-transformed concentrations was used which 
corresponds to proportional error on untransformed data, expressed as: 
    ,           (3) 
where  is the value of the observed propofol concentration of ith individual at time j,  
is the value of the predict d propofol concentrati n f the ith individual at time j, nd  is a 
random variable for this observation from a normal distribution with mean zero and variance 
. 
Covariate Model 
In all 19 combined datasets, post hoc propofol clearances were described by bodyweight 
using the allometric scaling function of equation (1). For the other pharmacokinetic 
parameters, bodyweight was also incorporated in an allometric manner (equation 4) if this 
would decrease the OFV significantly (p<0.005). 
    (4) 
In this equation,  is the individual parameter;  is the population parameter;  and 
 are corresponding to the individual and median bodyweight;  is the allometric 
exponent. Allometric scaling functions for clearance and/or covariate functions for other 
 (4)
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In this equation, P
i
 is the individual parameter; P
TV





 are corresponding to the individual and median bodyweight; 
k is the allometric exponent. Allometric scaling functions for clearance and/or 
covariate functions for other parameters were accepted if the criteria described 
under Model Building & Assessment were met (p<0.05).
Table 3-1 Characteristics of the six study populations used in the type I models
Study-
population
Reference Number of 
individuals
Weight (kg) Age (yrs) Samples per 
subject (range)
Neonates [17] 25 2.82(0.68-4.03) 8(1-25) † 4-14
Infants [18] 20 9(4.8-12.5) 10.2(3.8-17.3) ‡ 4-15
Toddlers [19] 12 11.2(8.74-18.9) 1.25(1-2.6) 11-12
Children [20] 53 23.3(15-60.5) 7(3-11) 5-18
Adolescents [21] 14 51(36.6-82) 14.5(9.6-19.8) 6-21
Adults [22,23] 48 79.4(44.4-122.7) 53(26-81) 18-21
† age in days
‡ age in months
3.3. Results
An overview of the data of the seven propofol pharmacokinetic studies [17-23], 
which were merged into six study populations for the type I models and into 
five paediatric FDA age groups for the type II models, are summarized in Table 
3-1 and Table 3-2, respectively.
Table 3-3 provides an overview of of the results of all 19 models (15 Type I 
models and 4 Type II models) indexed by the model number with their 
estimated allometric exponent, including the relative standard error (RSE%) and 
corresponding ninety-five percent confidence interval (95%CI), for propofol 
clearance. Information on model structure, inter-individual variability on 
clearance and shrinkage values for the inter-individual variabilities on clearance 
are also listed in Table 3-3. Shrinkage values for clearance for all models were 
very low with values varying between 2.06% and 13.45%, indicating acceptable 
reliability of individual clearance values from the model. Given the designated 
allometric scaling model for clearance, all models were optimized in the 
covariate analysis with respect to covariates for pharmacokinetic parameters 
other than clearance in order to minimize the objective function and obtain 
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optimal goodness-of-fit plots. Diagnostic plots (observed versus population 
predicted plots) of the 15 type I models are shown in Figure 3-1, while the 
diagnostic plots for the 4 type II models are presented in Figure 3-2.
Table 3-2 Characteristics of age groups according to FDA guidance [16] used in the type II 
models
Age group Number of 
individuals
Weight (kg) Age (yrs) Samples per subject 
(range) 
Neonates 25 2.82(0.68-4.03) 8(1-25) † 4-14
Infants 31 9(4.8-14.2) 304.8(113.7-689) † 4-15
Children 58 36.6(11.2-74) 9.6(2-11.3) 5-18
Adolescents 9 53(40-82) 14.5(13.6-15.7) 6-21
Adults 48 79.4(44.4-122.7) 53(26-81) 18-21
† age in days
Of the type I models, 5 models (model 1-5) included the neonate population. 
Estimation of the allometric exponent for clearance in those five models 
resulted in values varying betweeen 1.11 and 2.01 (Table 3-3). The performance 
of those models (model 1-5) in terms of goodness of fit were quite adequate 
as shown in Figure 3-1 although there was some bias left. In the log-log 
scaled post hoc clearances versus bodyweight plot (Figure 3-3 A), all post hoc 
individual clearances from model 1 to model 5 are shown, with the allometric 
scaling functions that resulted from these models (see Table 3-3 for estimated 
exponents). In addition, the ¾ fixed allometric scaling line that was extrapolated 
from the adult sub-population was inserted to Figure 3-3 as a reference line. 
Figure 3-3 A shows that for model 1-5, none of the allometric functions 
estimated in the models was able to capture the change in clearance within 
the preterm and term neonate subpopulation completely, independently from 
which other sub-population they were scaled from.
There were 10 type I models (model 1-4, 6-8,10-11,13, Table 3-3) which scaled 
clearance within two different paediatric populations. The estimated allometric 
exponent in those models varied largely with values between 0.20 (model 6) 
and 2.01 (model 1) without a trend (Table 3-3). The diagnostic plots of those 10 
models were good except for some small bias when the infant population was 
included (Figure 3-1). In Figure 3-3, the panels B, C, D and E depict the post hoc 
individual clearance values and estimated scaling curves of the models scaling 
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to infants (model 6, 7, 8, 9, Figure 3-3 B), toddlers (Model 10, 11,12, Figure 3-3 
C), children (Model 13, 14, Figure 3-3 D) and adolescents (Model 15, Figure 
3-3 E). These subfigures 3B-3E suggest that with increasing age of the target 
scaling population, the range in post hoc clearances was smaller. In addition, 
these subfigures show that with increasing age, the scaling lines deviate less 
from the ¾ allometric line.
Table 3-3 Model results including estimated allometric exponent for clearance (Exp
cl
) for 
type I models on two study populations (model 1-15) and type II models on one paediatric 









ExpCL (RSE%) 95% CI ηCL% (RSE%) Shrink 
ηCL%
1 Neonate Infant 3-COM 2.01 (15.20%) 1.41-2.61 79% (21.30%) 4.38%
2 Neonate Toddler 3-COM 1.64 (12.40%) 1.24-2.04 81% (19.40%) 2.55%
3 Neonate Child 3-COM 1.39 (6.80%) 1.20-1.58 54% (16.30%) 2.06%
4 Neonate Adolescent 3-COM 1.13 (5.40%) 1.01-1.25 75% (17.40%) 2.31%
5 Neonate Adult 3-COM 1.11 (5.50%) 0.99-1.23 46% (17.90%) 2.37%
6 Infant Toddler 3-COM 0.20 (98%) -0.18-0.57 34% (13.60%) 4.20%
7 Infant Child 3-COM 0.46 (16.60%) 0.31-0.61 28% (11.60%) 7.43%
8 Infant Adolescent 2-COM 0.32 (16.30%) 0.21-0.42 24% (13.90%) 8.25%
9 Infant Adult 2-COM 0.56 (7.40%) 0.48-0.64 21% (10.70%) 12.08%
10 Toddler Child 3-COM 0.88 (9.20%) 0.72-1.04 22% (10.60%) 9.90%
11 Toddler Adolescent 3-COM 0.72 (6.20%) 0.63-0.81 17% (14.30%) 5.64%
12 Toddler Adult 3-COM 0.81 (4.20%) 0.74-0.87 18% (9.90%) 6.88%
13 Child Adolescent 3-COM 0.55 (11.10%) 0.43-0.67 21% (8.80%) 5.12%
14 Child Adult 3-COM 0.69 (4.90%) 0.62-0.75 19% (8.50%) 7.46%
15 Adolescent Adult 3-COM 0.84 (11.90%) 0.64-1.03 19% (9.40%) 4.77%
16 FDA neonate Adult 3-COM 1.11 (5.50%) 0.99-1.23 46% (17.90%) 2.37%
17 FDA infant Adult 2-COM 0.60 (6.00%) 0.53-0.67 22% (10.70%) 13.45%
18 FDA child Adult 3-COM 0.70 (4.90%) 0.63-0.77 20% (7.80%) 7.15%
19 FDA 
adolescent
Adult 3-COM 0.74 (17.00%) 0.49-0.98 18% (10.20%) 5.23%
Younger subpopulation = the younger sub-population of the combined dataset of type I or type II 
models; Older sub-population = the older sub-population of the combined dataset of type I or type 
II models; 3-COM = three-compartment model; 2-COM = two-compartment model; ExpCL (RSE%) = 
estimate of the allometric exponent for clearance (equation 1) and corresponding relative standard 
error in percentage; 95%CI = ninety-five percent confidence interval of the estimate of the allometric 
exponent for clearance; η
CL
% (RSE%) = estimate of inter-individual variability of clearance in percentage 
and corresponding relative standard error in percentage; Shrink η
CL
% = shrinkage of the inter-individual 
variability of clearance in percentage
In the four type II models (model 16-19), modelling was performed on 
combined datasets comprising data from the adult population and data 
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from one paediatric age group according to the FDA guideline [16] that was 
exctracted from the available merged dataset.
Figure 3-1 Observed versus population predicted concentration plots for type I models 
(model 1-15), each of which was based on a combined dataset comprising two out of the 
six study populations of Table 3-1 (neonates, infants, toddlers, children, adolescents, and 
adults).
Open circle: younger sub-population of the combined dataset (Table 3-3); Filled triangle: older sub-
population of the combined dataset (Table 3-3); neo=neonates, inf=infants, tod=toddlers, chd=children, 
ado=adolescents, adt=adults.
The estimated allometric exponent values were relatively close to each other 
when scaling from FDA adults to infants, children and adolescents (0.60, 0.70 
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and 0.74, respectively), while for scaling from adults to neonates a value higher 
than 1 was identified (i.e. 1.11) (Table 3-3). Figure 3-3 F illustrates the results 
of these type II models 16-19 with post hoc clearances and scaling curves 
estimated in the models versus bodyweight. This figure shows that scaling 
to infants leads to the lowest value for the allometric exponent (i.e. 0.60) and 
scaling to neonates to the highest value for the allometric exponent (i.e. 1.11), 
with the latter having a wide variability in post hoc clearances.
Figure 3-2 Observed versus population predicted concentration plots for type II models 
(model 16-19), each of which was based on a combined dataset comprising one paediatric 
FDA age group (neonates: birth-1month, infants: 1 month- 2years, children: 2 years-12 years, 
and adolescents: 12 years-16 years [16]) and one adult (above 16 years) age group (Table 3-2).
Open circle: younger sub-population of the combined dataset (Table 3-3); Filled triangle: older 
sub-population of the combined dataset (Table 3-3); neo=neonates, inf=infants, chd=children, 
ado=adolescents, adt=adults




The allometric scaling method is often propagated when scaling for size in 
paediatric pharmacokinetic modeling [5] while there is more recently also 
interest for this scaling function when scaling for size in (morbid) obesity [29, 
30]. Particularly in early drug development when based on adult data a first-
time-in-kids dose needs to be selected, this ¾ allometric scaling approach for 
scaling clearance seems attractive. In addition, as the fixed value of 0.75 for the 
allometric exponent of clearance has also lead to acceptable results in children 
[12, 31-34], its use is increasingly popular for scaling between paediatric 
populations. However, as this allometric scaling theory is particularly based 
on the combination of the 0.75 fixed allometric equation together with an 
age-based maturation function [5], the question is how valid the value of the 
exponent of 0.75 is in absence of these age-based functions which are often 
not available. Therefore in this study, where relatively rich pharmacokinetic 
datasets of propofol were available across the entire human age range, a series 
of hypothetical analyses were performed to identify the allometric exponent 
for clearance between populations that varied in age.
The results of this study show that a large variety in the value for the allometric 
exponent for clearance can be expected ranging from 0.2 to 2.01, when two 
paediatric populations are analysed (model 1-4, 6-8, 10-11, 13, 15). While the 
lowest exponent of 0.2 was identified between infants and toddlers (model 
6), the highest exponent of 2.01 was found between neonates and infants 
(model 1). These findings seem in accordance with previous reports stating 
that the fixed ¾ allometric function is inappropriate to describe and predict 
drug clearance in preterm and term neonates, infants and young children, 
as it systematically over-predicts clearance for neonates and under-predicts 
clearances for infants [6, 21, 35, 36]. In addition, for busulfan clearance across 
very young neonates to adolescents, Paci et al. also idenfified two exponents; 
an exponent of 1.25 for children < 9 kg and an exponent of 0.76 for children 
> 9 kg [37]. Concerning our finding of an exponent of 0.88 for toddlers and 
children (model 10), this value seems in good agreement with findings on 
oxycodone clearance in children 6 months to 7 years reporting a value of 0.875 
[13]. It therefore seems from these findings that for scaling clearance between 
two paediatric populations, the allometric exponent needs to be estimated 
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instead of fixed to 0.75 in order to account for differences in maturation rates in 
different age groups. However, as with increasing age the estimated allometric 
scaling line moved slowly towards 0.75 (Figure 3-3 B to E), it may seem that ¾ 
allometric scaling function may be of value in older children (>3 or 4 yrs).
In drug development situations, paediatric pharmacokinetic information is 
neccesary if the drug will be prescribed for paediatric population. A decision 
tree has been proposed by the FDA [38] to determine when and what kind of 
paediatric study (PK, PD, safety) should be conducted, depending on similarities 
in disease and response to treatment between children and adults [16, 38]. 
Adequate selection of the first-time-in-kids dose is thereby highly relevant, 
which is in early drug development based on results of adult PK studies. 
Our type II models mimic this situation by studying the allometric exponent 
between the adult group and one paediatric group defined according to the 
age range defined by FDA (0-1 month, 1 month-2 years, 2-12 years and 12-
18 years) [16]. The results show that among FDA adolescents and children 
the exponent of the allometric scaling curve is close to 0.75 (0.74 and 0.70, 
respectively, Figure 3-3 F) at low inter-individual variblility in clearance (18% 
and 20%, respectively). For adolescents, this result seems in accordance with 
the recent conclusion of the FDA advisory committee which agreed that 
dose(s) for adolescents (>12 years) can be derived from adults data on the 
basis of allometric scaling with a fixed exponent of 0.75 without the need for a 
dedicated PK study [39]. In contrast, the estimates of the allometric exponents 
in FDA defined groups of infants and neonates were found to deviate from 
0.75 (0.60 and 1.11 respectively), while the resulting allometric functions were 
also not capable of describing all individuals across these two groups (Figure 
3-3 F, infants and neonates). As such it seems that extrapolation from adults 
to infants and neonates is not possible using either ¾ allometric scaling or 
allometric scaling with another exponent, while scaling to adolescents and 
potentially children older than toddler age (3 or 4 yrs) could be considered.















































































































































A. Neonates B. Infants
C. Toddlers D. Children




























Bodyweight (kg) Bodyweight (kg)
Bodyweight (kg) Bodyweight (kg)
Bodyweight (kg) Bodyweight (kg)
Figure 3-3 Post hoc individual clearance values (symbol) and estimated allometric function 
from the model (line) versus bodyweight plots for all 19 Type I and Type II models in log-log 
scale (with ¾ reference line).
A. Neonates): Post hoc clearances versus bodyweight from the five type I models that comprise the 
neonates sub-population (model 1-5, Table 3-3). Dark green filled circles are median post hoc clearances 
of neonates from the models 1-5; Light green filled triangle: post hoc clearances of infants from model 
1; Dark blue filled square: post hoc clearances of toddlers from model 2; Light blue filled circle: post hoc 
clearances of children from model 3; Dark orange filled triangle: post hoc clearances of adolescents from 
model 4; Light orange filled square: post hoc clearances of adults from model 5; Dark green solid line: 
¾ allometric scaling line that scales from the adult population; Light green dash line: the allometric 
scaling line with exponent value 2.01 from model 1; Dark blue solid line: the allometric scaling line 
with exponent value 1.64 from model 2; Light blue dash line: the allometric scaling line with exponent 
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value 1.39 from model 3; Dark orange solid line: the allometric scaling line with exponent value 1.13 
from model 4; Light orange dash line: the allometric scaling line with exponent value 1.11 from model 5
B. Infants): Post hoc clearances versus bodyweight from the four type I models that comprise the infants 
population (model 6-9, Table 3-3). Light green filled triangles are median post hoc clearances of infants 
from the models 6-9; Dark blue filled square: post hoc clearances of toddlers from model 6; Light blue 
filled circle: post hoc clearances of children from model 7; Dark orange filled triangle: post hoc clearances 
of adolescents from model 8; Light orange filled square: post hoc clearances of adults from model 9; Dark 
green solid line: ¾ allometric scaling line that scales from the adult population; Light green dash line: 
the allometric scaling line with exponent value 0.20 from model 6; Dark blue solid line: the allometric 
scaling line with exponent value 0.46 from model 7; Light blue dash line: the allometric scaling line with 
exponent value 0.32 from model 8; Dark orange solid line: the allometric scaling line with exponent 
value 0.56 from model 9
C. Toddlers): Post hoc clearances versus bodyweight from the three type I models that comprise the 
toddlers population (model 10-12, Table 3-3). Dark blue filled squares are median post hoc clearances of 
toddlers from the models 10-12; Light blue filled circle: post hoc clearances of children from model 10; 
Dark orange filled triangle: post hoc clearances of adolescents from model 11; Light orange filled square: 
post hoc clearances of adults from model 12; Dark green solid line: ¾ allometric scaling line that scales 
from the adult population; Light green dash line: the allometric scaling line with exponent value 0.88 
from model 10; Dark blue solid line: the allometric scaling line with exponent value 0.72 from model 11; 
Light blue dash line: the allometric scaling line with exponent value 0.81 from model 12
D. Children): Post hoc clearances versus bodyweight from the two type I models that comprise the 
children population (model 13-14, Table 3-3). Light blue filled circles are median post hoc clearances of 
children from the models 13 and 14; Dark orange filled triangle: post hoc clearances of adolescents from 
model 13; Light orange filled square: post hoc clearances of adults from model 14; Dark green solid line: 
¾ allometric scaling line from the adult population; Light green dash line: the allometric scaling line 
with exponent value 0.55 from model 13; Dark blue solid line: the allometric scaling line with exponent 
value 0.69 from model 14
E. Adolescents): Post hoc clearances versus bodyweight from the type I model that comprises the 
adolescent population (model 15). Dark orange filled triangle: post hoc clearances of adolescents from 
model 15; Light orange filled square: post hoc clearances of adults from model 15; Dark green solid line: 
¾ allometric scaling line that scales from the adults population; Light green dash line: the allometric 
scaling line with exponent value 0.84 from model 15
F. Model 16-19): Post hoc clearances versus bodyweight from the type II models, each of which was based 
on a combined datasets comprising one paediatric FDA age group (neonates: birth-1month, infants: 1 
month- 2years, children: 2 years-12 years, and adolescent: 12 years-16 years) and one adult (above 16 
years) age group (model 16-19, Table 3-3). Dark orange filled triangles are median post hoc clearances 
of adults from four models; Dark green filled circle: post hoc clearances of neonates from model 16; 
Light green filled triangle: post hoc clearances of infants from model 17; Dark blue filled square: post hoc 
clearances of children from model 18; Light blue filled circle: post hoc clearances of adolescents from 
model 19; Dark green solid line: ¾ allometric scaling line that scales from the adults population; Light 
green dash line: the allometric scaling line with exponent value 1.11 from model 16; Dark blue solid line: 
the allometric scaling line with exponent value 0.60 from model 17; Light blue dash line: the allometric 
scaling line with exponent value 0.70 from model 18; Dark orange solid line: the allometric scaling line 
with exponent value 0.74 from model 19
In the models analysing neonates as one of the two groups, we found in our 
study that estimates for the allometric exponent for clearance were larger 
than 1, and were larger than the estimates for the exponent in other paediatric 
groups. Beside propofol, an exponent larger than 1 has been reported before for 
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morpine in (preterm) neonates to children of 3 years of age [15]. Also, Mahmood 
reported that the exponent of 1.2 performs better compared to an exponent of 
1.0 when predicting drug clearance in children < 3 months, while an exponent 
of 1.0 was superior over an exponent of 1.2 for children ≥3 months to 1 year 
[40]. In addition, Paci et al. found two different allometric exponents for busulfan 
clearance, with an exponent larger than 1 for children < 9 kg [37]. This finding 
that in neonates the value for the allometric exponent for clearance is high, while 
lower values are identified at higher age and bodyweight ranges, are captured 
in our recently developed bodyweight dependent exponent (BDE) model [8]. In 
this BDE model, changes in propofol clearance across the entire human life-span 
were very well described using an allometric function in which the exponent 
was allowed to vary with bodyweight (range 1.34 for neonates to 0.55 for 
adults), without the need for an additional age-base function [8]. Considering 
the results of the current study in relation to the full analysis of all datasets [8], it 
seems that fairly similar exponents are identified, i.e. values between 1 and 1.5 
for neonates to values between 0.5 and 1 for older children and adults. More 
recently, this BDE function in a simplifed manner was also applied with success 
to busulfan for children from 1 month to adults in which the exponent was 
found to vary from 1.21 to 0.54 [9]. Given the similarities in these exponents, it 
seems that this BDE model should be studied across different drugs for which 
data are available over the entire human age range including neonates, as it 
may capture in a continuous function changes in clearance from neonates to 
adults despite the fact that maturation rates may vary at different ages.
In this study, we investigated the allometric scaling approach for clearance of 
propofol. As propofol is a high hepatic extraction ratio drug and it is mainly 
metabolised by the UGT-1A9 iso-enzyme, the results may not be necessarily 
the same for other drugs which have medium or low extraction ratio or have 
different metabolism pathway. We also recognize the allometric scaling 
approach is not physiologically based and it cannot explain the physiological 
mechanisms, such as the maturation of enzyme capacity etc. Furthermore, it 
should be considered that the estimated allometric exponents for clearance in 
this study may be influenced by the inclusion of covariates for other parameters 
such as volume of distribution. Given such limitations, we can only assure our 
findings for propofol and the feasibility and boundary of the allometric scaling 
approach for other drugs remains to be investigated.
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Different allometric exponents for propofol clearance were identified 
depending on the included age-range, with the largest difference in allometric 
exponent between neonates and infants and between infants and toddlers 
(2.01 versus 0.2, respectively). Our findings show that for scaling clearance, ¾ 
allometric scaling may be of value for scaling from adults to adolescents and 
perhaps children, while it can not be used for scaling from adults to neonates, 
within neonates or between two paediatric populations.
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Appendix: NONMEM code of the model
Example model with 3 compartments
$SUBROUTINE ADVAN11 TRANS4 
$PK   
TVCL     = THETA(1)*(BW/68)**THETA(7)    
CL         = TVCL*EXP(ETA(1))    
Q2        = THETA(2)*EXP(ETA(2))    
TVQ3    = THETA(3)*(BW/68)    
Q3        = TVQ3 *EXP(ETA(3))    
TVV1    = THETA(4)*(BW/68)    
V1         = TVV1*EXP(ETA(4))    
TVV2    = THETA(5)*(BW/68)    
V2        = TVV2*EXP(ETA(5))    
TVV3   = THETA(6)*(BW/68)    
V3        = TVV3*EXP(ETA(6))    
S1        = V1    
ETCL    = ETA(1)    
ETQ2   = ETA(2)    
ETQ3   = ETA(3)    
ETV1   = ETA(4)    
ETV2   = ETA(5)    
ETV3   = ETA(6) 
$ERROR    
IPRE = LOG(.000001)    
IF (F.GT.0) IPRE=LOG(F)    
IRES=DV-IPRE    
W = 1    
IWRES=IRES/W    
Y=IPRE+W*ERR(1) 
$THETA    
( 0, 1.6,  )   ; TH1 CL    
( 0, 1.7,  )   ; TH2 Q2    
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( 0, 1.5,  )   ; TH3 Q3    
( 0, 4,    )   ; TH4 V1    
( 0, 5,    )   ; TH5 V2    
( 0, 100,  )   ; TH6 V3    
( 0, 1.3,  )   ; TH7 EXP of BW on clearance        
$OMEGA    
0.2     ; OMEGA1 CL    
0 FIX   ; OMEGA2 Q2    
0.2     ; OMEGA3 Q3    
0.2     ; OMEGA4 V1    
0 FIX   ; OMEGA5 V2    
0.3     ; OMEGA6 V3 
$SIGMA    
0.1     ; SIGMA1 
$EST NOABORT PRINT=15 MAXEVALS=9999 METHOD=1 INTERACTION 
$COV COMP PRINT=E
Example model with 2 compartments
$SUBROUTINE ADVAN3 TRANS4 
$PK    
TVCL = THETA(1)*(BW/63.5)**THETA(5)    
CL   = TVCL*EXP(ETA(1))    
TVQ  = THETA(2)*(BW/63.5)    
Q    = TVQ *EXP(ETA(2))    
TVV1 = THETA(3)*(BW/63.5)    
V1   = TVV1*EXP(ETA(3))    
TVV2 = THETA(4)*(BW/63.5)    
V2   = TVV2*EXP(ETA(4))    
S1   = V1    
ETCL =ETA(1)    
ETQ  =ETA(2)    
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ETV1 =ETA(3)    
ETV2 =ETA(4) 
;------------------------------------------------------------------------- 
$ERROR    
W=1       
IPRE = LOG(.000001)    
IF (F.GT.0) IPRE=LOG(F)    
IRES=DV-IPRE    
IWRES=IRES/W    
Y=IPRE+W*ERR(1) 
;------------------------------------------------------------------------- 
$THETA    
( 0, 1.2,  )   ; TH1 CL    
( 0, 0.8,  )   ; TH2 Q    
( 0, 5,    )   ; TH3 V1    
( 0, 20,   )   ; TH4 V2    
( 0, 0.5,  )   ; TH5 EXP of BW on CL  
$OMEGA    
0.15    ; OMEGA1 CL    
0 FIX   ; OMEGA2 Q    
0 FIX   ; OMEGA3 V1    
0.1     ; OMEGA4 V2  
$SIGMA    
0.1     ; SIGMA1 
$EST NOABORT PRINT=15 MAXEVALS=9999 METHOD=1 INTERACTION 
$COV COMP PRINT=E
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Purpose: In this study, we explored different allometric equations for scaling 
clearance across the human life-span using propofol as a model drug.
Methods: Data from seven previously published propofol studies ((pre)term 
neonates, infants, toddlers, children, adolescents and adults) were analysed 
using NONMEM VI. To scale clearance, a bodyweight-based exponential equation 
with four different structures for the exponent was used: (I) ¾ allometric scaling 
model; (II) mixture model; (III) bodyweight-cut-point separated model; (IV) 
bodyweight-dependent exponent model.
Results: Model I adequately described clearance in adults and older children, 
but overestimated clearance of neonates and underestimated clearance 
of infants. Use of two different exponents in Model II and Model III showed 
significantly improved performance, but yielded ambiguities on the boundaries 
of the two subpopulations. This discontinuity was overcome in Model IV, 
in which the exponent changed sigmoidally from 1.35 at a hypothetical 
bodyweight of 0 kg to a value of 0.56 from 10 kg onwards, thereby describing 
clearance of all individuals best.
Conclusions: A model was developed for scaling clearance over the entire 
human life-span with a single continuous equation, in which the exponent of 
the bodyweight-based exponential equation varied with bodyweight.
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For scaling pharmacokinetics across the human life-span, the ¾ allometric 
scaling approach [1] has gained in popularity in the field of pediatrics. 
While the ¾ allometric scaling approach was originally designed to 
describe metabolic rates between different species covering a wide range 
in bodyweight [2], this function is now being applied to parameterize the 
influence of changes in body size on drug clearance parameters within the 
human weight-range.
In contrast with the reports supporting the ¾ allometric scaling principles [3-5], 
there is a number of theoretical arguments against these scaling principles in 
general [6-8]. Furthermore, the value of the allometric exponent is debated [9, 
10], the existence of a unique and universal value for the exponent is thought 
to be unlikely [11, 12] and the application of allometric scaling principles 
to pharmacokinetics in the human weight-range is disputed [13, 14]. For 
paediatrics, the covering of changes in body size made by this bodyweight-
based allometric equation with a fixed exponent of 0.75 for clearance are 
specifically insufficient to describe and predict drug clearance in preterm and 
term neonates, infants and young children [13, 15, 16]. When applying the ¾ 
allometric scaling method to different drugs, it has been found that the model 
systematically over-predicted clearances for neonates and under-predicted 
clearances for infants [15, 17].
In order to account for the discrepancy of the ¾ allometric method in young 
children, an augmentation of the ¾ allometric equation with an age-based 
sigmoidal equation has been proposed [18, 19]. However, this age-adjustment 
is unidirectional, whereas bi-directional changes from the ¾ allometric line 
have been reported in the papers aforementioned, that depend on the age of 
the children [15, 17]. Furthermore, introduction of this age-based maturation 
equation introduces age into the model in addition to bodyweight. While 
age and bodyweight are highly correlated in the paediatric population in a 
nonlinear manner, this may result in a collinearity problem [20]. In this respect, 
it is emphasized that recent research shows that a priori inclusion of a false 
predefined covariate relationship into a model may decrease the predictive 
performance of that model [21]. As a result of these limitations, in some reports 
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the exponent of the allometric scaling equation was estimated instead of fixed 
to 0.75, resulting in values higher than 1 in datasets of young infants [22, 23]. 
From these reports, it seems that an optimized and statistically sound scaling 
approach is needed for scaling of clearance in paediatrics.
The aim of this study was therefore to explore new approaches to scale drug 
clearance over the entire human life-span. Propofol was used as a model drug, 
and for this study seven datasets were available from preterm neonates with 
a median (range) gestational age of 37 (26-40) weeks to 81 year old adults [15, 
24-29].
4.2. Materials and methods
4.2.1. Subjects
A total of 174 subjects from seven previously published propofol studies were 
included in the current study. These studies are described in detail elsewhere 
and are briefly discussed as relevant to the current analysis.
Neonates [24]
Twenty-five cardiovascularly and respiratory stable neonates with a median of 
bodyweight of 2.93 (range 0.68-4.03) kilograms, postnatal age of 8 (1-25) days 
and gestational age of 37 (26-40) weeks were given an intravenous bolus dose 
of propofol (3 mg×kg-1) for the elective removal of chest tubes, (semi)elective 
chest tube placement or endotracheal intubation.
Infants [25]
Twenty-two non-ventilated infants after major craniofacial surgery with a 
median bodyweight of 8.9 (4.8-12.5) kilograms, aged 10 (3.8-17.3) months 
received 2-4 mg×kg-1·h-1 propofol during a median of 12.5 (6.0-18.1) hours.
Toddlers [26]
Twelve toddlers with minor burns, who had a median bodyweight of 11.2 (8.7-
18.9) kilograms and age of 17.8 (12-31) months, were administered 4 mg×kg-1 
propofol just before bathing.
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Fifty-three healthy unpremedicated children with a median bodyweight 
of 23.3 (15-60.5) kilograms and median age of 7 (3-11) years were studied. 
Twenty children received an intravenous loading dose of 3 mg×kg-1 propofol. 
In the remaining 33 children, an intravenous loading dose of 3.5 mg×kg-1 was 
followed by a maintenance infusion. In 18 of the 33 children, a single infusion 
rate of 0.15 mg×kg-1×min-1 was administered, while 15 children received an 
infusion of 0.20 mg×kg-1×min-1 for 30 minutes, followed by an infusion of 0.125 
mg×kg-1×min-1 till the end of the procedure.
Adolescents [15]
Fourteen adolescents with a median bodyweight of 51 (36.6-82) kilograms 
and median age of 14.7 (9.8-20.1) years were anaesthetized with propofol-
remifentanil (2-10 mg×kg-1·h-1) for scoliosis surgery during 6.8 (3.3-7.7) hours 
with an intra-operative wake-up test followed by re-induction of anesthesia.
Adults I [28]
Twenty-four women undergoing gynaecological surgery, with a median 
bodyweight of 68.5 (55-80) kilograms and a median age of 45.5 (33-57) years, 
received 2.5 mg×kg-1 propofol over 60 seconds for induction of anesthesia.
Adults II [29]
Twenty-four healthy volunteers with a median bodyweight of 79.4 (44.4-122.7) 
kilograms and median age of 53 (26-81) years were administered a bolus dose 
of propofol, followed 1 hour later by a 60 minutes infusion with an infusion 
rate of 25, 50, 100, or 200 mg×kg-1·min-1 in a study which investigated the 
influences of method of administration, infusion rate, patient covariates, and 
EDTA (ethylenediaminetetraacetic acid) on the pharmacokinetics of propofol.
4.2.2. Pharmacokinetic Modeling 
Model Building
The population pharmacokinetic analysis was performed with the non-linear 
mixed effects modeling software NONMEM version 6.2. (ICON Development 
Solutions, Ellicott City, MD, USA) using the first-order conditional estimation 
method with the interaction option (FOCEI). Tools like S-PLUS interface for 
NONMEM (LAP&P Consultants BV, Leiden, NL), S-Plus (version 8.1, Insightful 
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Software, Seattle, WA, USA), XPose and R (version 2.10.0) were used to visualize 
the output and evaluate the models.
Propofol concentrations were logarithmically transformed and fitted 
simultaneously, since the range in concentrations was more than 1000 
fold. Model building was performed in four steps: (1) selection of structural 
model, (2) selection of statistical sub-model, (3) covariate analysis, (4) model 
validation. A difference in objective function (OFV) between models of 
more than 7.88 points was considered as statistically significant (p<0.005 
assuming a Chi-square distribution). Furthermore, the goodness-of-fit plots 
(observed versus individual predicted concentrations and versus population 
predicted concentrations, and conditional weighted residuals versus time 
and versus population prediction concentrations) were evaluated [30]. Finally, 
improvement of the individual concentration-time profiles, the confidence 
intervals of the parameter estimates and the correlation matrix were assessed.
Structural Model
Based on previous reports [31-33] the time-course of propofol concentrations 
was modeled with a three-compartment model, which was parameterized in 
terms of total clearance (CL), volume of distribution of the central compartment 
(V1), volume of distribution of the rapid-equilibrating peripheral compartment 
(V2) and slow-equilibrating peripheral compartment (V3), and inter-
compartmental clearances between central compartment and two peripheral 
compartments (Q2,Q3). In addition, the performance of a two compartment 
model with the parameters CL, Q2, V1 and V2 was evaluated.
Statistical Model
Inter-individual variability in the pharmacokinetic parameters was tested in the 




compart ents (Q2,Q3). In addition, the performance of a two compartment model with the 
parameters CL, Q2, V1 and V2 w s evaluated. 
Statistical Model 
Inter-individual variability in the pharmacokinetic parameters was tested in the model 
assuming log-nor al distributions, exp essed as 
                                               ,                    (1) 
where  is the individual pharmacokinetic parameter value for the ith individual,  is the 
population pharmacokinetic parameter value or typical value, and  is a random variable for 
the ith individual from a normal distribution with mean zero and variance . In addition to 
testing the inclusion of inter-individual variability on individual parameters, model 
improvement by inclusion of covariance between these variability parameters was tested as 
well.  
For the residual error, an additive model for log-transformed concentrations was used which 
corresponds to proportional error on untransformed data, expressed as: 
    ,           (2) 
where  is the value of the observed propofol concentration of ith individual at time j,  
is the value of the predicted propofol concentration of the ith individual at time j, and  is a 
random variable for this observation from a normal distribution with mean zero and variance 
. 
Covariate Models 
To visualize potential relationships, candidate covariates such as age and bodyweight were 
plotted independently versus the empirical Bayes post hoc estimates for all pharmacokinetic 
parameters. Potential covariates were separately implemented into the model using a linear 
or power equation over the studied covariate range: 
    (3) 
In this equation,  represents the individual parameter estimate of the ith subject,  
represents the population parameter estimate, Cov is the covariate of interest with subscript 
median indicating the median value of the particular covariate and  is the exponent which 
was fixed to 1 for a linear function or estimated for a power function.  
The significance of a covariate was statistically tested by use of the objective function. A p 




 is the ndividu l pharmacokinetic parameter value for the ith in ividual, 
q
TV
 is the population pharmacokinetic parameter value or typical value, and h
i
 
is a random variable for the ith individual from a normal distribution with mean 
zero and variance w2. In addition to testing the inclusion of inter-individual 
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variability on individual parameters, model improvement by inclusion of 
covariance between these variability parameters was tested as well.
For the residual error, an additive model for log-transformed concentrations 
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Statistical Model 
Inter-individual variability in the pharmacokinetic parameters was tested in the model 
assuming log-normal distributions, expressed as 
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improvement by inclusion of covariance between these variability parameters was tested as 
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where  is the value of the observed propofol concentration of ith individual at time j,  
is the value of the predict d propofol concentrati n of the ith individual at time j, and  is a 
random variable for this observation from a normal distributi  with mean zero and variance 
. 
Covariate Models 
To visualize potential relationships, candidate covariates such as age and bodyweight were 
plotted independently versus the empirical Bayes post hoc estimates for all pharmacokinetic 
parameters. Potential covariates were separately implemented into the model using a linear 
or power equation over the studied covariate range: 
    (3) 
In this equation,  represents the individual parameter estimate of the ith subject,  
represents the population parameter estimate, Cov is the covariate of interest with subscript 
median indicating the median value of the particular covariate and  is the exponent which 
was fixed to 1 for a linear function or estimated for a power function.  
The significance of a covariate was statistically tested by use of the objective function. A p 
value < 0.005 was considered significant in the forward inclusion while on the other hand a 
 (3)
In this equation, q
i
 represents the individual parameter estimate of the ith 
subject, q
TV
 represents the population parameter estimate, Cov is the covariate 
of interest with subscript median in icating the median value of the particular 
covariat  and k is the exponent which was fixed to 1 for a linear function or
estimated for a power function.
The significance of a covariate was statistically tested by use of the objective 
function. A p value < 0.005 was considered significant in the forward inclusion 
while on the other hand a more stringent p value of <0.001 was used in the 
backward deletion. In addition, individual and population parameter estimates 
were plotted against the most predictive covariate to evaluate whether the 
individual predicted parameters are evenly distributed around the population 
predicted values [30]. When two or more covariates were found to significantly 
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improve the model, the covariate causing the largest reduction in the objective 
function was retained in the model and served as the basis for subsequent 
inclusion of additional covariates. Furthermore, for the final covariate model, 
general criteria for model evaluation were considered as described under 
‘Model Building’, while also the results of the model validation procedures were 
taken into account.
As bodyweight proved to be superior over age as a covariate for clearance, four 
covariate models based on bodyweight were tested. For propofol clearance, 
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individual variability on Cl was kept the same for both sub-populations. The assignment of 
individuals to one of the sub-populations was determined by a probability model [34]. Briefly, 
the probability model assumed two log-normal distributions for clearance with different mean 
values but common standard deviation for two sub-populations. Each individual has a 
probability of  belonging to POP1 and has 1- probability of belonging to POP2.The mixture 
model was implemented by the $MIX option in NONMEM VI.  
Model III: The bodyweight-cut-point separated model; in which different values for the 
exponent k were estimated for two sub-populations: POPbw<d and POPbw≥d. These sub-
populations were determined by a cut-point bodyweight d which is a fixed effect parameter in 
NONMEM: individuals with bodyweight less than the cut-point belonged to POPbw<d and 
individuals with bodyweight greater than or equal to the cut-point belonged to POPbw≥d.  
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Model IV: The bodyweight-dependent exponent (BDE) model; in which 
the allometric exponent k changed in a sigmoidal fashion with bodyweight 








  (5) 
in which BWi is bodyweight of an individual i; k0 is the value of the exponent at a theoretical 
bodyweight of 0 kg; kmax is the maximum decrease of the exponent; k50 is the bodyweight at 
which a 50% decrease in the maximum decrease of exponent is attained, and γ is the Hill 
coefficient determining the steepness of sigmoidal decline in the exponent.  
4.2.3. Model Validation  
Stratified bootstrap re-sampling was performed to obtain the same numbers of patients of 
each of the seven study populations in the new re-sampled datasets compared to the original 
dataset. This stratified bootstrap was implemented by the “bootstrap” command and the “-
stratify_on” option in Perl-speaks-NONMEM (copyright by Mats Karlsson, Niclas Jonsson and 
Andrew Hooker). The median, standard deviation and the 90% confidence interval of the 
parameter estimates were calculated based on the results of the runs that minimized 
successfully.  
In addition, the normalized prediction distribution errors (NPDE) method [35] was used as a 
simulation-based diagnostic. The dataset was simulated 2000 times in NONMEM, each 
observed concentration was subsequently compared to the simulated reference distribution 
using the NPDE add-on package in R. A histogram of the NPDE distribution in the total 
dataset and plots of NPDE versus individual predicted concentration and versus time were 
used to evaluate the final model. 
In order to evaluate the precision of the population predicted clearances by the four different 
covariate models for clearance, we used the root mean square error (RMSE) which was 
calculated as follows: 
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                (7) 
in which Clp is the population predicted clearance; Cli is the individual predicted clearance; n 
is the number of individuals. 
4.3. Results  
The analysis was based on a total number of 4396 observations from 174 individuals aged 
between 1 day to 81 years and with a bodyweight varying between 0.68 to 122.7 kilograms. 
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 is the population predicted clearance; Cl
i
 is the individual predicted 
clearance; n is the number of individuals.
4.3. Results
The analysis was based on a total number of 4396 observations from 174 
individuals aged between 1 day to 81 years and with a bodyweight varying 
between 0.68 to 122.7 kilograms. An overview of the datasets used for model 
building is shown in Table 4-1.
Table 4-1 Overview of propofol pharmacokinetic datasets used in the current analysis 
(values expressed as median (range))
Population N Indication Weight (kg) Age (yrs) Administration Samples*
Neonates (24) 25 Removal of 
chest tubes
2.93(0.68-4.03) 8(1-25) † Bolus 4-14




9(4.8-12.5) 10.2(3.8-17.3) ‡ Infusion 4-15




11.2(8.74-18.9) 1.25(1-2.6) Bolus 11-12
Children (27) 53 Superficial 
body surface 
surgery 










68.5(55-80) 45.5(33-57) Bolus 18
Adults (29) 24 PK study 
in healthy 
volunteers
79.4(44.4-122.7) 53(26-81) Infusion 20-21
† age in days
‡ age in months
* number of samples per subject (range)
A three compartment model performed better than a two compartment model. 
In this three compartment model, four different bodyweight-based allometric 
equations for clearance were seperately tested and evaluated for their performance. 
All parameter estimates including their coefficients of variation (CV values) and 
objective functions of these four covariate models are listed in Table 4-2.
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The ¾ allometric model (Model I) with a fixed allometric exponent of 0.75 had 
an OFV of -2339.7 (Table 4-2). With this model population values of propofol 
clearance in children weighing less than 15 kg, were both over-estimated (in 
children between 0.5 and 5 kg) and under-estimated (in children between 5 
and 15 kg) (Figure 4-1).
For the mixture model (Model II) the OFV decreased significantly (p<0.001) 
compared to Model I (Table II). The estimated allometric exponent value 
for clearance of population POP
1
 was less than 1 (0.676), whereas its value 
for clearance of population POP
2
 was greater than 1 (1.321) (Table II). The 
probability of an individual belonging to POP
1
 (p) in Model II was found to be 
0.2. Figure 4-1 shows that the population line of Model II described the post 
hoc propofol clearances better than Model I.
The bodyweight-cut-point separated model (Model III) had an OFV of -2464.4, 
which was an increase of 21.8 (P<0.001) points compared to Model II and a 
decrease of 124.7 points (p<0.001) compared to Model I (Table 4-2). The 
bodyweight cut-point was estimated to be 16.5 kg, which was fixed to this value 





 were 1.68 and 0.614, respectively (Table 4-2). 
Figure 4-1 shows that Model III results in improved the fit of the population line 
to the post hoc clearances compared to Model I.
The bodyweight-dependent exponent model (Model IV) had the lowest OFV of 
-2489 of the four allometric covariate models, which was significantly superior 
over the ¾ allometric model and the bodyweight-cut-point separated model 
(p<0.001) (Table 4-2). The OFV of this model was not significantly different 
from the OFV of the mixture model. In order to get a successful covariance step, 
the exponent of bodyweight at 0 kg (k
0
) and the hill factor (γ) were fixed to the 
estimated values from a successful run without covariance step, which were 
1.35 and 5.24, respectively. Visually, Model IV had the best overall distribution 
of post hoc clearances versus population clearance (Figure 4-1). Finally, model 
IV had the lowest inter-individual variability in clearance (Table 4-2), indicating 
that this new equation indeed accounts for variability in clearance in the entire 
range of bodyweight of the subjects.
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Table 4-2 Parameter values, corresponding coefficients of variation (CV%), and objective 
function for the four different covariate models for clearance.
Parameter Model
Model I Model II Model III Model IV
Fixed effect















    of POP
1
2.52(9.7%)






    of POP
bw<d
15.4(29.3%)




    of POP
1
1.32(4.2%)




    of POP
bw<d
1.68(8.4%)
    of POP
bw<d
0.61(5.9%)
p  (i=1) 0.2(27.7%)
d  (kg) 16.5 FIX




   k
0
1.35 FIX
   k
max
0.79(8.5%)
   k
50 
(kg) 3.71(7.4%)
   g 5.1 FIX












 (L/min·70kg) 1.55 (4.8%) 1.54(4.8%) 1.55 (4.8%) 1.59 (5.5%)
























 (L/70kg) 228 (6.8%) 219 (7.0%) 216 (7.0%) 226 (8.6%)
Inter-individual variability
ω2 CL 0.44(20.7%) 0.11 (17.4%) 0.21 (24.5%) 0.08(17.1%)
ω2 V1 1.55(15.2%) 1.52(16.0%) 1.53(15.9%) 1.53(16.3%)
ω2 Q3 0.23(14.5%) 0.22(16.3%) 0.22(15.7%) 0.27(20.1%)
ω2 V2 0.81(11%) 0.82((11.4%) 0.81(11.4%) 0.82(11.5%)
ω2 V3 0.3(17.4%) 0.31(17.8%) 0.32(17.4%) 0.76(39.3%)
Residual error
σ2 additive 0.06(10.1%) 0.06(10.2%) 0.06(10.3%) 0.06(10.3%)
OFV -2339.7 -2486.2 -2464.4 -2489
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Model I: ¾ allometric model; Model II: the mixture model; Model III: the bodyweight-cut-point 
separated model; Model IV: the bodyweight-dependent exponent (BDE) model. bw=bodyweight; p 
= the probability of the individuals belonging to POP1 in the mixture model (Model II); d = the cut-
point in bodyweight dividing the two sub-populations in the bodyweight-cut-point separated model 
(Model III); k
0
= value of the exponent at a theoretical bodyweight of 0 kg; k
max
= the maximum decrease 
of the exponent; k
50
= the bodyweight at which a 50% decrease in the maximum decrease of exponent is 
attained; g= the Hill coefficient determining the steepness of sigmoidal decline in the exponent.
Table 4-3 lists the %RMSE values for the different paediatric subpopulations for 
all four covariate models. The precision of clearance prediction shows a trend of 
decrease from adult population to neonate population for the four models. In 
neonates, infants, and children, the bodyweight-dependent exponent model 
(Model IV) had the lowest %RMSE, and thus the highest precision, of the four 
models. In toddlers, the mixture model (Model II) had the lowest %RMSE value 
compared to other models.
Table 4-3 %RMSE of the four bodyweight-based exponential equations for the different 
human subpopulations, Model I: ¾ allometric model; Model II: the mixture model; Model 
III: the bodyweight-cut-point separated model; Model IV: the bodyweight-dependent 
exponent (BDE) model.
Population Model I (%) Model II (%) Model III (%) Model IV (%)
Neonates 160 149 61 49
Infants 63 41 53 40
Toddlers 25 37 38 33
Children 32 26 26 23
Adolescents 24 53 30 27
Adults I & II 24 26 21 20
Based on these results, Model IV was selected as covariate model and further 
optimized. The parameter estimates of the final PK model are listed in Table 4-4. 
Figure 4-2 shows how the bodyweight dependent exponent for clearance (k, 
equation 5) changes with bodyweight according to the estimated parameters 
of equation 5 in Table 4-4. The figure shows that k decreased from a highest 
value of 1.35 (k
0





). At a bodyweight of 3.78 kg (k
50
), half of the maximum decrease was 
reached (Table 4-4). The Hill coefficient (g) of 5.24 reflected the rapid decrease 
in the exponent (k) with bodyweight (Figure 4-2).
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Table 4-4 Parameter estimates, bootstrap results and their corresponding coefficients of 
variation (CV%) values for the final PK model.
Parameter Final model Bootstrap†
Fixed effect



















 (kg) 3.78(15.1%) 3.75(7.5%)









 (L/min·70kg) 1.65(5.0%) 1.64((4.8%)
V1 (L) if PNA≥100 then =V1p, if PNA<100 then =V1p×(bw/70)
V1
p

















 (L/70kg) 221(8.9%) 225(8.9%)
Inter-individual variability
ω2 CL 0.09(18.0%) 0.08(19.4%)
ω2 V1 1.19(41.3%) 1.22 (18.3%)
ω2 Q3 0.25(17.0%) 0.26(19.9%)
ω2 V2 0.52(40.8%) 0.54(16.6%)
ω2 V3 0.71(44.0%) 0.75(46%)
Residual error
σ2 additive 0.06(10.3%) 0.06(10.1%)
OFV -2580.7
† Mean estimated parameter values and their coefficient of variation in percentage from 200 stratified 
bootstrapping re-samples. bw=bodyweight; k
0
= the exponent at a theoretical bodyweight of 0 kg; k
max
= 
the maximum decrease of the exponent; k
50
= the bodyweight at which a 50% decrease in the maximum 
decrease of exponent is attained; g= the Hill coefficient determining the steepness of sigmoidal decline 
in the exponent; m = the exponent of bodyweight on V2.
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Figure 4-1 Plots of post hoc and population clearance values versus bodyweight.
For the 3/4 allometric model (Model I), ○: individual post hoc clearances, solid line: population predicted 
clearance curve; the mixture model (Model II), ■: individual post hoc clearances of POP
1
, ○: individual 
post hoc clearances of POP
2
, dashed line: population predicted clearance curve of the POP
1
, solid line: 
population predicted clearance curve of POP
2
; the bodyweight-cut-point separated model (Model 
III), ■: individual post hoc clearances of POP
bw<d
, ○: individual post hoc clearances of POP
bw≥d
, dashed 
line: population predicted clearance curve of the POP
bw<d
, solid line: population predicted clearance 
curve of POP
bw≥d
; the bodyweight-dependent exponent (BDE) model (Model IV), ○: individual post hoc 
clearances, solid line: population predicted clearance curve.
Concerning other parameters than clearance, a linear function for bodyweight 
on V1 for the children who were younger than 100 days was identified, 
while for V2 a power equation based on bodyweight was found. Inclusion 
of these covariates resulted in a further decrease of 91.7 point (p<0.001) in 
the OFV compared to Model IV. The observed versus population predicted 
plots stratified by study in Figure 4-3 confirm that the final model not only 
describes the study population as a whole, but also describes the individual 
study populations without bias. Results of the bootstrap analysis show that the 
median estimated values based on resampled data were close to the estimated 
values from the final model fit of the original data and that all CV percentages 
are below 50%. This suggests the final model to be stable and the estimated 
26664_Chenguang Wang.indd   75 23-09-13   10:37
Chapter 4
76
parameter values to be accurate and precise. The results of the bootstrap are of 
particular relevance for the parameters that were fixed in model IV, i.e. k
0
 and 
g, as they justify the actual value these parameters were fixed to. Furthermore, 
the results from the normalized prediction distribution errors (NPDE) analysis 
in Figure 4-4 show that the model can predict the median concentration in the 
overall dataset accurately, even though there is a slight over-prediction of the 
variability in the model. Finally, no trend in the plots of NPDE versus time and 
predicted concentration were observed.
Figure 4-2 The relationship between the allometric exponent k (equation 5) for clearance 
and bodyweight in the bodyweight-dependent exponent (BDE) model (Model IV).
The parameter k
0
 represents the value of the exponent at a theoretical bodyweight of 0 kg, k
max
 
represents the maximum decrease of the exponent, k
50
 represents bodyweight at which 50% of the 
maximum decrease in the exponent is attained, and γ represents the Hill coefficient that determines the 
steepness of the sigmoidal decline.






, and g of the 
bodyweight dependent exponent k of equation 5 results in different curves 
for clearance versus bodyweight, including the observed curve in the current 
analysis on propofol clearance. This figure illustrates that the developed 
bodyweight-dependent exponent model is capable of capturing different 
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maturation profiles of clearance versus bodyweight allowing in principle to be 
applied to different drugs and/or different metabolic pathways.
Figure 4-3 Observed versus population predicted propofol concentrations of the 
bodyweight-dependent exponent model (Model IV).
‘All’ presents data of all datasets together. Other panels represent data of neonates [24], infants [25], 
toddlers [26], children [27], adolescents [15], adults I [28] and adults II [29].
4.4. Discussion
In this study, we tested four different allometric equations to capture changes in 
propofol clearance in seven datasets comprising almost every stage of human 
life. We found that fixing the allometric exponent to 0.75 (the ¾ allometric 
model, Model I) resulted in adequate description of clearance in adults, 
adolescents, children and toddlers, but yielded significant under-prediction in 
infants and over-prediction in term and preterm neonates. Results of the mixture 
model (Model II) and the bodyweight-cut-point separated model (Model III) 
showed that an allometric exponent other than 0.75 was more suitable for 
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neonates and infants. In fact, both models identified an allometric exponent 
greater than 1 for the subpopulation that was composed of mainly neonates 
and infants resulting in improved description of clearance in these youngest 
and lightest patient groups in comparison with the ¾ allometric model. This 
has been reported before for morphine clearance in children younger than 
3 years of age, where an exponent of 1.44 was found to best describe the 
developmental changes in clearance [22]. Similarly, Mahmood reported that 
the error in the prediction of clearance decreased when the scaling exponent 
increased from 0.75 towards 1 when studying different drugs in children 
less than 1 year of age [13]. Even though the overall performance improved 
significantly, the use of two different allometric exponents for different human 
subpopulations as implemented in Model II and Model III resulted in ambiguous 
clearance predictions for the individuals on the boundaries of the paediatric 
subpopulations. In the current study, the observed issue of different exponents 
at different weight ranges was overcome by implementing an allometric 
equation with an exponent that varies with bodyweight. This bodyweight-
dependent exponent (BDE) model contains a continuous bodyweight-based 
equation which allowed for the best description of maturational changes in 
propofol clearance in individuals covering the entire human life-span. While 
the current model needs to be further evaluated in an external validation 
procedure, according to the advanced model evaluation criteria for pediatric 
population models [30], the descriptive and predictive performances of this 
model were affirmed by stratified diagnostics (Figure 4-3), bootstrap validation 
(Table 4-4), NPDE (Figure 4-4), and %RMSE results (Table 4-3).
Figure 4-4 NPDE results of the final PK model for propofol. Left panel: histogram of NPDE 
distribution in the full dataset with the solid line representing a normal distribution as a 
reference; Middle panel: NPDE versus time; Right panel: NPDE versus log transformed 
concentration.
An important question is whether this bodyweight-dependent exponent may 
reflect underlying physiological maturation processes. Unfortunately, we were 
26664_Chenguang Wang.indd   78 23-09-13   10:37




not able to establish a direct link between the change in exponent and the 
physiological maturation process, due to the lack of physiological information in 
our data. The results of this study are therefore to be compared to other studies. 
The reported high value of the exponent at very low bodyweights (Figure 4-2), 
is the result of rapid changes in propofol clearance with bodyweight at these 
young age ranges (Figure 4-1, model IV). The lower value for the exponent 
at higher weight ranges, results from the accomplishment of the maturation 
process of propofol clearance (Figure 4-2). According to the well-stirred model, 
hepatic clearance is determined by hepatic extraction ratio and liver blood 
flow. As propofol is a drug with a high extraction ratio, systemic clearance is 
driven by liver blood flow [36, 37]. While there are no good data on hepatic 
blood flow in relation to age, hepatic blood flow in infants was suggested to 
be comparable to adult values. Therefore maturation of metabolic capacity 
could be considered the cause of the rapid changes in clearance in the young 
individuals [38]. For propofol, glucuronidation by the UGT1A9 isoenzyme is 
the major elimination pathway. UGT1A9 was reported to undergo an age-
dependent quantitative differential regulation extending up to 24 months of 
age [39], and it was found that only part of the reduced glucuronidation rate 
was compensated by hydroxylation in neonates [40]. Even though this cannot 
be proven, it can be speculated that the rapid change in the bodyweight-
dependent exponent at low bodyweight ranges may be the result of the 
change in the capacity of the UGT1A9 isoenzyme.
In recent years, there has been a debate on how bodyweight and age, 
which are two correlated covariates in the paediatric population, should be 
included in population pharmacokinetic models. It has been proposed that 
the ¾ allometric equation can be used to standardize drug clearance to the 
average adult bodyweight of 70 kg, after which age-based equations can be 
added to account for maturational differences in the younger populations 
compared to the older ones [1, 41]. These age based functions are needed 
because poor prediction performance of the ¾ allometric model can be 
expected when scaling clearance to children under a certain age [15-17]. 
However, this addition of age to the ¾ allometric bodyweight based scaling 
function may result in collinearity. The effect of the collinearity on parameter 
estimates in nonlinear mixed effect models has already been studied and it was 
found that high collinearity between predictors, defined as data collinearity, 
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increased the bias of the parameter estimates and enlarged the corresponding 
standard errors [20]. More recently, it has been shown that when one of two 
correlated covariates that contain information about a model parameter is 
pre-selected over the other, the predictive performance of the resulting model 
may be diminished, unless the pre-selected covariate relationship reflects the 
true biological relationship [21]. With the great amount of theoretical and 
experimental evidence against the ¾ allometric model [6-12, 14], and the 
risk of collinearity when introducing age to correct for deviations from this 
model, new scaling approaches are needed. As such, data-driven approaches, 
as applied in the current analysis, are more suitable for the development of 
population pharmacokinetic models thereby resulting in a continuous function 
using only bodyweight as a covariate.
Figure 4-5 Simulations for the bodyweight-dependent exponent (BDE) model (Model IV) on 
the basis of different values for the parameters of Model IV (equation 5).
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The bodyweight-dependent exponent model we described in this paper 
is of particular relevance for scaling clearance parameters to the youngest 
age ranges including infants, term and preterm neonates. Since in these 
age groups changes in the pharmacokinetics may be expected to be large, 
there is currently great interest in scaling clearance parameters from older 
populations to neonates or infants younger than 2 years of age [15, 16, 42]. It 
is however uncertain whether the parameters of the bodyweight-dependent 
exponent model we developed for propofol can be generalized to other drugs. 
Propofol has very specific characteristics such as a high extraction ratio, direct 
glucuronidation and high lipophilicity. However, as Figure 4-5 shows, the 
function is very flexible, and in our opinion the proposed model can be applied 
to other drugs provided data in young children are available to estimate the 
exact parameters of equation 5 of the bodyweight dependent exponent model 
for that drug.
4.5. Conclusion
In this study, we have developed a model for scaling propofol clearance 
over the entire human life-span with a single continuous bodyweight based 
equation, in which the exponent of the equation varies with bodyweight. The 
flexibility of this bodyweight-dependent exponent (BDE) model may increase 
the applicability of this type of models to scale clearance of other drugs over 
large parts of the human life-span. This function may provide an alternative 
for allometric scaling approaches in the extrapolation of drug clearances from 
older to younger human age-ranges.
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Appendix: NONMEM code of the model
Model I: The ¾ allometric model
$SUBROUTINE ADVAN11 TRANS4 
$PK    
TVCL = THETA(1)*(BW/70)**0.75    
CL   = TVCL*EXP(ETA(1))    
Q2   = THETA(2)*EXP(ETA(2))    
Q3   = THETA(3)*(BW/70)*EXP(ETA(3))    
V1   = THETA(4)*EXP(ETA(4))    
TVV2 = THETA(5)*(BW/70)    
V2   = TVV2*EXP(ETA(5))    
V3   = THETA(6)*(BW/70)*EXP(ETA(6))    
S1   = V1    
ETCL =ETA(1)    
ETQ2 =ETA(2)    
ETQ3 =ETA(3)    
ETV1 =ETA(4)    
ETV2 =ETA(5)    
ETV3 =ETA(6) 
;------------------------------------------------------------------------- 
$ERROR    
W=1       
IPRED = LOG(.000001)    
IF (F.GT.0) IPRED=LOG(F)    
IRES=DV-IPRED    
IWRES=IRES/W    
Y=IPRED+W*ERR(1) 
;------------------------------------------------------------------------- 
$THETA    
( 0, 1.6,  )   ; TH1 CL    
( 0, 1.7,  )   ; TH2 Q2    
( 0, 1.5,  )   ; TH3 Q3    
( 0, 4,    )   ; TH4 V1    
( 0, 15,   )   ; TH5 V2    
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( 0, 200,  )   ; TH6 V3
 
$OMEGA    
0.4     ; OMEGA1 CL    
0 FIX   ; OMEGA2 Q2    
0.2     ; OMEGA3 Q3    
1       ; OMEGA4 V1    
0.6     ; OMEGA5 V2    
0.3     ; OMEGA6 V3
 
$SIGMA    
0.1     ; SIGMA1 
$EST NOABORT PRINT=15 MAXEVALS=9999 METHOD=1 INTERACTION 
$COV COMP PRINT=E
Model II: The mixture model
$DATA analysis.csv IGNORE=# 
$SUBROUTINE ADVAN11 TRANS4 
$PK    
IF (MIXNUM .EQ. 1) THEN    
TVCL = THETA(1)*(BW/70)**THETA(7) 
ELSE    
TVCL = THETA(8)*(BW/70)**THETA(9) 
ENDIF    
CL   = TVCL*EXP(ETA(1))    
Q2   = THETA(2)*EXP(ETA(2))    
Q3   = THETA(3)*(BW/70)*EXP(ETA(3))   
V1   = THETA(4)*EXP(ETA(4))   
TVV2 = THETA(5)*(BW/70)    
V2   = TVV2*EXP(ETA(5))    
V3   = THETA(6)*(BW/70)*EXP(ETA(6))    
S1   = V1    
ETCL = ETA(1)    
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ETQ2 = ETA(2)    
ETQ3 = ETA(3)    
ETV1 = ETA(4)    
ETV2 = ETA(5)    
ETV3 = ETA(6)    
EST  = MIXEST
 ;------------------------------------------------------------------------- 
$MIX    
NSPOP=2    
P(1)=THETA(10)    
P(2)=1-P(1) 
;------------------------------------------------------------------------- 
$ERROR    
W=1       
IPRED = LOG(.000001)    
IF (F.GT.0) IPRED=LOG(F)    
IRES=DV-IPRED    
IWRES=IRES/W    
Y=IPRED+W*ERR(1) 
;------------------------------------------------------------------------- 
$THETA    
( 0, 2,     )   ; TH1 CL OF SUBPOP2 WITH HIGH EXP    
( 0, 1,     )   ; TH2 Q2    
( 0, 1.5,   )   ; TH3 Q3    
( 0, 4,     )   ; TH4 V1    
( 0, 15,    )   ; TH5 V2    
( 0, 200,   )   ; TH6 V3    
( 0, 1.3,   )   ; TH7 BW EXPONENT OF SUBPOP1 WITH HIGH EXP    
( 0, 1.5,   )   ; TH8 CL OF SUBPOP2 WITH LOW EXP    
( 0, 0.6,   )   ; TH9 BW EXPONENT OF SUBPOP2 WITH LOW EXP    
( 0, 0.2, 1 )   ; TH10 PORTION OF SUBPOP1 
$OMEGA    
0.1     ; OMEGA1 CL    
0 FIX   ; OMEGA2 Q2    
0.2     ; OMEGA3 Q3    
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0.5     ; OMEGA4 V1    
0.5     ; OMEGA5 V2    
0.3     ; OMEGA6 V3 
$SIGMA    
0.1     ; SIGMA1 
$EST NOABORT PRINT=15 MAXEVALS=9999 METHOD=1 INTERACTION 
$COV COMP PRINT=E
Model III: The bodyweight-cut-point separated model
$SUBROUTINE ADVAN11 TRANS4 
$PK    
CUTP= THETA(10)    
IF (BW .GT. CUTP) 
THEN     
TVCL = THETA(1)*(BW/70)**THETA(7)    
ELSE      
TVCL = THETA(8)*(BW/70)**THETA(9)    
ENDIF    
CL   = TVCL*EXP(ETA(1))    
Q2   = THETA(2)*EXP(ETA(2))    
Q3   = THETA(3)*(BW/70)*EXP(ETA(3))   
 V1   = THETA(4)*EXP(ETA(4))    
TVV2 = THETA(5)*(BW/70)    
V2   = TVV2*EXP(ETA(5))    
V3   = THETA(6)*(BW/70)*EXP(ETA(6))    
S1   = V1    
ETCL = ETA(1)    
ETQ2 = ETA(2)    
ETQ3 = ETA(3)    
ETV1 = ETA(4)    
ETV2 = ETA(5)    
ETV3 = ETA(6) 




$ERROR    
W=1       
IPRED = LOG(.000001)    
IF (F.GT.0) 
IPRED=LOG(F)    
IRES=DV-IPRED    
IWRES=IRES/W    
Y=IPRED+W*ERR(1) 
;------------------------------------------------------------------------- 
$THETA    
( 0,  2.113,    )    ; TH1 CL OF SUBPOP1    
( 0,  1.869,    )    ; TH2 Q2    
( 0,  1.877,    )    ; TH3 Q3    
( 0,  6.216,    )    ; TH4 V1    
( 0,  20.59,    )    ; TH5 V2    
( 0,  194.2,    )    ; TH6 V3    
( 0,  0.5096,   )    ; TH7 BW EXPONENT OF SUBPOP1 WITH LOW EXP    
( 0,  18.01,    )    ; TH8 CL OF SUBPOP2    
( 0,  1.527,    )    ; TH9 BW EXPONENT OF SUBPOP2 WITH HIGH EXP     
16.5 FIX            ; TH10 CUT POINT OF BW   
$OMEGA    
0.193       ; OMEGA1 CL    
0 FIX       ; OMEGA2 Q2    
0.247       ; OMEGA3 Q3    
0.617       ; OMEGA4 V1    
0.781       ; OMEGA5 V2    
0.207       ; OMEGA6 V3   
$SIGMA    0.1         ; SIGMA1  
$EST NOABORT PRINT=15 MAXEVALS=9999 METHOD=1 INTERACTION 
$COV COMP PRINT=E
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Model IV: The bodyweight-dependent exponent (BDE) model
$SUBROUTINE ADVAN11 TRANS4 
$PK    
MDEX = THETA(7)     ;MSEX is the Maximum Decrease of Exponent    
EX0  = 0.556+MDEX     ;EX0  is the starting exponent    
EB50 = THETA(8)    
HILL = THETA(9)    
EX   = EX0-(MDEX*BW**HILL)/(EB50**HILL+BW**HILL)    
TVCL = THETA(1)*(BW/70)**EX    
CL   = TVCL*EXP(ETA(1))    
Q2   = THETA(2)*EXP(ETA(2))    
Q3   = THETA(3)*(BW/70)*EXP(ETA(3))    
V1   = THETA(4)*EXP(ETA(4))    
TVV2 = THETA(5)*(BW/70)   
 V2   = TVV2*EXP(ETA(5))    
V3   = THETA(6)*(BW/70)*EXP(ETA(6))    
S1   = V1    
 ;-------------------------------------------------------------------------- 
$ERROR    
W=1       
IPRED = LOG(.000001)    
IF (F.GT.0) IPRED=LOG(F)    
IRES=DV-IPRED    
IWRES=IRES/W    
Y=IPRED+W*ERR(1) 
;---------------------------------------------------------------------- 
$THETA    
( 0,   1.3,      )    ; TH1 CL    
( 0,   0.5,      )    ; TH2 Q2    
( 0,   0.8,      )    ; TH3 Q3    
( 0,   5,        )    ; TH4 V1    
( 0,   5,        )    ; TH5 V2    
( 0,   50,       )    ; TH6 V3    
( 0,   0.8,      )    ; TH7 MDEX    
( 1.5, 3.7,      )   ; TH8 EB50     
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5.1  FIX             ; TH9 HILL 
;---------------------------------------------------------------------------  
$OMEGA    
0.154   ; OMEGA1 CL    
0 FIX   ; OMEGA2 Q2    
0.199   ; OMEGA3 Q3    
0.5     ; OMEGA4 V1    
0.607   ; OMEGA5 V2    
0.304   ; OMEGA6 V3 
$SIGMA    0.15        ; ERROR 
$EST NOABORT PRINT=15 MAXEVALS=9999 METHOD=1 INTERACTION 
$COV COMP PRINT=E
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Introduction: Morphine clearance has been successfully scaled from preterm 
neonates to 3-year–old children on the basis of a bodyweight-based exponential 
function and age younger or older than 10 days. The aim of current study is 
to characterize the developmental changes in morphine clearance across the 
entire paediatric age-range.
Methods: Morphine and morphine-3-glucuronide (M3G) concentration data 
from 358 (pre)term neonates, infants, children and adults, and morphine 
concentration data from 117 adolescents were analyzed using NONMEM 7.2. 
Based on available data, two models were developed: I. using morphine data; 
II. using morphine and M3G data.
Results: In model I, morphine clearance across the paediatric age range was 
very well described by a bodyweight-based exponential function in which the 
allometric exponent decreased in a sigmoidal manner with bodyweight (BDE 
model) from 1.47 to 0.88, with half the decrease in exponent reached at 4.01 kg. 
In model II, the exponent for the formation and elimination clearance of M3G 
was found to decrease from 1.56 to 0.89 and from 1.06 to 0.61, with half the 
decrease reached at 3.89 and 4.87 kg, respectively. Using the BDE model, there 
was no need to use additional measures for size or age.
Conclusion: The BDE model was able to scale both total morphine clearance 
and glucuronidation clearance through the M3G pathway across all age-ranges 
between (pre)term neonates and adults by allowing the allometric exponent 
to decrease across the paediatric age range from values higher than 1 for 
neonates to values lower than 1 for infants and children.
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The pharmacokinetics of morphine have been widely studied in the paediatric 
population using different approaches and modeling techniques [1]. In paediatric 
population pharmacokinetic models, bodyweight was reported the most 
significant covariate for morphine clearance [2-4]. While a variety of bodyweight-
based functions has been used, i.e. exponential equations using a 0.75 fixed 
exponent or an estimated exponent of 1.44, in all models additional age-related 
variables were needed to adequately describe clearance across paediatric age-
ranges [1-5]. This may be explained by the fact that single exponent functions 
based on body weight may not be expected to be suitable for the prediction of 
drug clearance in children of all ages [6, 7]. However, as bodyweight and age are 
correlated in a complex and highly nonlinear manner as part of a child’s growth 
and development, the use of both bodyweight and age as covariates on a single 
parameter may harm the predictive performance of the resulting model [8, 9]. 
Additionally, many studies on morphine clearance in paediatrics are limited 
to small age-ranges [2-4, 10] and no study has proven adequate extrapolation 
potential outside the studied age-range. This highly limits the development of 
unambiguous continuous dosing guidelines for children.
Recently, a bodyweight dependent exponent (BDE) model was developed 
to scale clearance from preterm neonates to adults [11]. Using this function, 
clearance scales with bodyweight on the basis of an allometric function. 
However, because the allometric exponent is allowed to vary with bodyweight, 
the BDE function offers maximal flexibility to capture different maturation rates 
at varying stages of pediatric development [11]. Typically, this exponent k has 
a certain value k
0
 at a hypothetical bodyweight of 0 kg after which it decreases 
with bodyweight sigmoidally according to an Emax model [11]. More recently, 
also simplified decreasing functions on the basis of a power function have been 
proposed when a smaller weight range is concerned (i.e. lack of data of preterm 
neonates) [12]. In both analyses, the BDE function proved to optimally describe 
the changes in clearance between neonates and adults using bodyweight 
without of the need for a secondary age-related covariate [11, 12].
Therefore, in the current study, we analyzed morphine concentration – time 
profiles from 475 preterm and term neonates, infants, children, adolescents 
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and adults with the aim to characterize developmental changes in morphine 
clearance across the entire human lifespan. Given the strong evidence for a 
high maturation rate (exponent of 1.44) in children under the age of 3 years 
[4, 10] and the need to reach a plateau for the maturation rate at older age 
ranges with a lower value for the exponent, the recently developed BDE model 
was applied [11]. This analysis also allows us to study whether the changes in 
clearance of morphine and its metabolite can be described by the BDE function 
without subsequent need for additional age-related covariates.
5.2. Methods
5.2.1. Subjects
Morphine concentration – time data from a total of 475 subjects participating 
in eight different clinical studies [13-20] were included in the current analysis. 
Studies represented three age groups: neonates and young children (0-3y), 
older children and adolescents (6-15y), adults (18-36y) (Table 5-1). The studies 
were performed at different centers in different countries resulting in the 
administration of two different morphine salts. To compare the administered 
doses, the amount of administered morphine base was calculated for each 
individual in each study.
Neonates and Young children [13-18]
Morphine and morphine-3-glucuronide (M3G) metabolite concentrations 
in 338 pediatric patients (age 0.1-1070 days; bodyweight 0.57-16.8 kg) of six 
different studies [13-18] were included in our analysis. Detailed demographic 
and clinical information on the patients in the six studies can be found in 
original publications [13-18]. In Table 5-1, a summary of patient demographics 
is presented of these six studies.
Older children and Adolescents [19]
The study in older children and adolescents was a prospective, genotype blinded, 
clinical observational study to investigate the impact of race and genotype 
on morphine clearance [19]. Children of all races aged 6-15 years scheduled 
for elective adenotonsillectomy with American Society of Anesthesiologists 
(ASA) physiological status 1 or 2 were included. As African-American children 
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were found to have higher morphine clearance than Caucasian children [19], 
we excluded 29 African subjects out of the total of 146 subjects, leaving 117 
patients aged between 6 – 15 years with a bodyweight between 17.9 – 79.5 kg) 
for our modeling analysis (Table 5-1).
Table 5-1 Overview of the datasets used to develop the population PK model for parent 
morphine (Model I) and for parent morphine and M3G metabolite (Model II).





neonates, infants and 
children





Preterm and term 
neonates on artificial 
ventilation





Preterm neonates on 
artificial ventilation














9 2.64–8.1 1–271 
days
Morphine: 16 [17]
Term neonates and 
infants on artificial 
ventilation








Older children and 
Adolescents after 
adenotonsillectomy
117 17.9–79.5 6–15 
years
Morphine: 264 [19]





M; morphine; M3G: morphine-3-glucuronide
Adults [20]
This prospective study compared the analgesic effects of a bolus and short 
infusion of morphine in healthy male and female volunteers [20]. Twenty 
healthy non-obese adults were given 0.1mg/kg intravenous bolus of morphine 
followed by an infusion of 0.03 mg×kg-1×h-1 for 1 hour after which15 samples 
per individual were collected.
5.2.2. Pharmacokinetic Modeling
The population pharmacokinetic analysis was performed with the non-linear 
mixed effects modeling software NONMEM version 7.2. (ICON Development 
Solutions, Ellicott City, MD, USA) using the first-order conditional estimation 
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method with the interaction option (FOCEI). The S-PLUS interface for NONMEM 
(LAP&P Consultants BV, Leiden, NL), S-Plus (version 8.1, Insightful Software, 
Seattle, WA, USA), PsN, Pirana and R (version 2.14.2) were used to visualize the 
output and evaluate the models.
Structural model
As morphine concentrations were available for all three age groups whereas 
M3G metabolite concentrations were only available in neonates and young 
children and adults (not in older children and adolescents), two different 
structural models were used in our pharmacokinetic analysis.
Parent morphine model (Model I)
A two-compartment structural model [4] was applied to the parent morphine 
concentration data for all three age groups depicted in Table 5-1.
Parent morphine and M3G metabolite model (Model II)
A two-compartment structural model for parent morphine and a one 
compartment structural model for M3G [4] was applied to parent morphine 
and M3G metabolite concentration data that were available in datasets of 
neonates and young children and the adult population (Table 5-1).
Statistical model
The inter-individual variability on morphine and M3G clearance and volumes 
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where   is the individual parameter value for i-th individual,  is the population parameter 
value, and  is a random variable from a normal distribution with mean zero and variance . 
All concentration data were log-transformed in the analysis. An additive residual error model 
was applied on the log-transformed data, which corresponds to the proportional error on the 
linear scale, expressed as: 
    ,          [eq.2] 
where  is the observed concentration of i-th individual at time j and  is the 
corresponding predicted concentration.  is a random variable from a normal distribution 
with mean zero and variance .  
Covariate model 
The BDE function, as shown in equation 3 [eq.3], was applied to the total morphine clearance 
in Model I and the formation clearance of morphine-3-glucuronide and the elimination 
clearance of the morphine-3-glucuronide in Model II: 
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standardized adult with a bodyweight of 70 kg;  is bodyweight of an individual i; k is the 
exponent; k0 is the value of the exponent at a theoretical bodyweight of 0 kg; kmax is the 
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The BDE function, as shown in equation 3 [eq.3], was applied to the total morphine clearance 
in Model I and the formation clearance of morphine-3-glucuronide and the elimination 
clearance of the morphine-3-glucuronide in Model II: 
        ,         [eq.3] 
in which  is clearance in the i-th individual with bodyweight ;  is the clearance in a 
standardized adult with a bodyweight of 70 kg;  is bodyweight of an individual i; k is the 
exponent; k0 is the value of the exponent at a theoretical bodyweight of 0 kg; kmax is the 
maximum decrease of the exponent; k50 is the bodyweight at which a 50% decrease in the 
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 is the observed concentration of i-th individual at time j and C
predij
 
is the corresponding predicted concentration. e
ij
 is a random variable from a 
normal distribution with mean zero and variance s2.
Covariate model
The BDE function, as shown in equation 3 [eq. 3], was applied to the total 
morphine clearance in Model I and the formation clearance of morphine-3-
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the clearance in a standardized adult with a bodyweight of 70 kg; BW
i
 is 
bodyweight of an individual i; k is the exponent; k
0
 is the value of the exponent 
at a theoretical bodyweight of 0 kg; k
max
 is the maximum decrease of the 
exponent; k
50
 is the bodyweight at which a 50% decrease in the maximum 
decrease of exponent value is attained, and γ is the Hill coefficient determining 
the steepness of sigmoidal decline in the exponent.
Beside the BDE function for bodyweight that was tested on the different 
clearance parameters, bodyweight was tested in a linear or power function on 




maximum decrease of exponent value is attained, and γ is the Hill coefficient determining the 
steepness of sigmoidal decline in the exponent.  
Beside the BDE function for bodyweight that was tested on the different clearance 
parameters, bodyweight was tested in a linear or power function on other pharmacokinetic 
parameters, as shown in equation 4 [eq.4]: 
            [eq.4] 
In this equation,  is the parameter of i-th individual with bodyweight ;  is the parameter 
standardized adult with a bodyweight of 70kg;  is bodyweight of an individual i. In case of 
a power function, m represents the exponent value, while for a linear relationship m is fixed to 
1.  
The covariate was included in the model if the decrease in objective function value (OFV) was 
greater than 7.88 points, which correspo nds to p<0.005 in the Chi-square test. In addition, 
criteria as defined under Model Validation were considered. 
5.2.3. Model Validation 
The two models were validated internally using five criteria that were recently proposed for 
pediatric population model evaluation [5]. (i) It was checked whether the coefficient of 
variation (CV) of the parameter estimates either from the covariance step in NONMEM or 
from stratified bootstrap resampling results was less than 50%. (ii) The basic diagnostic plots 
and particularly the plots of the observed versus population predicted concentrations stratified 
for age, were visually assessed for bias. (iii) The η-shrinkage was calculated according to 
Karlsson and Savic was considered [21]. (iv) The individual and population predicted 
parameters were plotted against bodyweight to evaluate whether the individual predicted 
parameters were equally distributed around the population predicted parameters. (v) The 
simulation-based normalized prediction distribution error (NPDE) proposed by Brendel et al 
[22], was calculated based on 2,000 simulations of the entire dataset and were evaluated 
visually for bias and precision. 
5.3. Results 
For the analysis, data of 475 subjects varying from preterm and term neonates to adults were 
available from eight different clinical studies (Table 5-1). Data of all 475 subjects were used in 
the model describing the time-course of the parent drug concentration (parent morphine 
model; Model I), whereas data of 358 individuals in which both morphine and M3G 
concentrations were available, were used to describe the time-course of both morphine and 
M3G concentration (parent morphine and M3G metabolite model; Model II). A summary of the 
available datasets is given in Table 5-1.  
(eq. 4)
In this equation, q
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 is the parameter standardized adult with a bodyweight of 70kg; BW
i
 is 
bodyweight of an individual i. In case of a power function, m represents the 
exponent value, while for a linear relationship m is fixed to 1.
The covariate was included in the model if the decrease in objective function 
value (OFV) was greater than 7.88 points, which corresponds to p<0.005 in the 
Chi-square test. In addition, criteria as defined under Model Validation were 
considered.




The two models were validated internally using five criteria that were recently 
proposed for pediatric population model evaluation [5]. (i) It was checked 
whether the coefficient of variation (CV) of the parameter estimates either 
from the covariance step in NONMEM or from stratified bootstrap resampling 
results was less than 50%. (ii) The basic diagnostic plots and particularly the 
plots of the observed versus population predicted concentrations stratified 
for age, were visually assessed for bias. (iii) The η-shrinkage was calculated 
according to Karlsson and Savic was considered [21]. (iv) The individual and 
population predicted parameters were plotted against bodyweight to evaluate 
whether the individual predicted parameters were equally distributed around 
the population predicted parameters. (v) The simulation-based normalized 
prediction distribution error (NPDE) proposed by Brendel et al. [22], was 
calculated based on 2,000 simulations of the entire dataset and were evaluated 
visually for bias and precision.
5.3. Results
For the analysis, data of 475 subjects varying from preterm and term neonates 
to adults were available from eight different clinical studies (Table 5-1). Data 
of all 475 subjects were used in the model describing the time-course of the 
parent drug concentration (parent morphine model; Model I), whereas data 
of 358 individuals in which both morphine and M3G concentrations were 
available, were used to describe the time-course of both morphine and M3G 
concentration (parent morphine and M3G metabolite model; Model II). A 
summary of the available datasets is given in Table 5-1.
A BDE model in which the exponent decreased with bodyweight in a sigmoidal 
manner [eq. 3] very well described the developmental changes in total clearance 
of morphine (CLT) in the parent morphine model (Model I). Similarly, a BDE 
model well described changes in the formation clearance of M3G (CLM
M3G
) and 
the elimination clearance of M3G (CLE
M3G
) across all ages in the parent morphine 
and M3G metabolite model (Model II). Figure 5-1 (upper panels) shows the post 
hoc estimates of total morphine clearance, formation clearance of M3G and 
elimination clearance of M3G versus bodyweight (η-shrinkage values being 
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24.9%, 18.9% and 20.4%, respectively). The lower panels in Figure 5-1 show 
how the bodyweight-dependent exponent (k) of total morphine clearance, 
formation clearance of M3G and elimination clearance of M3G was found to 
change with bodyweight. For the parent morphine model (Model I), the value of 
k for CLT dropped from 1.47 (k
0





) and reached half this decrease at 4.01 kilogram (k
50
) (see Table 
5-2 for estimated parameters for the exponent k). For parent morphine and 
M3G metabolite model (Model II), the value of k for CLM
M3G
 dropped from 1.56 
(k
0




) and reached 
half this decrease at 3.89 kilogram (k
50









) and reached half this decrease at 4.87 kilogram 
(k
50
) (see Table 5-3 for estimated parameters for the exponent k).
Table 5-2 Parameter estimates of the parent morphine model (Model I).
Parameter Estimated value Bootstrap §
Fixed Effect
CLT (L/min) CLT = TVCLT × (BW/70) k
TVCLT (L/min•70kg) 1.62 (5.3%) 1.63 (6.1%)




·BW γ / (k
50
γ + BW γ )
     k
0
 1.47 (3.7%) 1.47 (5.8%)
     k
max
 0.59 (4.7%) 0.59 (9.3%)
     k
50
 (kg) 4.01 (3.9%) 4 (4.1%)
     γ 4.62 (9.5%) 6.4 (88.5%)
Q (L/min) Q = TVQ × (BW/70)
TVQ (L/min•70kg)
   Pop ≠ 2 1.9 (9.6%) 1.95 (11.9%)
   Pop = 2 0.5 (19%) 0.49 (16.1%)
Vc  (L) Vc = TVVc × (BW/70)
TVVc (L/70kg)
   Pop ≠ 2 81.2 (7.8%) 79.16 (6.4%)
   Pop = 2 46 (5.1%) 45.44 (3.8%)
Vp (L) Vp = TVVp × (BW/70)
TVVp (L/70kg) 128 (8%) 129.91 (7.2%)
Inter-individual variability
ω2 (CLT) 0.16 (6.9%) 0.156 (12.9%)
ω2 (Vc) 0.25 (27.5%) 0.24 (43.6%)
Residual error
σ2 0.19 (8.7%) 0.19 (7.7%)
σ2 for time>1900min 0.46 (113.2%) 0.79 (76.9%)
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CLT: total morphine clearance; TVCLT: CLT normalized to bodyweight value of 70kg; BW: bodyweight in 
kilogram; k: bodyweight dependent exponent (BDE) on BW for total clearance; k
0
: BDE at the theoretical 
bodyweight of zero; k
max
: maximum decrease of the exponent; k
50
: the bodyweight at which a 50% 
decrease in the maximum decrease of exponent is attained; γ is the Hill coefficient determining the 
steepness of sigmoidal decline in the exponent; Q: inter-compartmental clearance; TVQ: Q normalized 
to bodyweight value of 70kg Vc: volume of distribution of the central compartment of morphine; TVVc: 
Vc normalized to bodyweight value of 70kg; Pop=2: population of older children and adolescents; Pop ≠ 
2: population of neonates and young children or adults; Vp: the volume of distribution of the peripheral 
compartment of morphine; TVVp: Vp normalized to bodyweight value of 70kg; ω2 variance of the normal 
distribution that quantifies the inter-individual variability on the designated parameter according to 
equation 1; σ2: variance of the normal distribution that quantifies the residual error of the morphine 
observations according to equation 2; σ2 for time>1900min: variance of the normal distribution that 
quantifies the residual error of extra additive error for concentrations of morphine when the time after 
dose is beyond 1900 minutes [4]
§ Bootstrap mean and CV percentage
Figure 5-1 Post hoc clearance values of total clearance, formation clearance of M3G, and 
elimination clearance of M3G and values of the corresponding bodyweight dependent 
exponent (k) versus bodyweight from Model I (parent morphine model) and Model II (parent 
morphine and M3G metabolite model).
Upper panels: open circles are post hoc values of total clearance (A), formation clearance of M3G (B), or 
elimination clearance of M3G (C); solid curves are corresponding model predicted values.
Lower panels: k is the bodyweight dependent allometric exponent (eq.3) of total clearance (A), formation 
clearance of M3G (B), or elimination clearance of M3G (C); k
0
 is the value of the exponent at a theoretical 
bodyweight of 0 kg; k
max
 is the maximum decrease of the exponent; k
50
 is the bodyweight at which a 50% 
decrease in the maximum decrease of exponent is attained; upper blue dash line is the reference line of 
k
0




; red vertical dash line is the reference line of k
50
.
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Figure 5-2 Age-stratified observed versus population predicted log-transformed 
concentrations of morphine from Model I (parent morphine model) and of parent morphine 
and M3G metabolite from Model II (parent morphine and M3G metabolite model)





the parent morphine and M3G metabolite model (Model II), no additional 
covariates could be identified based on visual inspection of the corresponding 
inter-individual variability against covariate plot and given the criteria as 
defined under Methods (Covariate Model and Model Validation). In the parent 
morphine model (Model I), bodyweight was identified as a covariate in a linear 
equation for volume of distribution of the central compartment of morphine 
(Vc), volume of distribution of the peripheral compartments of morphine 
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(Vp), and inter-compartmental clearance (Q) (Table 5-2). In addition, lower 
bodyweight normalized population values of Q and Vc were identified for 
the older children and adolescents (0.071 L/kg/min and 0.66 L/kg) compared 
to children younger than 3 years and adults (0.027 L/kg/min and 1.16 L/kg) 
(Table 5-2). In the parent morphine and M3G metabolite model (Model II), 
bodyweight was identified as a covariate in a linear equation for clearance 
of morphine through other routes than M3G (CL
0
), volume of distribution 
of the central compartment of morphine (Vc), volume of distribution of 
the peripheral compartments of morphine (Vp), and inter-compartmental 
clearance (Q) (Table 5-3). For the volume of distribution of M3G (V
M3G
), a 
population value of 20L was estimated, which proved in accordance with 
literature [23] and which was later on fixed to this value in order to achieve 
successful minimization with a covariance step. V
M3G
 was found to vary with 
bodyweight, which was best described by a power function with an estimated 
exponent value of 0.71. In both the parent and the parent and metabolite 
model (Model I and Model II respectively), no other covariates were identified 
on any of the other parameters based on the criteria as described in section 
Methods (Covariate Model and Model Validation).
Figure 5-2 shows that both the parent morphine model (Model I) and 
the parent morphine and M3G metabolite model (Model II) described the 
morphine and M3G concentration data in all different age groups well. The 
NPDE analysis as a simulation based validation method, shows that morphine 
and M3G concentrations in the models were normally distributed around the 
median prediction and that there was no trend in the NPDE versus TIME and 
versus the log-transformed individual predicted concentrations (Figure 5-3). 
All parameter estimates and results of the bootstrap validation of the parent 
morphine model (Model I) and the parent morphine and M3G metabolite 
model (Model II) are listed in Table 5-2 and Table 5-3, respectively.
Figure 5-4 illustrates that postnatal age (PNA) younger or older than 10 days, 
which was reported as a covariate for morphine glucuronidation clearance in a 
previous study in children younger than 3 years of age [4], was not a covariate 
for clearance in the final model of the current study.
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Table 5-3 Parameter estimates of the parent morphine and M3G metabolite model (Model II 
(based on morphine and M3G concentrations)).











 (L/min•70kg) 1.67 1.66 (5.2%)






·BW γ / (k
50
γ + BW γ )














(kg) 3.89 3.91 (3.8%)









 × (BW/70) k 
TVCLE
M3G
 (L/min•70kg) 0.23 0.22 (7.1%)






·BW γ / (k
50
γ + BW γ )














 (kg) 4.87 4.68 (6.4%)












 (L/min•70kg) 0.06 0.06 (40.3%)
Q (L/min) Q = TVQ × (BW/70)
TVQ (L/min•70kg) 4.2 4.12 (4.9%)
Vc  (L) Vc = TVVc × (BW/70)
TVVc (L/70kg) 29.3 27.67 (13.5%)
Vp (L) Vp = TVVp × (BW/70)







 × (BW/70) p
V
M3G
 (L/70kg) 20 FIX 20 FIX











ω2 Vc 0.51 0.47 (26.4%)





σ2 additive morphine 0.20 0.19 (8.1%)
σ2 additive M3G 0.14 0.13 (10.1%)
σ2 for time>1900min 1.85 1.92 (32.5%)
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CLMM3G: formation clearance of morphine-3-glucuronide; TVCLMM3G: CLMM3G normalized to 
bodyweight value of 70kg; BW: bodyweight in kilogram; CLEM3G: elimination clearance of morphine-
3-glucuronide; TVCLEM3G: CLEM3G normalized to bodyweight value of 70kg; k: bodyweight 
dependent exponent (BDE) of BW CLMM3G or CLEM3G; k0: BDE at the theoretical bodyweight of 
zero; kmax: maximum decrease of the exponent; k50: the bodyweight at which a 50% decrease in 
the maximum decrease of exponent is attained; γ is the Hill coefficient determining the steepness 
of sigmoidal decline in the exponent; CL0: clearance of morphine via other elimination routes; 
TVCL0: CL0 normalized to bodyweight value of 70kg; Q: inter-compartmental clearance; TVQ: Q 
normalized to bodyweight value of 70kg; Vc: the volume of distribution of the central compartment 
of morphine; TVVc: Vc normalized to bodyweight value of 70kg; Vp: the volume of distribution of 
the peripheral compartment of morphine; TVVp: Vp normalized to bodyweight value of 70kg; VM3G: 
volume of distribution of the morphine-3-glucuronide; TVVM3G: VM3G normalized to bodyweight 
value of 70kg; p: exponent value of the power function of BW for VM3G; ω
2 variance of the normal 
distribution that quantifies the inter-individual variability on the designated parameter according to 
equation 1; σ2: variance of the normal distribution that quantifies the residual error of the morphine 
or morphine-3-glucuronide observation according to equation 2; σ2 for time>1900min: variance of 
the normal distribution that quantifies the residual error of extra additive error for concentrations 
of morphine or morphine-3-glucuronide when the time after dose is beyond 1900 minutes [4]
§ Bootstrap mean and CV percentage
Figure 5-3 NPDE results of morphine concentrations from Model I (parent morphine model) 
and parent morphine and M3G metabolite concentrations from Model II (parent morphine 
and M3G metabolite model).
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Morphine is metabolized mainly through glucuronidation mediated by the 
enzyme UDP-glucuronosyltransferase 2B7 (UGT2B7), which was reported to 
be expressed at very low levels in early life [24-26]. In the past, several models 
have been developed to describe the changes in glucuronidation clearance 
of morphine and to predict its clearance in children for the purpose of dosing 
guidance [2-4]. Among those models, a model was developed for pediatric 
patients aged less than 3 years including preterm and term neonates [4], in 
which an allometric exponent value of 1.44 for morphine clearance was 
identified. Additional extensive investigations confirmed this finding using 
external data [10] and data from another UGT2B7 substrate [27]. Upon these 
studies, the allometric exponent of 1.44 for UGT2B7-mediated glucuronidation 
in children under the age of 3 years was proposed to be a system-specific 
parameter reflecting the maturation of the UGT2B7 enzyme in humans [27, 
28]. The current study confirms not only the validity of the exponent value as 
high as 1.44 in neonates and young infants given the estimated exponent at a 
hypothetical bodyweight of 0 kg of 1.56 in this study, but also provides a basis 
for extrapolation to older age-ranges by the quantification of the maturation 
of glucuronidation across the entire pediatric age-range with the estimation of 
a lower exponent for higher bodyweight ranges.
In this study, we successfully scaled morphine clearance from preterm and 
term neonates to infants, children, adolescents and adults using an allometric 
function, in which the exponent (k) was allowed to vary with bodyweight in a 
bodyweight-dependent exponent (BDE) function (eq.3). In both Model I and 
Model II of our study, the BDE function was able to capture the changes in 
the clearance parameters (total morphine clearance, formation of M3G, and 
elimination of M3G), such despite the fact that they were highly nonlinear 
in nature (Figure 5-1, upper panels). According to Karlsson and Savic [21], 
diagnostics based on the empirical Bayes estimates (EBE) should be assessed 
in combination with corresponding η-shrinkages as they may distort covariate 
relationships. Based on a simulation study, it was reported that EBE-based 
diagnostics generally lose their power with false indications starting to appear 
at a level of 20-30% [29]. In our study, the η-shrinkages of total clearance, 
formation clearance of M3G and elimination clearance of M3G were all below 
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25%, which is on the border of what is acceptable. In addition, both the age-
stratified goodness-of-fit diagnostic plots (Figure 5-2) and simulation based 
NPDE diagnostics (Figure 5-3) demonstrate good population and individual 
prediction performance of the final bodyweight-dependent exponent (BDE) 
models for concentrations of morphine and its M3G metabolite. Based on 
these results, it is concluded that the bodyweight-dependent exponent 
(BDE) model allows for the description of maturational changes in morphine 
glucuronidation clearance using a single continuous function, which has not 
been possible in previous attempts based on the use of allometric equations 
with single exponents [2-5].
Figure 5-4 Inter-individual variability of formation clearance of M3G from Model II (parent 
morphine and M3G metabolite model) stratified by postnatal age (PNA) of 10 days
filled circle: individuals PNA < 10 days; triangle: individuals PNA >= 10 days







 and γ, were found to be similar for total morphine clearance 
(parent morphine model; Model I) and formation clearance of M3G (parent 
morphine and M3G metabolite model; Model II). This result can in our opinion 
be explained by the fact that morphine-3-glucuronide is the major metabolite 
of morphine and glucuronidation of morphine is the rate-limiting step in the 
clearance of morphine. On the contrary, these sigmoidal equations describing 
the changes in the exponent k differed between the formation and elimination 
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of M3G (Figure 5-1, lower panel A and B versus C). In our view, these results can 
be explained by differences in maturation of the glucuronidation of morphine 
versus the renal elimination of M3G. Even though we do not intend to enforce 
any physiological meaning on the parameters in the BDE function, as the aim 
of this analysis was primarily to most optimally describe the observations from 
preterm neonates to adults, this limitation does in our opinion not preclude 
studies in which the parameters of the BDE function reported for morphine 
glucuronidation in this study are explored for the prediction of maturational 
changes in clearance of morphine or other drugs that are glucuronidated. In a 
similar manner, the parameters of the BDE function for the renal excretion of 
the M3G metabolite can be explored for its predictive value for the maturation 
in excretion of other renally excreted compounds as this approach may largely 
accelerate paediatric data analysis [27, 28].
Previously, for children younger than 3 years of age, postnatal age (PNA) of 
less than 10 days was identified as a separate covariate for formation clearance 
of M3G, M6G and their corresponding elimination clearances in addition to 
the allometric scaling function with an exponent of 1.44 [4]. While it has been 
suggested before that single allometric exponent functions would not be 
suitable for the prediction of drug clearance in children of different age-groups 
[6], different publications have confirmed this conclusion by reporting that 
an additional covariate function on the basis of an age-related covariate was 
needed when using single exponent functions [2-4]. In our study, we found an 
exponent that changed with bodyweight from an initial value at a hypothetical 
bodyweight of 0 kg of 1.47 and 1.56 for total clearance and formation clearance 
of M3G, respectively. While the initial value is in good agreement with the 
previously obtained value of 1.44, in the current analysis, no additional age 
or weight related covariates could be identified after inclusion of the (BDE) 
covariate model. From these results, it seems that the changes that were 
accounted for by the inclusion of the additional covariate relationship based 
on PNA [4] are now captured by the BDE function, in which the exponent was 
allowed to change with bodyweight being of specific relevance in the youngest 
age ranges (Figure 5-4). In this respect, Figure 5-5 illustrates these findings 
with a graphical comparison of post hoc values for glucuronidation clearance of 
morphine to M3G versus bodyweight between the previous model in children 
younger than 3 years [4] and Model II. In the figure, two parallel lines are placed 
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with different intercepts for subjects with PNA<10 days and PNA>=10 days at 
the lower end of the bodyweight range from our study (Figure 5-5 B), which 
were found to be quite similar to the patterns described by the previous model 
(Figure 5-5 A). The two simulated lines in Figure 5-5 B have slope values of 1.56, 
which corresponds with k
0
 in the BDE function for CLM
m3g
, and can roughly 
describe the changes in M3G formation clearance in children in two subgroups 
(PNA>10 days and PNA<10 days) up to a bodyweight of 10 kg. From this figure, 
it seems that applying an allometric function in which the exponent is allowed 
to vary with bodyweight itself results in an optimal description of the varying 
rates of maturation of glucuronidation clearance of morphine across all age 
ranges without the need for additional age-based covariates.
















































Figure 5-5 Comparison of formation clearance of M3G versus bodyweight in log-log scale 
between current Model II (parent morphine and M3G metabolite model) that included 
all age ranges except for older children and adolescents (B) and a previously published 
population model for morphine in children younger than 3 years by Knibbe et al. [4] (A). 
PNA=postnatal age.
(A): Orange filled triangle: children with PNA<10 days; Blue filled circle: children with PNA>= 10 days; 
Orange dotted line: Knibbe’s model [4] predicted clearance curve for PNA<10 days (CL (mL/min) = 3.48 
* BW1.44); Blue solid line: Knibbe’s model [4] predicted clearance curve for PNA>=10 days (CL (mL/min) 
= 8.62 * BW1.44) (B): Orange filled triangle = children with PNA<10 days; Blue filled circle: children with 
PNA>= 10 days; Green filled square: adults; Orange dotted line: simulated population clearance curve 
for PNA<10 days (CL (L/min) = 0.0023 * BW1.56); Blue solid line: simulated population clearance curve for 
PNA>=10 days (CL (L/min) = 0.0069 * BW1.56); Red dash line: the BDE model predicted clearance curve of 
Model II in which, 
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scale between current Model II (parent morphine and M3G metabolite model) that 
included all age ranges except for older children and adolescents (B) and a previously 
published population model for morphine in children younger than 3 years by Knibbe 
et al. [4] (A). PNA=postnatal age. 
 
(A): Orange filled triangle: children with PNA<10 days; Blue filled circle: children with PNA>= 10 days; Orange dotted 
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line: simulated population clearance curve for PNA>=10 days (CL (L/min) = 0.0069 * BW1.56); Red dash line: the BDE 
model predicted clearance curve of Model I  i  
 
 
The development of the bodyweight dependent exponent model was triggered by the reports 
that single exponent functions are not suitable for the prediction of drug clearance in children 
of all age ranges [6] and the idea of using a continuous function describing clearance across 
a large age-span without the need for an additional age based function [11]. Beside 
application to propofol [11], this BDE model has been successfully applied to busulfan [12] 
and midazolam[30], albeit in a simplified power equation ( ). However, in the 
current analysis on morphine glucuronidation clearance between preterm neonates and 
adults, the full sigmoidal BDE model was more appropriate. This was the result of the S-
shape in the double log plot of clearance versus bodyweight (Figure 5-1), which can be 
captured by the Emax function with Hill factor of the full BDE model [11], but not by the 
simplified function that consists of a power function [12, 30]. From these results it seems that 
the choice for a full BDE model which was applied in this study and for propofol, or for a 
simplified BDE model as applied for busulfan and midazolam is related to both the age range 
studied and the properties of the drug. Further study of the BDE model on datasets of other 
drugs across the entire paediatric age range will demonstrate in which cases the simplified or 
full BDE model is applicable. In any case, the choice for the final model should depend on the 
observed data in this data-driven approach whereby the model with the lowest number of 
parameters should be chosen (the principle of parsimony). 
The development of the bodyweight dependent exponent model was triggered 
by the reports that single exponent functions are not suitable for the prediction of 
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drug clearance in children of all age ranges [6] and the idea of using a continuous 
function describing clearance across a large age-span without the need for an 
additional age based function [11]. Beside application to propofol [11], this BDE 
model has been successfully applied to busulfan [12] and midazolam [30], albeit 
in a simplified power equation (). However, in the current analysis on morphine 
glucuronidation clearance between preterm neonates and adults, the full 
sigmoidal BDE model was more appropriate. This was the result of the S-shape 
in the double log plot of clearance versus bodyweight (Figure 5-1), which can be 
captured by the Emax function with Hill factor of the full BDE model [11], but not 
by the simplified function that consists of a power function [12, 30]. From these 
results it seems that the choice for a full BDE model which was applied in this 
study and for propofol, or for a simplified BDE model as applied for busulfan and 
midazolam is related to both the age range studied and the properties of the 
drug. Further study of the BDE model on datasets of other drugs across the entire 
paediatric age range will demonstrate in which cases the simplified or full BDE 
model is applicable. In any case, the choice for the final model should depend 
on the observed data in this data-driven approach whereby the model with the 
lowest number of parameters should be chosen (the principle of parsimony).
5.5. Conclusion
In this study, developmental changes in total morphine clearance were 
described in 475 preterm and term neonates, infants, children, adolescents 
and adults using an allometric function, in which the exponent decreased with 
bodyweight in a sigmoidal manner from 1.47 for preterm neonates to 0.88 in 
adults, with no need to use other body size or age-based measures. Similarly, 
we identified values for the exponent for formation clearance of M3G to vary 
from 1.56 to 0.89 while these values varied from 1.06 to 0.61 for elimination of 
M3G. From these results, it can be concluded that an allometric function with 
a bodyweight-dependent exponent (BDE) may be of great value when scaling 
clearance of drugs across the entire pediatric age-range.




This study was performed within the framework of Top Institute Pharma project 
number D2-104. The work of C.A.J. Knibbe is supported by the Innovational 
Research Incentives Scheme (Veni grant, July 2006) of the Dutch Organization 
for Scientific Research (NWO). The clinical study on morphine pharmacokinetics 
in older children and adolescents was supported in part by USPHS Grant #UL1 
RR026314 from the National Center for Research Resources, NIH and with 
the Place Outcomes Research Award and Translational Research Award (PI: 
Sadhasivam) and was supported by the Department of Anesthesia, Cincinnati 
Children’s Hospital Medical Center, Cincinnati, Ohio, USA. The authors would 
like to thank Dr. Richard van Lingen, Dr. Caroline van der Marel, Professor Imti 
Choonara and Professor Anne Lynn for their willingness to share their morphine 
and morphine-3-glucuronide data in children in this project.
26664_Chenguang Wang.indd   112 23-09-13   10:37





1. Krekels EH, Tibboel D, Danhof M, Knibbe CA. Prediction of Morphine Clearance in the Paediatric 
Population : How Accurate are the Available Pharmacokinetic Models? Clin Pharmacokinet. 
2012;51(11):695-709. doi:10.1007/s40262-012-0006-9.
2. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine 
and its metabolites in neonates, infants and young children. Br J Anaesth. 2004;92(2):208-17. 
3. Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B et al. Morphine pharmacokinetics 
and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. 
Br J Anaesth. 2008;101(5):680-9. doi:aen248 [pii] 10.1093/bja/aen248.
4. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M et al. Morphine 
glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet. 
2009;48(6):371-85. doi:10.2165/00003088-200948060-000033 [pii].
5. Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of the descriptive 
and predictive performance of paediatric morphine population models. Pharm Res. 2011;28(4):797-
811. doi:10.1007/s11095-010-0333-1.
6. Mahmood I. Prediction of drug clearance in children from adults: a comparison of several 
allometric methods. Br J Clin Pharmacol. 2006;61(5):545-57. doi:BCP2622 [pii] 10.1111/j.1365-
2125.2006.02622.x.
7. Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, 
and age. Ther Drug Monit. 2007;29(3):271-8. doi:10.1097/FTD.0b013e318042d3c4 00007691-
200706000-00002 [pii].
8. Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. 
Pharm Res. 1999;16(5):709-17.
9. Khandelwal A, et al. Influence of Correlated Covariates on Predictive Performance for Different 
Models. PAGE 20 (2011) Abstr 2220, 2011.
10. Krekels EH, DeJongh J, van Lingen RA, van der Marel CD, Choonara I, Lynn AM et al. Predictive 
performance of a recently developed population pharmacokinetic model for morphine and its 
metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet. 
2011;50(1):51-63. doi:10.2165/11536750-000000000-00000.
11. Wang C, Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Krekels EH, Tibboel D et al. A Bodyweight-
Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span. Pharm Res. 
2012. doi:10.1007/s11095-012-0668-x.
12. Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB et al. Body weight-dependent 
pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: 
towards individualized dosing. Clin Pharmacokinet. 2012;51(5):331-45. doi:10.2165/11598180-
000000000-00000.
13. van Dijk M, Bouwmeester NJ, Duivenvoorden HJ, Koot HM, Tibboel D, Passchier J et al. Efficacy of 
continuous versus intermittent morphine administration after major surgery in 0-3-year-old infants; 
a double-blind randomized controlled trial. Pain. 2002;98(3):305-13.
14. Simons SH, van Dijk M, van Lingen RA, Roofthooft D, Duivenvoorden HJ, Jongeneel N et al. Routine 
morphine infusion in preterm newborns who received ventilatory support: a randomized controlled 
trial. JAMA : the journal of the American Medical Association. 2003;290(18):2419-27. doi:10.1001/
jama.290.18.2419.
15. van Lingen RA. Pain assessment and analgesia in the newborn: an integrated approach. Rotterdam: 
Erasmus University; 2000.
16. van der Marel CD, Peters JW, Bouwmeester NJ, Jacqz-Aigrain E, van den Anker JN, Tibboel D. Rectal 
acetaminophen does not reduce morphine consumption after major surgery in young infants. Br J 
Anaesth. 2007;98(3):372-9. doi:10.1093/bja/ael371.
17. Lynn AM, Nespeca MK, Bratton SL, Shen DD. Intravenous morphine in postoperative infants: 
intermittent bolus dosing versus targeted continuous infusions. Pain. 2000;88(1):89-95.
18. Choonara I, Lawrence A, Michalkiewicz A, Bowhay A, Ratcliffe J. Morphine metabolism in neonates 
and infants. Br J Clin Pharmacol. 1992;34(5):434-7.
26664_Chenguang Wang.indd   113 23-09-13   10:37
Chapter 5
114
19. Sadhasivam S, Krekels EH, Chidambaran V, Esslinger HR, Ngamprasertwong P, Zhang K et al. 
Morphine clearance in children: does race or genetics matter? Journal of opioid management. 
2012;8(4):217-26. doi:10.5055/jom.2012.0119.
20. Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuijs D et al. Sex differences in 
morphine analgesia: an experimental study in healthy volunteers. Anesthesiology. 2000;93(5):1245-
54; discussion 6A.
21. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17-20. 
doi:6100241 [pii] 10.1038/sj.clpt.6100241 [doi].
22. Brendel K, Comets E, Laffont C, Laveille C, Mentre F. Metrics for external model evaluation with 
an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036-49. 
doi:10.1007/s11095-006-9067-5.
23. Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML. Limited phase I study of morphine-3-glucuronide. 
Journal of pharmaceutical sciences. 2001;90(11):1810-6.
24. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B et al. Developmental aspects of 
human hepatic drug glucuronidation in young children and adults. Gut. 2002;50(2):259-65. 
25. Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in 
children. Clin Pharmacokinet. 2006;45(7):683-704.
26. Zaya MJ, Hines RN, Stevens JC. Epirubicin glucuronidation and UGT2B7 developmental expression. 
Drug metabolism and disposition: the biological fate of chemicals. 2006;34(12):2097-101. 
doi:10.1124/dmd.106.011387.
27. Krekels EHJ, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M et al. From Pediatric Covariate 
Model to Semiphysiological Function for Maturation: Part I-Extrapolation of a Covariate Model From 
Morphine to Zidovudine. CPT: pharmacomet syst pharmacol. 2012;1:e9. doi:http://www.nature.
com/psp/journal/v1/n10/suppinfo/psp201211s1.html.
28. Krekels EHJ, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D et al. From 
Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to 
Physiological and Physicochemical Properties. CPT: pharmacomet syst pharmacol. 2012;1:e10. 
29. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: 
problems and solutions. The AAPS journal. 2009;11(3):558-69. doi:10.1208/s12248-009-9133-0.
30. Ince I, de Wildt SN, Wang C, Peeters MY, Burggraaf J, Jacqz-Aigrain E et al. A Novel Maturation 
Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to 
Adults. Clin Pharmacokinet. 2013. doi:10.1007/s40262-013-0050-0.
26664_Chenguang Wang.indd   114 23-09-13   10:37





Model I: Parent morphine model
$SUBROUTINES ADVAN5 
;-------------------------------------------------------------------------------
$MODEL NCOMPARTMENTS=2   
COMP (CENTRAL, DEFDOSE)  ;MORPHINE CENTRAL 
COMP =(2)                ;PERPHERAL COM OF MORHINE 
;------------------------------------------------------------------------------- 
$PK 
KDEC    = THETA(1)                      ; DECREASE OF EXPONENT FOR CLM1 
KMAX    = THETA(2)+KDEC                 ; MAXIMUM EXPONENT OF CLM1 
KHAL    = THETA(3)                      ; K50 OF CLM1 
GAMMA   = THETA(4)                      ; GAMMA OF CLM1 
KBDE    = KMAX-KDEC*(BW**GAMMA)/(KHAL**GAMMA+BW**GAMMA)  
;------------------------------------------------------------------------------- 
TVCL    = THETA(5)*(BW/70)**KBDE        ; POPULATION CLEARANCE OF MORPHINE 
CL      = TVCL*EXP(ETA(1))              ; INDIVIDUAL ... 
TVQ2    = THETA(6)*(BW/70)              ; POPULATION INTERCOMPARTMENTAL 
CLEARANCE OF MORHPINE 
IF (POP.EQ.2) TVQ2= THETA(10)  
Q2      = TVQ2*EXP(ETA(2))              ; INDIVIDUAL ...  
;------------------------------------------------------------------------------- 
TVV1    = THETA(7)*(BW/70)              ; POPULATION VOLUME OF MORPHINE CENTRAL 
COMPARTMENT 
IF (POP.EQ.2) TVV1=THETA(11)*(BW/70); 
V1      = TVV1 * EXP(ETA(3))            ; INDIVIDUAL ...  
TVV2    = THETA(8)*(BW/70)              ; POPULATION VOLUME OF MORPHINE PEREPHERAL 
COMPARTMENT 




K10  = CL/V1 
K12  = Q2/V1 
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K21  = Q2/V2   
F1      = 1 




IF (F.GT.0) IPRED = LOG(F)  
W   =  THETA(9) 
IRES  = IPRED-DV 
IWRES = IRES/W 
TEH=0 
IF (TIME.GT.1900.AND.NKOD.EQ.1) TEH = 1 
IF (TIME.GT.1900.AND.NKOD.EQ.2) TEH = 1 
Y = IPRED + ERR(1)*W + TEH*ERR(2)      ; MORPHINE  
;------------------------------------------------------------------------------- 
$THETA (0.1,  0.5,     )        ;KDEC 
(0.2,  0.9,     )        ;KMAX-KDEC OR MINMUM EXP (TH2) 
(0.05,  4,   20 )        ;KHAL 
(1,   5,        )        ;GAMMA 
(0.001, 1.5,    )        ;CL 
(0.01,  1.7,    )        ;Q2 
(0.1, 70,       )        ;V1 
(0.1,   100,    )        ;V2 
(0,  0.33,      )        ;ERR1 
(0.1, 1.1,      )        ;Q2 ADO 
(0.1,  50,      )        ;V1 ADO 
;------------------------------------------------------------------------------- 
$OMEGA 0.15     ;CL 
0 FIX    ;Q2 
0.1      ;V1 
0 FIX      ;V2
 ;------------------------------------------------------------------------------- 
$SIGMA 
1  FIX ; ERR1 
2      ; ERR2 >1900min 
;------------------------------------------------------------------------------- 
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$EST NOABORT SIGDIG=3 PRINT=15 MAXEVAL=9999 METHOD=1 INTERACTION 
POSTHOC 
$COV COMP PRINT=E





COMP (CENTRAL, DEFDOSE) ;MORPHINE CENTRAL
COMP=(2) ;M3G
COMP=(3) ;PERPHERAL COM OF MORHINE
;-------------------------------------------------------------------------------
$PK
KDEC1   = THETA(1)                      ; DECREASE OF EXPONENT FOR CLM1
KMAX1   = THETA(2)+KDEC1                ; MAXIMUM EXPONENT OF CLM1
KHAL1   = THETA(3)                      ; K50 OF CLM1
GAMMA1  = THETA(4)                      ; GAMMA OF CLM1
KBDE1   = KMAX1-KDEC1*(BW**GAMMA1)/(KHAL1**GAMMA1+BW**GAMMA1)
KDEC2   = THETA(5)                      ; DECREASE OF EXPONENT FOR CLE2
KMAX2   = THETA(6)+KDEC2                ; MAXIMUM EXPONENT OF CLE2
KHAL2   = THETA(7)                      ; K50 OF CLE2
GAMMA2  = THETA(8)                      ; GAMMA OF CLE2
KBDE2   = KMAX2-KDEC2*(BW**GAMMA2)/(KHAL2**GAMMA2+BW**GAMMA2)
;-------------------------------------------------------------------------------
TVCLM1  = THETA(9)*(BW/70)**KBDE1       ; POPULATION METABOLISM OF 
MORPHINE TO M3G
CLM1    = TVCLM1*EXP(ETA(1))            ; INDIVIDUAL ...
TVCLE1  = THETA(10)*(BW/70)             ; POPULATION EXCRETION OF MORPHINE + 
METABOLISM TO M6G
CLE1    = TVCLE1*EXP(ETA(2))            ; INDIVIDUAL ...
TVCLE2  = THETA(11)*(BW/70)**KBDE2      ; POPULATION EXCRETION OF M3G
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CLE2    = TVCLE2*EXP(ETA(3))            ; INDIVIDUAL ...
;-------------------------------------------------------------------------------
TVV1    = THETA(12)*(BW/70)             ; POPULATION VOLUME OF MORPHINE CENTRAL 
COMPARTMENT
V1      = TVV1 * EXP(ETA(4))            ; INDIVIDUAL ...
TVV2    = THETA(13)*(BW/70)**THETA(18)  ; POPULATION VOLUME OF M3G
V2      = TVV2 * EXP(ETA(5))            ; INDIVIDUAL ...
TVQ2    = THETA(14)*(BW/70)             ; POPULATION INTERCOMPARTMENTAL 
CLEARANCE OF MORHPINE
Q2      = TVQ2*EXP(ETA(6))              ; INDIVIDUAL ...
TVV3    = THETA(15)*(BW/70)             ; POPULATION VOLUME OF MORPHINE 
PEREPHERAL COMPARTMENT
V3      = TVV3*EXP(ETA(7))              ; INDIVIDUAL ...
F1      = 1





K10  = CLE1/V1
K12  = CLM1/V1
K13  = Q2/V1
K20  = CLE2/V2









IF (F.GT.0) IPRED = LOG(F)
W1   =  THETA(16)          ;ERR Morphine
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W2   =  THETA(17)          ;ERR M3G
IRES  = IPRED-DV
IWRES = IRES/(COM1*W1+COM2*W2)
TEH=0
IF (TIME.GT.1900.AND.NKOD.EQ.1) TEH = 1
IF (TIME.GT.1900.AND.NKOD.EQ.2) TEH = 1
Y1 = IPRED + ERR(1)*W1 + TEH*ERR(3)    ; MORPHINE
Y2 = IPRED + ERR(2)*W2 + TEH*ERR(3)    ; M3G
Y=COM1*Y1+COM2*Y2   
;-------------------------------------------------------------------------------
$THETA
(0.1,  0.74,    )        ;KDEC1
(0.4,  0.7,     )        ;KMAX1-KDEC1 OR MINMUM EXP1 (TH2)
(0.05, 4,    20 )        ;KHAL1
(1,    3,       )        ;GAMMA1
;--------------------------------------------------------
(0.1,  0.47,    )        ;KDEC2
(0.4,  0.6,     )        ;KMAX2-KDEC2 OR MINMUM EXP2 (TH15)
(0.05,  5,    20)        ;KHAL2
(1,    6,       )        ;GAMMA2
;---------------------------------------------------------
(0.001, 1.4,    )        ;CLM1
(0.001, 0.1,    )        ;CLE1
(0.001, 0.23,   )        ;CLE2
(0.01 , 30,     )        ;V1
20 FIX              ;V2
(0.001, 4,      )        ;Q2
(0.01 , 180,    )        ;V4 
(0,  0.435,     )        ;ERR MORP
(0,  0.362,     )        ;ERR M3G
(0.1,   0.7,    )        ;EXP V2
;-------------------------------------------------------------------------------




0.2       ;CLM1
0.1       ;CLE1
0.19      ;CLE2
0.2       ;V1
0.2       ;V2
0 FIX     ;Q2





2         ;ERR3
;-------------------------------------------------------------------------------
$EST NOABORT SIGDIG=3 PRINT=15 MAXEVAL=9999 METHOD=1 INTERACTION 
POSTHOC
$COV COMP PRINT=E
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Introduction: In order to characterize the variation in pharmacokinetics 
of paracetamol across the human age span, we performed a population 
pharmacokinetic analysis from preterm neonates to adults with specific focus 
on clearance.
Methods: A total of 220 (pre)term neonates, infants, children and adults from 
eight previously published studies on paracetamol pharmacokinetics were 
analysed using NONMEM 7.2. In the covariate analysis, covariates were tested 
in linear functions, power functions and a power function with a bodyweight-
dependent exponent.
Results: Between preterm neonates and adults, linear bodyweight functions 
were identified for Q2, Q3, V1, V2 and V3, while for CL a power function with 
a bodyweight-dependent exponent k was identified (CLi = CLp • (BW/70)
k). The 
exponent k was found to decrease in a sigmoidal manner with bodyweight 
from 1.2 to 0.75, with half the decrease in exponent reached at 12.2 kg. No 
other covariates such as age were identified.
Conclusions: A pharmacokinetic model for paracetamol characterising changes 
in pharmacokinetic parameters across the pediatric age-range was developed 
in which clearance was found to change in a highly nonlinear manner with 
bodyweight. Based on the final model, dosing guidelines are proposed from 
preterm neonates to adolescents resulting in similar exposure across all age 
ranges.
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Paracetamol or acetaminophen is an antipyretic and analgesic agent widely 
used in both adult and pediatric populations. Typically, paracetamol is given to 
patients orally or rectally 1. Recently, an intravenous formulation of paracetamol 
has become available, which is also regularly used as analgesic in neonates 
even though the USFDA only approved its use for the treatment of acute pain 
and fever in children aged 2 years and older and adults. In latest years, there 
has also been great interest in intravenous paracetamol in preterm neonates 
for closure of neonatal ductus 2-4 at even higher dosages than when used as an 
analgesic.
To derive evidence based dosing guidelines for intravenous paracetamol 
across all age ranges including neonates and infants, information is needed 
on the pharmacokinetics. While the pharmacokinetics of paracetamol have 
been modeled in neonates and infants 5-7, different models have been derived 
upon paracetamol or its prodrug given orally, rectally or intravenously 8-10. 
Regardless of whether in these analyses data from preterm and term neonates 
were available 8 or not available 9,10, in all these studies, paracetamol clearance 
was modeled on the basis of bodyweight with a ¾ allometric function, after 
which an age-based maturation function was added 8-10. As the use of both 
bodyweight and age as covariates on a single parameter was recently reported 
to potentially harm the predictive performance of the resulting model 
because bodyweight and age are correlated in a complex and highly nonlinear 
manner as part of a child’s growth and development 11,12, further study on the 
influence of bodyweight on the pharmacokinetics of paracetamol across the 
entire human lifespan with inclusion of data from (pre)term neonates seems 
important. Preferably in this analysis, the influence of bodyweight on clearance 
is optimized in a way that the inclusion of an additional maturation functions 
based on age is not required 11,12. For this purpose, an allometric function on the 
basis of bodyweight in which the allometric exponent was allowed to vary with 
bodyweight was proposed for scaling clearance across the human age range13. 
Following the successful application of this so called bodyweight dependent 
exponent (BDE) model to the scaling of the clearances of propofol 13, morphine 
14, busulfan 15 and midazolam 16, the current analysis focuses on the utilization 
of this model for scaling paracetamol clearance over a large lifespan including 
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preterm neonates. Given the fact that dosing in children including preterm and 
term neonates is typically performed on the basis of bodyweight, the results 
can also be used to derive bodyweight-based dosing guidelines for this drug 
in all pediatric subpopulations aiming to reach similar paracetamol exposure 
on the assumption of an identical exposure-effect relationship in pediatrics as 
in adults. 17
Therefore, in the current study, we included pharmacokinetic data from eight 
previously published paracetamol studies 7,18-24 in order to characterize its 
pharmacokinetics across the entire human lifespan. In the covariate analysis, 
there was specific focus on the optimization of the influence of bodyweight as 
predictor of inter-individual variability in clearance.
6.2. Methods
6.2.1. Subjects of the original studies
A total of 220 subjects from eight previously published studies 7,18-24 on 
paracetamol pharmacokinetics were included in the current study, including 
neonates (1- 76 days), infants (0.11-1.33 years), children (2-7 years) and 
adults (19-34 years). Detailed information on the studies is given below and 
summarized in Table 6-1.
Neonates 7,18,19
Study 1: Single dose intravenous propacetamol in neonates 18
Thirty preterm (gestational age 27 – 35 weeks) and term (gestational age 36 
- 40 weeks) neonates aged 1 day and weighing 0.5-4 kg, who received single 
dose of intravenous propacetamol, were included in the current analysis. 
Propacetamol dose was 20 mg/kg (10 mg/kg paracetamol) for the first 15 
neonates and 40 mg/kg (20 mg/kg paracetamol) for the next 15 neonates. 
Propacetamol bolus infusion was prepared from a 1 gram propacetamol 
(500 mg paracetamol) powder-containing vial diluted in 50 ml normal saline. 
Samples were collected 30, 60, 90, 120, 180, 240, and 600 minutes after the 
start of intravenous administration.
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Study 2: Repeated dose intravenous propacetamol in neonates 19
Eighteen preterm and term neonates aged 1-76 days (postconceptual age 27 – 
42 weeks) and weighing 0.84-4 kg, who received repeated doses of intravenous 
propacetamol, were included in the current analysis. The dosing regimen 
consisted of a loading dose (20 mg/kg paracetamol) with a maintenance 
dosing of 10 mg/kg/dose every 12, 8 or 6 hours for extreme preterm, preterm 
and term neonates, respectively. Samples were collected 30, 60, 90, 120, 180, 
240 and 600 min after initiation of intravenous administration.
Study 3: Repeated dose intravenous paracetamol in neonates 7
Sixty preterm and term neonates aged 1-28 days and weighing 0.6-4.8 kg, who 
received repeated dose intravenous paracetamol, were included in the current 
analysis. The dosing regimen consisted of a loading dose (20 mg/kg) followed 
by a maintenance dose of 5, 7.5 or 10 mg/kg every 6 hours for extreme preterm, 
preterm and term neonates, respectively. Samples were collected from an 
arterial line in the first 48 hours after the paracetamol loading dose.
Infants 20,23
Study 4: Repeated dose intravenous propacetamol and rectal paracetamol in 
infants 20
Twenty-six infants aged 0.11 – 1.33 years and weighing 7.5-12.2 kg after major 
craniofacial surgery were included in the current analysis. During surgery, 
all infants received a rectal loading dose of 40 mg/kg paracetamol 2 hours 
before anticipated extubation. On admittance to the pediatric surgical ICU, the 
children were randomized to receive either a 15 minutes intravenous infusion 
of 40 mg/kg propacetamol or 20 mg/kg paracetamol rectally every 6 hours. 
Blood samples were taken from the arterial catheter at 15 minutes, 1 and 6 
hours after the first dose, at 5 minutes, 4 and 6 hours after the third dose, and 
at 30 minutes, 2 and 3 hours after the fourth dose.
Study 5: Repeated dose rectal acetaminophen in infants 23
Twenty rectally dosed infants out of forty infants in the original study, aged 
0.67 -1.25 years and weighing 7.9-12.2 kg, were included in the current analysis. 
Approximately 2 hours before anticipated extubation, a loading dose of 
acetaminophen (40 mg/kg) was administered rectally. Two hours after arrival 
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in the pediatric surgical ICU, 20-mg/kg acetaminophen was administered 
rectally at t = 6, t = 12, and t =18 hours. Blood samples were taken at 30, 60, 
and 90 minutes after the rectal loading dose and at 5, 8, 11, 14, 17 and 20 hours 
after arrival in pediatric surgical ICU. One individual was excluded from the 
population pharmacokinetic analysis because specific dosage information was 
missing.
Children
Study 6: Repeated dose rectal acetaminophen in children 24
Twenty-nine children, aged 2-7 years and weighing 14-33 kg, received a loading 
dose of 40 mg/kg rectally resulting in a dose of 600, 700, 800, 900, 1000, 1100, 
1200 or 1300 mg when the child was in weight class 14 - 16 kg, 17 - 18 kg, 19 
- 21 kg, 22 - 23 kg, 24 - 26 kg, 27 - 28 kg, 29 - 31 kg or in weight class 32 - 33 
kg, respectively. The maintenance dose of 30 mg/kg was given rectally every 8 
hours and was a dose of 450, 525, 600, 675, 750, 825, 900 or 975 mg when the 
child was in weight class 14 - 16 kg, 17 - 18 kg, 19 - 21 kg, 22 - 23 kg, 24 - 26 kg, 
27 - 28 kg, 29 - 31 kg or 32 - 33 kg, respectively. Samples were taken at the start 
and at the end of surgery and 1, 2 and 3 hours postoperatively.
Adults 21,22
Study 7: Intravenous infusion of propacetamol in healthy male adults 21
Data from twelve healthy male volunteers aged 21-25 years and weighting 
63-83 kg from one sub-branch (Study I, Occasion B) in the original study were 
included in the current analysis. Each subject was given 1 gram of propacetamol 
HCL (=500 mg paracetamol) intravenously at a constant infusion rate over 15 
minutes. Samples were taken before the administration and at 15, 20, 30, 45 
minutes, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours after administration.
Study 8: Intravenous infusion of paracetamol in healthy adults 22
Twenty-six healthy volunteers aged 19-34 years and weighing 49.2-94 kg were 
included in the current analysis. Each subject received first a 15 minutes infusion 
of 2 gram of paracetamol (Perfalgan), followed by four additional 15 minutes 
infusions of 1 gram paracetamol each, at 6 hours intervals. Blood samples were 
collected before dosing and at 15 minute (the end of infusion), 30 minutes and 
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1 hour, 1.1 hour, 2, 3, 4, and 6 hour after the 2 gram dose and the first 1 gram 
dose; before dosing and at the end of infusion of the second and third 1 gram 
doses; before dosing and at 15 minutes (end of infusion), 30 minutes and 1 
hour, 1.5 hours, 2, 3, 4, 6, 8, 10, 12, and 24 hours after the last 1 gram dose.
6.2.2. Pharmacokinetic modelling
Model Building
The population pharmacokinetic analysis was performed with the non-linear 
mixed effects modeling software NONMEM version 7.2. (ICON Development 
Solutions, Ellicott City, MD, USA) using the first-order conditional estimation 
method with the interaction option (FOCEI). Tools like S-PLUS interface for 
NONMEM (LAP&P Consultants BV, Leiden, NL), S-Plus (version 8.1, Insightful 
Software, Seattle, WA, USA), XPose and R (version 2.15.1) were used to visualize 
the output and evaluate the models.
Paracetamol concentrations were logarithmically transformed and fitted 
simultaneously, since the range in concentrations was more than 1000 fold. 
Model building was performed in four steps: (1) selection of structural model, 
(2) selection of statistical sub-model, (3) systematic covariate analysis, (4) 
model validation. For selection of a structural or statistical model, a difference 
in objective function (OFV) between models of more than 3.84 points 
was considered as statistically significant (p<0.05 assuming a Chi-square 
distribution). Furthermore, the goodness-of-fit plots (observed versus individual 
predicted concentrations and versus population predicted concentrations, and 
conditional weighted residuals versus time and versus population prediction 
concentrations) of all data and data stratified per age category were evaluated. 
Finally, the total number of parameters, improvement of the individual 
concentration-time profiles, the confidence intervals of the parameter 
estimates and the correlation matrix were assessed. In case the subjects were 
given propacetamol intravenously, 1 unit propacetamol dose was converted to 
0.5 unit of paracetamol as dosing input for the pharmacokinetic analysis.
Structural Model
Based on previous reports 9,20, the distribution and elimination pharmacokinetics 
of paracetamol were primarily modelled with a two-compartment model, 
which was parameterized in terms of total clearance (CL), volume of 
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distribution of the central compartment (V1), volume of distribution of the 
peripheral compartment (V2) and inter-compartmental clearances between 
central compartment and peripheral compartment (Q2). To describe the 
process of rectal absorption for individuals who were given paracetamol 
rectally, a rectal deposit compartment was incorporated into the model with 
first-order absorption rate constant (Ka), bioavailability (F), and lag time (Tlag) 
as parameters. Since we had data upon bolus infusion of paracetamol in our 
analysis 21, we also explored the performance of a three-compartment model for 
distribution and elimination of paracetamol, which was parameterized in terms 
of total clearance (CL), volume of distribution of the central compartment (V1), 
volume of distribution of the rapidly-equilibrating peripheral compartment 
(V2) and slowly-equilibrating peripheral compartment (V3), and inter-
compartmental clearances between central compartment and two peripheral 
compartments (Q2, Q3).
Because in some of the studies included in this analysis propacetamol, 
an intravenous prodrug of paracetamol, was given, we tested a deposit 
compartment for propacetamol and its first order hydrolysis rate in order to 
describe the process of conversion from propacetamol to paracetamol. As the 
half-life of the hydrolysis rate turned out to be very short (<0.0001 hour), this 
compartment was neglected in the final model.
Statistical Model
Interindividual variability in the pharmacokinetic parameters was tested in the 
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where  is the individual pharmacokinetic parameter value for the ith individual,  is the 
population pharmacokinetic parameter value or typical value, and  is a random variable for 
the ith individual from a normal distribution with mean zero and variance . In addition to 
testing of the inclusion of interindividual variability on individual parameters, model 
improvement by inclusion of covariance between these variability parameters was tested as 
well.  
As bioavailability should be constrained between 0 and 1, interindividual variability in 
bioavailability was parameterized in a model proposed by Karlsson et al.25 using the following 
function: 
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is a random variable for the ith individual from a normal distribution with mean 
zero and variance w2. In addition to testing of the inclusion of interindividual 
variability on individual parameters, model improvement by inclusion of 
covariance between these variability parameters was tested as well.
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As bioavailability should be constrained between 0 and 1, interindividual 
variability in bioavailability was parameterized in a model proposed by Karlsson 
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For the residual error, an additive model for log-transformed concentrations was used which 
correspond  to proportional error on untransformed data, expressed as: 
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where  is the value of the observed paracetamol concentration of ith individual at time j, 
is the value of the predicted paracetamol concentration of the ith individual at time j, 
and  is a random variable for this observation from a normal distribution with mean zero 
and variance σ2. 
Covariate Model 
The covariates bodyweight and age were tested on the pharmacokinetic parameters in a 
linear function, power function or a power function with a bodyweight dependent exponent. 
This power function with a bodyweight dependent exponent is called a bodyweight dependent 
exponent (BDE) model 13 and is shown in equation 4, where it is applied to paracetamol 
clearance.  
     ,          [4] 
In equation 4,  is clearance in the ith individual with bodyweight ;  is the clearance in 
a standardized adult with a bodyweight of 70 kg;  is bodyweight of an individual i; k is the 
exponent; k0 is the value of the exponent at a theoretical bodyweight of 0 kg; kmax is the 
maximum decrease of the exponent; k50 is the bodyweight at which a 50% decrease in the 
maximum decrease of exponent value is attained, and γ is the Hill coefficient determining the 
steepness of sigmoidal decline in the exponent 13.  
The significance of a covariate for a parameter in the model was statistically evaluated by the 
use of the objective function. In the forward inclusion a p value <0.005 was considered as 
statistically significant while a more stringent p value <0.001 was used in the backward 
deletion. When two or more covariates were found to significantly improve the model, the 
covariate that reduces the objective function the most was retained into the model and served 
as a basis for subsequent inclusion of additional covariates. The choice of the covariate 
model was further evaluated as described under Model Building whereby the results of the 
model validation were also considered.  
6.2.3. Model Validation 
The model was validated internally using five criteria that were recently proposed for pediatric 
population model evaluation 26. (i) The coefficient of variation (CV) of the parameter estimates 
either from the covariance step in NONMEM or from 200 stratified bootstrap resampling 
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value <0.005 was considered as statistically significant while a more stringent p 
value <0.001 was used in the backward deletion. When two or more covariates 
were found to significantly improve the model, the covariate that reduces the 
objective function the most was retained into the model and served as a basis 
for subsequent inclusion of additional covariates. The choice of the covariate 
model was further evaluated as described under Model Building whereby the 
results of the model validation were also considered.
6.2.3. Model Validation
The model was validated internally using five criteria that were recently proposed 
for pediatric population model evaluation 26. (i) The coefficient of variation (CV) of 
the parameter estimates either from the covariance step in NONMEM or from 200 
stratified bootstrap resampling results is less than 50%, (ii) The basic diagnostic 
plots and particularly the plots of the observed versus population predicted 
concentrations stratified for age, are visually assessed for bias and precision, (iii) 
The η-shrinkage is calculated and evaluated according to Karlsson and Savic 
27, (iv) The individual and population predicted parameters are plotted against 
the primary covariate to evaluate whether the individual predicted parameters 
are equally distributed around the population predicted parameters, (v) The 
simulation based normalized prediction distribution error (NPDE) proposed 
by Brendel et al. is calculated based on at least 2,000 simulations of the entire 
dataset and is evaluated visually for bias and precision 28.
Simulations on the basis of the final model
Based on the final model paracetamol concentration-time profiles were 
simulated for children with bodyweight of 0.5, 1, 1.5, 2, 3, 5, 8, 9, 15, 20, 35 and 
50 kg. Two intravenous administration dosing regimens were simulated, i.e. a 
traditional dosing regimen and a model-based dosing regimen.
The traditional dosing regimen for prematurely born neonates and children 
was based on the Dutch Children’s Formulary [5mg/kg every 6 hours (group 1 
with weight 0.5, 1, 1.5 and 2 kg)] 29 while for term neonates and children it was 
based on the official labeling information in the Netherlands (for term neonates 
and children weighing less than 10 kg 7.5 mg/kg every 6 hours (group 2 with 
weight 3, 5, 8 and 9 kg) and for children weighing between 10 and 50 kg 15mg/
kg every 6 hours (group 3 with weight 15, 20, 35 and 50 kg).
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In the model-based dosing regimen, model based doses were derived for 
children of all bodyweights on the basis of a loading dose and a maintenance 
dose every 6 hours while aiming for steady state concentrations attained in 
group 3 using the traditional dosing regimen.
6.3. Results
For the analysis, data of 220 subjects varying from preterm and term neonates, 
infants, children and adults receiving paracetamol intravenously or rectally or 
propacetamol intravenously were available. An overview of the data of the 
eight paracetamol studies was summarized in Table 6-1.
Table 6-1 Summary of studies included in this analysis
Study Population Administration N Age Weight Reference
1 preterm and 
term neonates
i.v. propacetamol 30 1 day 0.505–4 kg (18)
2 preterm and 
term neonates
i.v. propacetamol 18 1-76 days 0.81–4 kg (19)
3 preterm and 
term neonates
i.v. paracetamol 60 1-28 days 0.6–4.3 kg (7)
4 infants rectal paracetamol i.v. 
propacetamol
26 0.11-1.33 yrs 7.5-12.2 kg (20)
5 infants rectal paracetamol 19 0.67-1.25 yrs 7.9-12.2 kg (23)
6 children rectal paracetamol 29 2-7 yrs 14-33 kg (24)
7 Male adults i.v. propacetamol 12 21-25 yrs 63-83 kg (21)
8 adults i.v. paracetamol 26 19–34 yrs 49.2-94 kg (22)
Table 6-2 presents the results of the final model. The results demonstrated 
that a three-compartment structural model for distribution and elimination 
of paracetamol was superior over a two-compartment model, based on 
the improvement of the goodness of fit plots and a decrease of 639 points 
(P<0.0001) in objective function value. The population lag time (Tlag) of the 
rectal dose was estimated to be 0.409 hour without interindividual variability. 
The rectal bioavailability was estimated to be 0.962 with a large interindividual 
variability of 205.9%. The rectal absorption rate constant (Ka) was estimated 
to be 0.28 (1/hour) with an interindividual variability of 86.7%. The population 
value for clearance in a typical adult with a bodyweight of 70kg was estimated 
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17.6 L/hr and the corresponding population volume of distribution of the 
central compartment was 25.1 L (Table 6-2).
Figure 6-1 Plot of paracetamol clearance of all individuals (post hoc parameter estimates) 
against bodyweight in log-log scale.
Filled circles: post hoc individual paracetamol clearance; Solid line: model predicted paracetamol 








 × BWγ / (k
50
γ + BWγ ) with parameters as 
shown in Table 6-2.
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Table 6-2 Parameter estimates of the final model
Parameter Model Estimates RSE Bootstrap Mean Bootstrap RSE
Fixed effect
CL = TVCL × (BW/70) k





 × BWγ / (k
50
γ + BWγ )
    k
max
0.454   5.4% 0.44 5.7%




§ 0.75 FIX - - -
    k
50 
(kg) 12.2 27.2% 28.3 202.9%
    γ 1.4 FIX - - -
V1 = TVVc × (BW/70)
TVV1 (L/70kg) 25.1 11.2% 24.4 16.1%
Q2 = TVQ × (BW/70)
TVQ2 (L/hr•70kg) 96.8 12.6% 103.7 19.5%
V2 = TVVp × (BW/70)
TVV2 (L/70kg) 36.1 5.5% 36.8 7.3%
Q3 = TVQ × (BW/70)
TVQ3 (L/hr•70kg) 1.36 9.8% 1.37 8.1%
V3 = TVV3 × (BW/70)
TVV3 (L/70kg) 21.6 12.8% 22.2 13.9%
Ka (1/hr) 0.252 13.8% 0.29 25.9%
Tlag (h) 0.409 5.7% 0.409 6.4%
F 0.962 8% 0.9 11.7%
Random effect (%)
ω CL 35.4% 9.1% 34.6% 17.6%
ω Vc 63.6% 12.6% 68.4% 36.6%
ω Ka
  
86.7% 14% 95.7% 42.5%
ω F
  
205.9% 76.4% 311% 110%
σ 21.4% 8.8% 21.4% 15.9%
k = bodyweight dependent exponent ; k
max 
= maximum decrease of k; k
0 
= value of k at a theoretical 
bodyweight of 0 kg; k
50 
= the bodyweight at which a 50% decrease in the maximum decrease of 
k is attained; γ = the Hill coefficient determining the steepness of sigmoidal decline in k; Ka = rectal 
absorption constant rate; Tlag = lag time in rectal absorption; F= rectal bioavailability; ω= standard 





 was parameterized as a fixed effect parameter (THETA) in NONMEM
Concerning the covariate analysis, bodyweight was identified a significant 
covariate for all structural pharmacokinetic parameters except for Ka, F and 
Tlag. For the parameters Q2, Q3, V1, V2 and V3, the influence of bodyweight was 
best described by a linear function (Table 6-2). For clearance, a power function 
in which the exponent k varied with bodyweight in a sigmoidal function (BDE 
model, eq.5) proved superior over a linear or a power function with a fixed 
exponent k. The bodyweight-dependent exponent k was estimated to decrease 
26664_Chenguang Wang.indd   135 23-09-13   10:37
Chapter 6
136
from a value of 1.2 (k
0





) and reached half this decrease at 12.2 kilogram (k
50
) (Table 6-2). The 






was fixed to 0.75, since this exponent 
proved successful in a separate pre-analysis based on adult data only. The Hill 
factor (γ) was found to be 1.4 and was fixed to this value in the final model 
in order to get the covariance step (Table 6-2). Figure 6-1 shows that on 
the basis of this BDE model, the change in individual paracetamol clearance 
over bodyweight of all individuals of this analysis was very well captured. As 
η-shrinkage was low (12.8%), the reliability of the individual clearance values 
in the subjects can be considered high 27. Concerning the evaluation of the 
implementation of the covariate model for clearance in the final model by the 
bodyweight-dependent exponent (BDE) model, Figure 6-2 shows that there 
were no remaining trends in the post hoc eta of clearance versus bodyweight, 
postnatal age (PNA), postmenstrual age (PMA) and gestational age (GA) plots. 
As the data of PMA and GA were only availabe in neonates, corresponding 
plots were limited to 50 weeks in the x-axes.
With respect to model validation, goodness of fit plots stratified by age (1. 
birth to 1 month; 2. 1 month to 2 years; 3. 2-12 years; 4 12-16 years) showed 
that the population predicted paracetamol concentrations of the final model 
were in good agreement with the observed paracetamol concentrations for 
the different age ranges (Supplemental Figure 6-S1). As a simulation based 
validation method, the normalized prediction distribution error (NPDE) showed 
that paracetamol concentrations in the models were normally distributed 
(mean=-0.02462, variance= 0.7756, p<0.001) around the median prediction 
and that there was no trend in the NPDE versus TIME and versus the logarithm 
of the individual predicted concentrations (Supplemental Figure 6-S2). In 
addition, the results of the bootstrap validation of the final model are listed in 
Table 6-2.
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Table 6-3 Model-based dosing regimen of intravenous paracetamol aiming for a target 
paracetamol concentration of 9 mg/L in individuals weighing between 0.5 and 50 kg. Both 
maintenance doses administered 4 times daily (MD) and loading doses (LD) are presented. 
























0.5 0.047 0.179 2.641 9 2.5 5.1 5 +2% 2.2 5.6 11.2
1 0.112 0.359 2.223 9 6.0 6.0 5 +20% 2 12.1 12.1
1.5 0.188 0.538 1.982 9 10.2 6.8 5 +36% 1.8 18.3 12.2
2 0.274 0.717 1.813 9 14.8 7.4 5 +48% 1.8 26.7 13.3
3 0.473 1.076 1.576 9 25.5 8.5 7.5 +13% 1.5 38.3 12.8
5 0.958 1.793 1.297 9 51.8 10.4 7.5 +39% 1.3 67.3 13.5
8 1.836 2.869 1.083 9 99.1 12.4 7.5 +65% 1.3 128.9 16.1
9 2.151 3.227 1.039 9 116.2 12.9 7.5 +72% 1.3 151.0 16.8
15 4.109 5.379 0.907 9 221.9 14.8 15 -1% 1.3 288.4 19.2
20 5.689 7.171 0.874 9 307.2 15.4 15 +3% 1.2 368.7 18.4
35 9.870 12.550 0.881 9 533.0 15.2 15 +1% 1.2 639.6 18.3
50 13.422 17.929 0.926 9 724.8 14.5 15 -3% 1.2 869.8 17.4
BW is body weight; CL is the predicted clearance from final model; V is the predicted volume of 
distribution from final model; t1/2 = ln(2) / (CL/V); Target Cavg is the target average concentration used 
for the model-based dosing regimen which was taken from the average steady state concentrations 
observed in individuals weighing 15, 20, 35, 50 kg upon the traditional dosing regimen; MD is the 
final model optimized Maintenance Dose = Target Cavg*CL*6h; MD/kg is the final model optimized 
Maintenance Dose Per Kilogram = MD/BW; TraditionalMD/kg is the Maintenance Dose per kilogram 
of the traditional dosing regimen; % DIFF MD/kg is the change of model based MD/kg from the 
TraditionalMD/kg in percentage =100%* (MD/kg – TraditionalMD/kg)/ TraditionalMD/kg; L/M Ratio is 
the ratio of loading dose to maintenance dose in the model-based dosing regimen; LD is the model-
based Loading Dose = MD * L/M Ratio; LD/kg is the final model optimized Loading Dose per kilogram
Simulations on the basis of the final model for both a traditional dosing 
regimen and a model-based dosing regimen are presented in Figure 6-3. For 
the traditional dosing regimen, 3 different maintenance doses were used 6 
hourly, i.e. 5 mg/kg, 7.5 mg/kg and 15 mg/kg for neonates with a body weight 
between 0.5 - 3 kg, 3 – 10 kg and children with weight 10 - 50 kg, respectively, 
according to the official label and the Dutch Childrens Formularium 29. The 
simulations upon the traditional dosing regimen in group 3 (Figure 6-3 a, 
buttom row, 10-50 kg) show that on average a concentration of 9 mg/L was 
attained (Figure 6-3 a, dotted reference line). For the other groups, a variety 
of average concentrations was attained upon this traditional mg/kg dosing 
regimen (Figure 6-3 a, upper two rows).
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Figure 6-2 Plot of interindividual variability (ETA) in paracetamol clearance of the final model 
versus candidate covariates, including bodyweight, postnatal age, postmenstrual age (only 
for neonates) and gestational age (only for neonates).
Table 6-3 shows the loading and maintenance doses for the model-based 
dosing regimen aiming for a concentration of 9 mg/L in all groups with 
individuals varying in bodyweight between 0.5 and 50 kg. Figure 6-3 b shows 
the simulated concentrations in all individuals upon this model-based dosing 
regimen.
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In this meta-pharmacokinetic analysis we studied the pharmacokinetics 
of paracetamol using data from eight different clinical studies in (pre)term 
neonates, infants, children and adults. The results show that, whereas changes 
in most pharmacokinetic parameters were linearly related to bodyweight, 
developmental changes in clearance were best described on the basis of a 
power function with an exponent that varied with bodyweight. This exponent 
was found to vary from the value of 1.2 for neonates to 0.75 for older children 
and adults. Using this function, the influence of bodyweight on clearance was 
implemented in an optimal way which was confirmed by advanced internal 
validation procedures, being particularly important for pediatric studies where 
datasets are often sparse and variability due to age is large 26. Most importantly, 
the Empirical Bayes Estimates (EBE) based post hoc interindividual variability 
of clearance had no trend against either bodyweight or age (including PNA, 
PMA and GA) (Figure 6-2), confirming that an appropriate final model has 
been reached 30. These results demonstrate that the influence of bodyweight 
on clearance as described by the highly nonlinear bodyweight dependent 
exponent (BDE) function also takes the influence of age (PNA, PMA or GA) 
into account. However, caution is needed in case of obese individuals. In our 
datasets, there were no obese individuals, and therefore the derived function 
should not be used in obesity. A graphical comparsion of clearance predictions 
between the BDE model and literature models 8-10 shows that the predictions of 
these four models were in reasonable agreement with each other, such despite 
the fact that different functions and covariates were used (Supplemental Table 
6-S1, Figure 6-S3).
The bodyweight-dependent exponent (BDE) function was originally developed 
on the basis of a very large and rich dataset from preterm neonates to adults on 
propofol 13. Later on, it was applied for scaling morphine across the entire human 
lifespan 14 and in the current study. Concerning the results from propofol, morphine 
and paracetamol from the current study, it seems that relatively similar values for 
k were found (exponent of 1.35 to 0.56, 1.47 to 0.88 and 1.2 to 0.75, respectively). 
We think that this may be explained by the fact that glucuronidation is the main 
pathway for these drugs upon which the question rises whether this function 
could be seen as a semiphysiological function for glucuronidation in humans. 
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For a previously developed function for morphine glucuonidation from preterm 
neonates to 3 year old children, this has recently been proposed and evaluated 
using phsyiologically based modelling principles 31,32. On the other hand, the 
current function for paracetamol differs from propofol and morphine by the k
50
 
being 12. 2 kg for paracetamol vs 3.78 and 4.01 kg for propofol and morphine, 
respectively, indicating that paracetamol clearance maturates at a slower rate than 
glucuronidation of propofol and morphine. An explanation for this finding is that 
paracetamol is not entirely metabolised through glucuronidation as sulphation 
plays an important role, particularly in neonates 9. Therefore the currently derived 
function is probably a mixture of glucuronidation and sulphation which each 
mature at their own rate. At least, it seems that the BDE model in which the 
exponent is allowed to vary with bodyweight is of relevance for scaling clearance 
across a large range in bodyweight on the basis of a single covariate.
Figure 6-3 Simulated paracetamol concentration profiles of intravenously administered 
paracetamol 4 times daily based on a traditional regimen as described in section Methods 
(panel a) and a final model optimized regimen (panel b, Table 6-3) for neonates with a body 
weight between 0.5 - 3 kg (upper row), neonates and infants weighing between 3 – 10 kg 
(middle row) and children with a weight between 10 - 50 kg (lower row).
Solid curves are paracetamol concentration profiles; horizontal dotted line is the target average 
paracetamol concentration (9 mg/L) used for the final model optimized regimen (panel b) which was 
calculated from the average steady state concentration obtained upon the traditional dosing regimen 
in individuals weighing 15, 20, 35, 50 kg (panel a); MD is the maintenance dose per kilogram; LD is the 
loading dose per kilogram.
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Intravenous paracetamol is not licensed for children younger than 2 years of 
age in the United States. Although intravenous paracetamol is licensed in the 
EU for children of all age ranges except prematurely born neonates, there is a 
large debate on the labelled dose for term neonates and children weighing 
less than 10 kg while doses for preterm neonates are based on expert opinion 
only 29. In our study, we used the final model that was derived on the basis 
of eight different datasets across the entire human lifespan to simulate 
concentrations both upon a traditional dosing regimen and a model-based 
dosing regimen. For the traditional dosing regimen, 3 different maintenance 
doses were used 6 hourly, i.e. 5 mg/kg, 7.5 mg/kg and 15 mg/kg for neonates 
with a body weight between 0.5 - 3 kg, 3 – 10 kg and children with weight 
10 - 50 kg, respectively. For the last two categories these doses are based 
on the official label, whereas the dose for preterm neonates is based on the 
Dutch Children’s Formulary 29. For the model-based dosing regimen a target 
paracetamol concentration was needed. Since the target therapeutic average 
paracetamol concentration for neonates is not known and the 6-hourly 15 mg/
kg dose is widely accepted for children weighing more than 10 kg, we took the 
average paracetamol concentration reached in this dose group (i.e. 9 mg/L) 
as the target concentration for the model-based dosing regimen. On the 
basis of the 9 mg/L concentration as the target concentration, loading doses 
and maintenance doses of intravenous paracetamol were optimized based 
on clearance and volume of distribution as estimated using the final model 
(Table 6-3). Simulation results confirmed that 15 mg/kg maintenance doses is 
sufficient for children with weight 10 - 50 kg (Figure 6-3 a and b). However, 7.5 
mg/kg was not enough to reach 9 mg/L average paracetamol concentration 
in neonates or infants weighing 5, 8 or 9kg, while 5 mg/kg proved too low of 
a dose for a prematurely born neonate weighing 1, 1.5 or 2 kg (Figure 6-3 a). 
Therefore bodyweight adjusted doses were proposed for these two categories 
as presented in Table 6-3, which proved to be in accordance with previous 
calls for adjustment of the labelled dose in infants and neonates. Palmer et al. 
recommended 10 mg/kg 6 hourly for preterm neonates with postmenstrual 
age (PMA) of 28-32 weeks, 12.5 mg/kg 6 hourly for neonates with PMA of 32-36 
weeks and 15 mg/kg 6 hourly for neonates with PMA more than 36 weeks 33. 
Allegaert et al. suggested a dosing regimen of 10 mg/kg every 6 hours within 
the age range 32–44 weeks postmenstrual age (PMA) 7. Although final dose 
recommendations should consider not only the pharmacokinetics but also 
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the pharmacodynamics and safety of paracetamol in neonates and infants, 
we think that our model is a first step towards an evidence based dosing in 
children of all ages including preterm and term neonates. In addition, our 
model can also be used to derive adjusted pediatric doses by use of Table 6-3 
in which another target concentration (higher or lower than 9 mg/L) can easily 
be filled in, for instance when another therapeutic target concentration for a 
specific age category would be identified.
6.5. Conclusion
A pharmacokinetic model for paracetamol characterising changes in 
pharmacokinetic parameters across the entire human lifespan was developed 
in which clearance was found to change in a highly nonlinear manner with 
bodyweight. The results may provide insight in the exact relation between 
weight and clearance and as such provide a guide for individualised dosing in 
children varying between preterm neonates and adults. Once the therapeutic 
target concentration is known, corresponding appropriate doses can be easily 
calculated based on this model.
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6.7.1 Notes for Figure 6-S1 and Figure 6-S2
The results obtained in this study were internally validated using advanced 
methods, which is highly important in particular for paediatric studies 
where datasets are often sparse and variability due to age is large 4. From the 
population predicted versus observed diagnostic plots (Figure 6-S1), it can 
be concluded that the model had adequate predictive value for each of the 
four different age groups, indicating that the model accounted for the changes 
in pharmacokinetics across the entire age span from preterm neonates to 
adults. In addition, simulation based NPDE validation results proved the model 
without significant deficiency or model misspecification (Figure 6-S2).
Figure 6-S1: Observed versus population predicted paracetamol concentrations stratified 
for four different age groups
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Figure 6-S2: Results of the Normalized Prediction Distribution Error (NPDE) validation with 
a histogram showing the NPDE distribution of paracetamol concentrations with a solid 
line indicating a normal distribution (left), distribution of NPDE versus time (middle) and 
distribution of NPDE versus the log of the paracetamol concentration (right).
6.7.2 Notes for Table 6-S1 and Figure 6-S3
Supplemental Table 6-S1 summarizes previously published functions to 
describe changes in paracetamol clearance in various age ranges across whole 
age span 1-3. From the age of 1.8 years onwards typically an allometric function 
with an exponent of 0.75 suffices to describe the change in clearance. However 
when including neonates 1,2, advanced functions and multiple covariates 
bodyweight and age (postconceptional age or postnatal age) are needed to 
describe the variation in clearance (Table 6-S1). In Figure 6-S3, we plotted the 
model predicted clearances from the three previously published models 1-3 and 
from our model, against the individual bodyweights of all our individuals. The 
model-predicted paracetamol clearances from these three models were derived 
by applying the respective maturation functions (Table 6-S1) to the individual 
data from our analysis. The predictions for these models were limited to the 
age range of the original studies (Table 6-S1) in order to prevent unintended 
extrapolations of these models. Figure 6-S3 shows that the predictions of these 
four models were in reasonable agreement with each other, such despite the 
fact that different functions and covariates were used. While Zuppa et al.2 did 
not study neonates and had mainly access to children of 7 kg onwards without 
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reporting bodyweight and Mohammed et al.3 studied children from 1.8 years 
onwards, Anderson et al. did have a large number of preterm and term neonates 
in the dataset 1. For the neonatal range, the performance of the latter model 1 
seemed in good agreement with the current model, such despite the fact that 
the models varied largely in functions and number of covariates (Table 6-S1). 
From neonates to infants of about 20 kg years, it seems that the models by 
Zuppa et al.2, by Anderson et al.1 and by Mohammed et al.3 slightly overestimated 
clearance compared to the values in our study. Finally, none of these analyses 
had adult data included even though predictions up to 30 kg were fairly similar 

















































































Figure 6-S3: Graphical comparison of predictions of paracetamol clearance versus 
bodyweight between the final model of the current analysis (gray circles and gray line) and 
three previously reported models (colored letters) in log-log scale. Gray circles: post hoc 
individual clearances estimated from the current model; Gray line: final model predicted 








 BWγ / (k50γ + BWγ ), see Table 
6-2 for parameter estimates); Green‘A’: predicted clearance with model from Anderson et al.1; 
Blue ‘Z’: predicted clearance with model from Zuppa et al.2; Pink ‘M’: predicted clearance with 
model from Mohammed et al.3
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Table 6-S1: Paracetamol clearance across the human age span: comparison between 
previously published reports and current study
Year Author Weight Age-span Covariate model for clearance
2005 Anderson et al.1 0.5 – 55 kg postconception age 
27 weeks -14 years
CL = 16.3×(BW/70)0.75×(1-
0.885×exp(-PCA in weeks 
×Ln(2)/26.6)
2011 Zuppa et al.2 not reported 29 days - less than 
18 years
CL = 18.4×(BW/70)0.75×(1-
0.678×exp(-PNA in weeks 
×Ln(2)/41)
2012 Mohammed et al.3 13.7 - 56 kg 1.8 - 15 years CL = 16.51×(BW/70)0.75
This study 0.5 – 94 kg postconception age 
27 weeks - 34 years
CL=17.6×(BW/70)k ; k= 1.204 – 
0.454×BW1.4 / (12.21.4 + BW1.4 )§
CL= paracetamol clearance; BW=bodyweight; PCA=postconception age; PNA=postnatal age












KDEC  = THETA(10)                      ; DECREASE OF EXPONENT
KMAX  = THETA(11)+KDEC                 ; MAXIMUM EXPONENT
KHAL  = THETA(12)                      ; K50
GAMMA = THETA(13)                      ; GAMMA
KBDE  = KMAX-KDEC*(BW**GAMMA)/(KHAL**GAMMA+BW**GAMMA)
TVCL  = THETA(1)*(BW/70)**KBDE
CL    = TVCL*EXP(ETA(1))
TVVC  = THETA(2)*(BW/70)
VC    = TVVC*EXP(ETA(2))
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Q2     = THETA(3)*(BW/70)
TVVP1  = THETA(4)*(BW/70)
VP1    = TVVP1*EXP(ETA(3))
Q3     = THETA(5)*(BW/70)
TVVP2  = THETA(6)*(BW/70)
VP2    = TVVP2*EXP(ETA(4))
KA    = THETA(7)*EXP(ETA(5))
ALAG1 = THETA(8)
TVF1  = THETA(9)
F1=EXP(LOG(TVF1/(1-TVF1))+ETA(6))/(1+EXP(LOG(TVF1/(1-TVF1))+ETA(6))) 
;-------------------------------------------------------------------------------
ET1  = ETA(1)
ET2  = ETA(2)
ET3  = ETA(3)
ET4  = ETA(4)
ET5  = ETA(5)




K12  = KA
K23  = Q2/VC
K32  = Q2/VP1
K24  = Q3/VC
K42  = Q3/VP2




IF (F.GT.0) IPRED = LOG(F)
Y = IPRED + EPS(1)
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; Y = IPRED + SQRT(THETA(10)**2+THETA(11)**2/F**2)*ERR(1)
;-------------------------------------------------------------------------------
$THETA
(0.01, 5,     )   ;TH1 CL
(2,   10,     )   ;TH2 VC
(0.01, 70,     )  ;TH3 Q2
(0.1,  30,    )   ;TH4 VP1
(0.01, 2,     )   ;TH5 Q3
(0.1,  30,    )   ;TH6 VP2
(0.01, 0.13,  )   ;TH7 KA
(0.01, 0.2,   )   ;TH8 ALAG
(0.01, 0.93, 1)   ;TH9 F1 
(0.1,  0.4,  1)   ;TH10 KDEC
0.75 FIX  ;TH11 KMAX-KDEC OR KMIN
(0.05, 3.5,   )   ;TH12 K50
1.4 FIX ;TH13 GAMMA
;-------------------------------------------------------------------------------
$OMEGA
0.12    ;CL
0.12    ;VC
0 FIX   ;VP1
0 FIX   ;VP2
0.11    ;KA





$EST NOABORT SIGDIG=3 PRINT=15 MAXEVAL=9999 METHOD=1 INTERACTION 
POSTHOC
$COV COMP PRINT=E
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Chapter
7
Scaling of clearance across the human
life span from neonates to adults: 
conclusions and perspectives




Drug treatment is more difficult in children than in adults. The wide variation 
in various physiological processes in children leads to a wide variation in 
treatment response and this warrants an individualized approach to drug 
treatment in this vulnerable group of patients. Identifying the optimal dose 
is the key element of a good drug treatment practice for children. At present 
dose adjustment on the basis of milligram per kilogram of body weight 
is still widely used. However, dose selection in children should be based on 
pertinent information with regard to the variation in pharmacokinetics and 
pharmacodynamics as the key determinants of the drug effect. In that regard 
also disease and other factors need to be taken into account [1-4].
Interindividual variation in pharmacokinetics and pharmacodynamics in 
the paediatric population is the result of complex physiological changes 
during growth and development. Clearance is one of the most important 
pharmacokinetic parameters of which the value needs to be known for rational 
dose adjustment. However, collecting blood samples for pharmacokinetic 
studies in children is not easy and the information available for estimation 
of drug clearance in children is typically scarce. Therefore, scaling of drug 
clearance with pharmacokinetic modeling techniques (between adults and 
children or within paediatric populations) is of great interest for both clinical 
practice and drug development in pediatrics [4]. In general, there are two 
modeling approaches to the description of pharmacokinetics: the population 
pharmacokinetic (POPPK) modeling approach and the physiologically based 
pharmacokinetic (PBPK) modeling approach. POPPK modeling is a data-driven 
method aiming at the fitting of pharmacokinetic models to observed drug 
concentrations, while PBPK modeling is a physiological knowledge based 
method aiming to predict pharmacokinetics based on pertinent information 
on the variation in the underlying processes.
To date, for the scaling of drug clearances under the POPPK approach three 
modeling approaches are used: i) allometric scaling, ii) allometric scaling with a 
fixed exponent value of 0.75 combined with an age based maturation function, 
and iii) systematic covariate analysis. As neither allometric scaling nor allometric 
scaling plus an age-based maturation model can describe the developmental 





changes in drug clearance with adequate statistical stability and predictive 
performance across the entire age-span, we explored, in a systematic covariate 
analysis, the utility of novel functions to describe developmental changes in 
clearance across the entire human life span. As bodyweight was found to be 
the best descriptor for drug clearance across different pediatric age groups in 
many studies, the research in this thesis focused on the identification of novel 
functions to describe the changes in drug clearance across the whole life span 
on the basis of bodyweight without additional covariates.
7.2.  The observation of different values for the 
allometric exponent
The objective of the research described in Chapter 3 was to explore the 
variation in the value of the allometric exponent for children in different age 
groups in a systematic covariate analysis. To this end a large database with 
pertinent information on the pharmacokinetics of propofol across the human 
lifespan was established. Data from seven propofol studies were included in 
the analysis (neonates, infants, toddlers, children, adolescents, adults1, and 
adults2). In a systematic manner, two out of the six study populations were 
randomly combined resulting in 15 combined datasets. In addition, the data 
of the seven studies were regrouped into five age-groups (according to FDA 
Guidance 1998), from which four combined datasets were prepared consisting 
of one paediatric age-group and the adult group. In each of these 19 combined 
datasets, the allometric scaling exponent for clearance was estimated using 
population pharmacokinetic modelling (NONMEM 7.2).
The results of this study show a large variety in the value of the allometric 
exponent for clearance with values ranging from 0.2 to 2.01 when analyzing 
combined datasets of two paediatric populations. While the lowest values of 
the exponent of 0.2 was identified between infants and toddlers, the highest 
exponent of 2.01 was found between neonates and infants. These findings 
show that there is no single unique value of the allometric exponent that can 
describe the variation in clearance across the human age-span. This implies 
that especially in the pediatric age range, the widely applied ¾ allometric 
function is inappropriate to describe and predict drug clearance in preterm 
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and term neonates, infants and young children. Also in literature, this function 
was found to systematically over-predict clearance for neonates and under-
predict clearances for infants [5-8]. There are indications that the results found 
for propofol in this chapter, apply to other drugs as well. For example, the 
value of the exponent of 0.88 for propofol in toddlers and children (model 10), 
appears to be in good agreement with findings on oxycodone clearance in 
children aged between 6 months to 7 years, where a value of the allometric 
exponent of 0.875 has been reported [9]. It is concluded that for the scaling 
of clearance between two paediatric populations, the allometric exponent 
needs to be estimated rather than fixed to the value 0.75 in order to account 
for differences in maturation between different age groups, since the values 
appear to be highly varyiable. However, as with increasing age the estimated 
allometric scaling line moved slowly towards 0.75 (Chapter 3, Figure 3-3 B to 
E), it seems that ¾ allometric scaling function may be of value in older children 
(>4 years) towards adults.
7.3.  Exploring a novel descriptive model for the scaling 
of the clearance of propofol
In Chapter 4, we tested four different models based on different allometric 
equations, to capture changes in propofol clearance in the complete dataset 
from chapter 3 comprising almost every stage of human life. The four different 
models were: model I - 3/4 allometric scaling model; model II- mixture model; 
model III - bodyweight-cut-point separated model and model IV - bodyweight-
dependent exponent model. We found that fixing of the allometric exponent 
to the value of 0.75 (the ¾ allometric model; model I) resulted in an adequate 
description of the variation in clearance in adults, adolescents, children and 
toddlers, but that it yielded a significant under-prediction in infants and an 
over-prediction in term and preterm neonates. The results of the mixture model 
(model II) and the bodyweight-cut-point separated model (model III) showed 
that a value of the allometric exponent different from 0.75 is more suitable for 
neonates and infants. In fact, both models identified an allometric exponent 
larger than 1 for the subpopulation that was composed of mainly neonates 
and infants, resulting in improved description of clearance in these youngest 
patients with the lowest body weight in comparison to the ¾ allometric model. 





This has been reported before for morphine clearance in children younger 
than 3 years of age, where a value of the allometric exponent of 1.44 was 
found to best describe the developmental changes in clearance [10]. Similarly, 
Mahmood reported that the error in the prediction of clearance decreased 
when the scaling exponent increased from 0.75 towards 1 when studying a 
range of different drugs in children younger than 1 year of age [11].
Even though the overall performance improved significantly, the use of 
two different allometric exponents for different human subpopulations as 
implemented in model II and model III resulted in ambiguous clearance 
predictions for the individuals on the boundaries of the pediatric 
subpopulations. Therefore, in this study, a novel approach to the description 
of the variation in clearance across the entire life span was introduced, which is 
based on an allometric equation with an exponent that varies in a continuous 
manner with bodyweight (model IV). This bodyweight-dependent exponent 
(BDE) model contains a sigmoidal function to describe the change in the value 
of the allometric exponent with bodyweight. It is shown that this function 
allows for the best description of maturational changes in propofol clearance 
across the entire human life span. For propofol clearance, the exponent was 
found to decrease in a sigmoidal manner with bodyweight from 1.34 to 0.55, 
with half the decrease in exponent reached at a body weight of 3.78 kg. It was 
also illustrated that the BDE function is flexible in capturing very different 
shapes of the relation between clearance and bodyweight (Figure 7-1).
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Figure 7-1 Simulations for the bodyweight-dependent exponent (BDE) model for scaling 
clearance (  )  on the basis of different values for the 
parameters of the bodyweight-dependent exponent ( ) .
Solid black curve: BDE model predicted clearance curve with k
0
 = 1.34, k
max
 = 0.79, k
50
 = 3.78, γ= 5.24 
(final PK model of Chapter 4); dashed grey curve: BDE model predicted clearance curve with k
0










 = 0.8, k
50





 = 1.1, k
50
 = 4.5, γ= 10; medium dash double dot grey curve: BDE model predicted clearance 
curve with k
0
 = 1.34, k
max
 = 0.8, k
50
 = 1, γ= 5.
7.4.  Applying the novel BDE model to morphine and 
morphine-3-glucuronide
In Chapter 5, the novel bodyweight-dependent exponent model was applied 
to characterize the developmental changes in morphine clearance across the 
entire pediatric age-range. To this end, morphine and morphine-3-glucuronide 
(M3G) concentration data from 358 (pre)term neonates, infants, children and 
adults, and morphine concentration data from 117 adolescents were analyzed 
using NONMEM 7.2. Based on available data, two models were developed: i) a 





model using morphine data only (model 1) and ii) using morphine and M3G 
data (model 2). In model 1, morphine clearance across the pediatric age range 
was very well described by a bodyweight-based exponential function in which 
the allometric exponent decreased in a sigmoidal manner with bodyweight 
(BDE model) from 1.47 to 0.88, with half the decrease in the value of the 
exponent reached at a body weight of 4.01 kg. In model 2, the exponent for the 
formation and elimination clearance of M3G was found to decrease from 1.56 
to 0.89 and from 1.06 to 0.61, with half the decrease reached at body weights 
of 3.89 and 4.87 kg, respectively. Using the BDE model, there was no need to 
use additional covariates to account for size or age. These study results not only 
confirmed the model results based on children less than 3 years in which an 
exponent of 1.44 was identified [10], but also provides a basis for extrapolation 
to older age-ranges by the quantification of the maturation of glucuronidation 
across the entire pediatric age-range with the estimation of a lower exponent 
for higher bodyweight ranges. Moreover, it seems that applying an allometric 
function in which the exponent is allowed to vary with bodyweight itself results 
in an optimal description of the varying rates of maturation of glucuronidation 
clearance of morphine across all age ranges without the need for additional 
age-based covariates (PNA <> 10 days) that were reported when a single 
allometric exponent is used [10, 12, 13] (Chapter 5, Figure 5-5).
7.5. Using the novel BDE model for paracetamol
In Chapter 6, we further tested the BDE model for describing variation in 
paracetamol clearance across whole paediatric age-span. A total of 220 subjects 
from eight previously published studies on paracetamol pharmacokinetics 
were included in the analysis, including (pre)term neonates, infants, children 
and adults. Population pharmacokinetic modelling was performed using 
NONMEM 7.2. In the covariate analysis for clearance, linear functions, power 
functions and a power function with a bodyweight-dependent exponent were 
tested. It was clearly shown that the BDE model describes the age-related 
changes in clearance of paracetamol across the human life span best, and 
without the need for inclusion of additional age variables as a covariate. For 
clearance, the exponent was found to decrease in a sigmoidal manner with 
bodyweight from 1.2 to 0.75, with half the decrease in exponent reached at a 
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body weight of 12.2 kg. Based on the final model, simulations were performed 
to derive optimized dosing guidelines across the entire paediatric age range. 
In this respect, a model based intravenous paracetamol dose calculation table 
for children was provided aiming for similar paracetamol exposure across 
the paediatric age range. This is of particular relevance because there is yet 
no dosing information on paracetamol iv in preterm neonates (Europe) or in 
children younger than 2 years of age (US).
7.6. Perspectives
7.6.1. The best descriptive predictor for clearance
In this thesis, an important question was how to accurately describe maturation 
in clearance across the human life span. A complicating factor in the analysis of 
age-related changes in pharmacokinetics is the correlation between covariates 
that can be used as the basis for the description of maturation. Specifically the 
covariates bodyweight and age are correlated during growth and development 
of a child. Bodyweight is often referred to as measure of size only, whereas age 
is referred to as a measure of maturation. The relationship between age and 
bodyweight has been investigated by demographic surveys. Based on these 
survey results, growth charts have been developed. In Figure 7-2, data from the 
CDC growth chart percentiles table (http://www.cdc.gov/growthcharts/data/
zscore/) are plotted in four panels demonstrating the relationship between 
weight and age for boys and girls younger or older than 2-3 years of age. These 
graphs show that between birth and adulthood the relation between age and 
bodyweight is highly non-linear.





Figure 7-2 CDC growth chart plot (5%, 50% and 95% percentile) for different age-ranges 
divided by gender based on CDC percentiles table (http://www.cdc.gov/growthcharts/data/
zscore/).
However, for neonates, in particular when both prematurely born neonates and 
term neonates are considered, the correlation between weight and postnatal 
age may not be that obvious. Figure 7-3 shows a plot of body weight against 
postnatal age (PNA), postmenstrual age (PMA), gestational age (GA) with the 
corresponding Pearson’s Correlation Coefficient values in 874 preterm and 
term neonates from a previous publication of our group [14]. The plot shows 
that bodyweight is highly correlated with PMA or GA, and that there is less 
correlation between bodyweight and PNA. In PBPK models, postnatal age 
instead of bodyweight is typically used as a basis for maturation functions in 
paediatrics. However, it seems from these results that in neonates, bodyweight, 
PMA or GA instead of PNA is preferred to describe maturation in clearance 
across the human age range.
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Figure 7-3 Scatter plots of bodyweight against postnatal age (PNA), postmenstrual age 
(PMA) and gestational age (GA) in 874 preterm and term neonates [14].
For scaling clearance across the pediatric age-range with inclusion of preterm 
and term neonates, we found in this thesis, that the bodyweight based scaling 
approach (BDE model) can describe the changes in drug clearance without the 
need for additional (age-related) covariates. We think that this can be explained 
by the fact that the BDE model is highly flexible in nature and can capture many 
different nonlinear relations between bodyweight and clearance (Figure 7-1). 
Describing changes in clearance across the human age range on the basis of one 
covariate only seems of importance as the implementation of two (correlated) 
covariates on one parameter may lead to bias in parameter estimates [15]. After 





implementation of the BDE function it was found that age variables have no 
influence on inter-individual variability in clearance of propofol, morphine and 
paracetamol. In previous studies in which a fixed exponent was used, very often 
other covariates were needed to obtain an optimal description of the data, as was 
reported for morphine under the age of 3 years for instance [10, 16]. From these 
results, it is concluded that body weight may play a role as a surrogate of different 
age variables (PNA, PMA, or GA) across the whole pediatric age-span. Eventually, 
the influence from both weight and age on clearance is explained by an advanced 
BDE equation with bodyweight as the only covariate. Results from this thesis on 
propofol (Chapter 3 and Chapter 4), morphine (Chapter 5), paracetamol (Chapter 
6), busulfan (Appendix I) and midazolam (Appendix II) show that the BDE model 
can result in adequate prediction of clearance across the entire pediatric age-
span. From a model diagnostic point of view, the BDE model has adequate 
goodness-of-fit properties for different age groups and has good empirical Bayes 
estimates (EBE) diagnostics. Besides, the BDE model also allows for a weight based 
dose recommendation, as was shown for paracetamol in Chapter 6. Therefore, we 
conclude that bodyweight alone can be used as descriptor for clearance across 
the human age range, provided advanced functions such as the BDE model are 
applied, and the results are confirmed by proper validations [17].
7.6.2. Full or simplified BDE function?
In this thesis we present the BDE model to describe maturation of clearance 
across the human life span for three drugs propofol (Chapter 4), morphine 
(Chapter 5), paracetamol (Chapter 6). In the meantime the model has also 
been applied to busulfan (Appendix I), midazolam (Appendix II) and a 
number of antibiotics (gentamicin, tobramycin and vancomycin; unpublished 
observations). The BDE model was developed based on a sigmoidal equation 
that was initially derived for propofol (Chapter 4). Later on, it was simplified 
to a power equation for busulfan, midazolam and antibiotics. Table 7-1 shows 
the BDE equations and the corresponding parameter estimates that were 
idenfified in those studies. In studies of propofol, morphine and paracetamol, 




model also allows for a weight based dose recommendation, as was shown for paracetamol 
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are applied, and the results are confirmed by proper validations [17].  
7.6.2. Full or simplified BDE function? 
In this thesis we present the BDE model to describe maturation of clearance across the 
human life span for three drugs propofol (Chapter 4), morphine (Chapter 5), paracetamol 
(Chapter 6). In the meantime the model has also been applied to busulfan (Appendix I), 
midazolam (Appendix II) and a number of antibiotics (gentamicin, tobramycin and 
vancomycin; unpublished obs rv tions). The BDE model was developed based on a 
sigmoidal equation that was initially derived for ropofol (Chapter 4). Later on, it was 
simplified to a power equation for busulfan, midazolam and antibiotics. Table 7-1 shows the 
BDE equations and the corresponding parameter estimates that were idenfified in those 
studies. In studies of propofol, morphine and paracetamol, for the exponent BDE or k a 
sigmoidal equation  
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was used in the BDE model, albeit with the identification of different parameter estimates for k 
(or the bodyweight dependent exponent). Table 7-1 shows that all estimates of the parameter 
k0 were found to be greater than 1 in studies for propofol, morphine and paracetamol (1.35, 
1.56 and 1.2 respectively). Besides, kmax, which represents the decrease in k from k0 at the 
hypothetical body weight of 0 kg, was found to vary between drugs (0.79, 0.67 and 0.45 for 
propofol, morphine and paracetamol, respectively) even though at adulthood similar values 
for k were observed (0.56, 0.89, and 0.75 at a weight of 70 kg) (Table 7-1, Figure 7-4 a). 
Concerning the parameters k50 and γ, for propofol and morphine, we observed an early and 
steep decrease in k with corresponding estimates of k50 = 3.71 kg, γ = 5.1 and k50 = 3.89 kg, γ 
= 3.61, respectively (Figure 7-4 a), which results in a stair-climbing pattern of increase in 
clearance over bodyweight from newborn babies to adults on a log-log scale (Figure 7-4 b). 
However, this decrease in k appears to be much slower for paracetamol with corresponding 
estimates for k50 = 12.2 kg and γ = 1.2 (Figure 7-4 a), resulting in a water-overflowing pattern 
of increase in clearance over bodyweight from newborn babies to adults in a log-log scale 
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was used in the BDE model, albeit with the identification of different parameter 
estimates for k (or the bodyweight dependent exponent). Table 7-1 shows that 
all estimates of the parameter k
0
 were found to be greater than 1 in studies 
for propofol, morphine and paracetamol (1.35, 1.56 and 1.2 respectively). 
Besides, k
max
, which represents the decrease in k from k
0
 at the hypothetical 
body weight of 0 kg, was found to vary between drugs (0.79, 0.67 and 0.45 for 
propofol, morphine and paracetamol, respectively) even though at adulthood 
similar values for k were observed (0.56, 0.89, and 0.75 at a weight of 70 kg) 
(Table 7-1, Figure 7-4 a). Concerning the parameters k
50
 and γ, for propofol and 
morphine, we observed an early and steep decrease in k with corresponding 
estimates of k
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 = 3.71 kg, γ = 5.1 and k
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 = 3.89 kg, γ = 3.61, respectively (Figure 
7-4 a), which results in a stair-climbing pattern of increase in clearance over 
bodyweight from newborn babies to adults on a log-log scale (Figure 7-4 b). 
However, this decrease in k appears to be much slower for paracetamol with 
corresponding estimates for k
50
 = 12.2 kg and γ = 1.2 (Figure 7-4 a), resulting 
in a water-overflowing pattern of increase in clearance over bodyweight from 
newborn babies to adults in a log-log scale (Figure 7-4 b).




Table 7-1 Summary of all studies in which the bodyweight-dependent exponent (BDE) 
model ( ) was used for scaling clearance from adults to children with 
either a sigmoidal or a power equation for k. 
1 Chapter 4 in this thesis  
2 Chapter 5 in this thesis  
3 Chapter 6 in this thesis  
4 Appendix I in this thesis 
5 Appendix II in this thesis 
6 Unpublished results  
In studies on busulfan, midazolam and antibiotics, a power equation  
,       (2) 
was used in the BDE model (Table 7-1, Figure 7-4 c). The decrease in k over bodyweight for 
those drugs is rather slow compared to previous three drugs, although the magnitude in 
decrease varies very much among those five drugs (Figure 7-4 c). In contrast to the 
sigmoidal BDE function, which is highly flexible (Figure 7-1), the simplified power BDE 
equation lacks the flexibility of capturing different shapes with a trade-off of stable model 
estimates. Obviously, the simplified BDE model is preferred because of the parsimonial rule 
(estimation of 2 parameters instead of 4 parameters for k, Table 7-1). In our analysis, the 
simplified model was selected for busulphan for which no data from preterm and term 
neonates were available (Figure 7-4 c,d, Table 7-1). However, also for midazolam the 
simplified BDE equation was able to capture changes in clearance, even though the study 
covered the whole life span including preterm and term neonates. We think that this may be 
explained by the pathway that is involved, which is CYP3A oxidation in case of midazolam. 
As such, beside the age range studied, the pathway involved may determine whether a 
simplified or a sigmoidal BDE function is needed. The study of three antibiotics is another 
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As such, beside the age range studied, the pathway involved may determine 
whether a simplified or a sigmoidal BDE function is needed. The study of three 
antibiotics is another example of the identification of a simplified or power 
BDE equation across the whole age-span, in this case for drugs that are all 
eliminated through Glomerular Filtration Rate (GFR). Although the three curves 
of k and clearance versus bodyweight in the antibiotics study were different 
from those identified for midazolam and busulfan, no large differences were 
found between these three antibiotics (Figure 7-4 c,d, Table 7-1). Given the 
fact that these three antibiotics are all eliminated through the same pathway 
(GFR), this finding may provide the basis for the extrapolation of this simplified 
BDE model to other drugs eliminated through GFR. This is an approach that 
has been proposed before [3] and was applied for glucuronidation as well [18].
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,       (2) 
was used in the BDE model (Table 7-1, Figure 7-4 c). The decrease in k over bodyweight for 
those drugs is rather slow compared to previous three drugs, although the magnitude in 
decrease varies very much among those five drugs (Figure 7-4 c). In contrast to the 
sigmoidal BDE function, which is highly flexible (Figure 7-1), the simplified power BDE 
equation lacks the flexibility of capturing different shapes with a trade-off of stable model 
estimates. Obviously, the simplified BDE model is preferred because of the parsimonial rule 
(estimation of 2 parameters instead of 4 parameters for k, Table 7-1). In our analysis, the 
simplified model was selected for busulphan for which no data from preterm and term 
neonates were available (Figure 7-4 c,d, Table 7-1). However, also for midazolam the 
simplified BDE equation was able to capture changes in clearance, even though the study 
covered the whole life span including preterm and term neonates. We think that this may be 
explained by the pathway that is involved, which is CYP3A oxidation in case of midazolam. 
As such, beside the age range studied, the pathway involved may determine whether a 
simplified or a sigmoidal BDE function is needed. The study of three antibiotics is another 
0.81 -0.135 CYP3A PNA: Birth – 31 yrs
BW: 0.77 – 89 kg
gentamicin6 2.6 -0.093 Glomerular 
Filtration Rate 
(GFR)
PNA: Birth – 15 yrs
BW: 0.44 – 80 kg
tobramycin6 2.67 -0.079 Glomerular 
Filtration Rate 
(GFR)
PNA: 2 days – 18 yrs
BW: 0.485 – 85 kg
vancomycin6 2.12 -0.065 Glomerular 
Filtration Rate 
(GFR)
PNA: Birth – 17 yrs
BW: 0.415 – 85 kg
1 Chapter 4 in this the is
2 Chapter 5 in this the is
3 Chapter 6 i  is
4 Ap endix I in this thesis
5 Ap endix II in this the is
6 Unpublished results
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Figure 7-4 Bodyweight-dependent exponent (BDE or k) (panels a and c) and clearance 
 
129
example of the identification of a simplified or power BDE equation across the whole age-
span, in this case for drugs that are all eliminated through Glomerular Filtration Rate (GFR). 
Although the three curves of k and clearance versus bodyweight in the antibiotics study were 
different from those identified for midazolam and usulfan, no large differences were found 
between these three antibiotics (Figure 7-4 c,d, Table 7-1). Given the fact that these three 
antibiotics are all eliminated through the same pathway (GFR), this finding may provide the 
basis for the extrapolation of this simplified BDE model to other drugs eliminated through 
GFR. This is an approach that has been proposed before [3] and was applied for 
glucuronidation as well [18].  
Figure 7-4 Bodyweight-dependent exponent (BDE or k) (panels a and c) and clearance 
( ) (panel b and d) versus bodyweight for the models derived for 
propofol, morphine and paracetamol in which a sigmoidal function ( ) for 
k was used (panel a and b) and for the models derived for busulfan, midazolam, 
gentamicin, tobramycin and vancomycin in which a simplified (or power) function 
( ) for k was used (panel c and d). For specific estimates see Table 7-1. 
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7.6.3. Physiologically based pharmacokinetic modeling in pediatrics
At present there is an increasing interest in the application f physiologically 
based pharmacokinetic (PBPK) modeling in paediatric drug development. 
In PBPK modeling, the hum n b dy is considered to be composed of multi-
compartments representing actual organs and other physiological spaces. Mass 
balance equations for each organ describe drug distribution in the organ from 
arterial blood and its exit into venous blood. The PBPK model is parameterized 
in relevant drug specific parameters (e.g. LogP and pKa) and biological system 





specific parameters (e.g. tissue volumes, the perfusion rates of these tissue 
compartments, the concentration of binding proteins, the values of the activities 
of drug metabolizing enzymes, the expression and function of transporters in 
the excretion). The use of PBPK models for prediction of pharmacokinetics in 
children from information in adults requires information on the change in the 
values of the system specific parameters across the paediatric life span. The 
common approach is to modify a PBPK model that has been validated with 
adult PK data and then to incorporate the differences in growth and maturation 
that can affect all system specific parameters. In PBPK modeling, information 
on the values of the changes in system specific parameters is typically obtained 
from in vitro studies, which is often not available for children of all age ranges 
including preterm and term neonates. Here we propose to use information from 
our descriptive BDE models for different metabolic or elimination pathways on 
the change in for example intrinsic clearance as a measure of developmental 
changes in system specific parameter in PBPK models. Given the fact that the 
in vitro data are extremely scarce in preterm neonates, the information from 
BDE model may be specifically helpful for this population. Recently, Krekels et 
al. explored such application of the POPPK model in describing developmental 
changes of UGT2B7-mediated glucuronidation parameters [19]. In the end, they 
suggested that the maturation profile for UGT2B7 ontogeny in a PBPK model 
can be improved based on information obtained from a covariate model of a 
paediatric population model derived for a specific substrate for UGT2B7 on the 
basis of a systematic covariate analysis [19]. Further studies on using POPPK 
(covariate) models in adjusting PBPK models for improving the simulation 
performance of PBPK models in pediatric drug development are encouraged.
7.7. Conclusion
In this thesis, we propose the body weight dependent exponent (BDE) model 
as novel approach for describing drug clearance over the entire pediatric age-
span. This provides us an alternative approach to the previous “weight plus age” 
approach with better statistical properties. The model offers the advantage 
of much improved clearance estimates of drugs in clinical practice enabling 
the prediction of the individualized dose in children, particularly neonates. 
Moreover, the model provides a basis for the incorporation of information on 
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the maturation of clearance from in vivo studies into physiologically-based 
pharmacokinetic models for the prediction of developmental changes in 
clearance for novel drugs. These predictions constitute the scientific basis for 
optimized clinical trial designs for studies in pediatrics.
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Schaling van de klaring van 
geneesmiddelen over de
levensduur van een mens van 
pasgeborenen tot volwassenen:
conclusies en perspectieven




Medicamenteuze behandeling is moeilijker bij kinderen dan bij volwassenen. 
De grote variatie in de verschillende fysiologische processen bij kinderen 
leidt tot een grote variatie in de respons op de behandeling en dit maakt een 
geïndividualiseerde benadering van de behandeling met geneesmiddelen 
in deze kwetsbare groep patiënten noodzakelijk. Het identificeren van de 
optimale dosis is het belangrijkste onderdeel van een goede behandeling 
met geneesmiddelen voor kinderen. Momenteel wordt in de klinische 
praktijk de dosis veelal aangepast op basis van kilogram lichaamsgewicht. 
Echter, de dosering bij kinderen zou moeten worden aangepast op basis 
van relevante informatie met betrekking tot de variatie in farmacokinetiek 
en farmacodynamiek als de belangrijkste factoren die bepalend zijn voor de 
werking van het geneesmiddel. In dit verband moeten ook ziekte en andere 
factoren in aanmerking worden genomen.
Interindividuele variatie in farmacokinetiek en farmacodynamiek van 
geneesmiddelen in de pediatrische populatie is het resultaat van complexe 
fysiologische veranderingen tijdens groei en ontwikkeling. Klaring is een 
van de belangrijkste farmacokinetische parameters waarvan de waarde 
bekend moet zijn voor rationele dosisaanpassing. Echter, het verzamelen van 
bloedmonsters voor farmacokinetische studies bij kinderen is niet eenvoudig 
en de beschikbare informatie over de klaring van specifieke geneesmiddelen 
bij kinderen is meestal schaars. Daarom is schaling van geneesmiddelklaring 
met farmacokinetische modelleertechnieken tussen volwassenen en kinderen 
of binnen de pediatrische populatie van groot belang voor zowel de klinische 
kinderpraktijk als voor de ontwikkeling van nieuwe geneesmiddelen in de 
kindergeneeskunde. In het algemeen zijn er twee modelmatige benaderingen 
voor de beschrijving van de farmacokinetiek: populatie farmacokinetische 
modellering (POPPK) en fysiologisch farmacokinetische modellering (PBPK). 
POPPK modellering is een data - gedreven benadering gericht op het 
beschrijven van variatie in de farmacokinetiek, terwijl PBPK modellering 
gebaseerd is op de fysiologische processen die ten grondslag liggen aan 
veranderingen in farmacokinetiek.





Tot voor kort werden bij de POPPK benadering voor de schaling van de klaring 
drie methoden toegepast:  i ) allometrische scaling op basis van lichaamsgewicht, 
ii ) allometric scaling op basis van lichaamsgewicht met een vaste exponent 
waarde van 0,75 in combinatie met een leeftijd gebaseerde rijping functie, 
en iii ) de systematische covariaat analyse. Omdat noch allometrische 
schaling op basis van lichaamsgewicht noch allometrische schaling op basis 
van lichaamsgewicht plus een op leeftijd gebaseerde rijping functie de 
ontwikkelingsgerelateerde verandering in klaring goed kan beschrijven met 
voldoende statistische stabiliteit en voorspellende waarde over het gehele 
leeftijdsbereik, hebben we in een systematische covariaat analyse de betekenis 
van nieuwe functies voor het beschrijven van veranderingen in de klaring over 
de gehele levensduur de mens onderzocht. Aangezien lichaamsgewicht de 
beste descriptor voor verandering in geneesmiddelklaring over verschillende 
pediatrische leeftijdsgroepen is gebleken, richt het onderzoek in dit proefschrift 
zich op de identificatie van nieuwe functies op basis van het lichaamsgewicht, 
die gebruikt kunnen worden om de veranderingen in geneesmiddelklaring 
over de hele levenscyclus van de mens zonder bijkomende covariaten te 
beschrijven. Deze functies kunnen vervolgens gebruikt worden als basis om 
geïndividualiseerd te kunnen doseren in kinderen.
De waarneming van verschillende waarden voor de 
allometrische exponent
Het doel van het in hoofdstuk 3 beschreven onderzoek was om de variatie 
in de waarde van de allometrische exponent voor kinderen in verschillende 
leeftijdsgroepen te bepalen in een systematische covariaat analyse. Hiertoe 
is een grote databasis met relevante informatie over de farmacokinetiek van 
propofol over het menselijke leeftijdsbereik opgezet. Gegevens uit 7 propofol 
studies die betrekking hebben op 6 verschillende leeftijdsgroepen werden in de 
analyse betrokken: pasgeborenen, zuigelingen, peuters, kinderen, adolescenten, 
en volwassenen. Op een systematische manier werden twee van de zes studie 
populaties willekeurig gecombineerd wat resulteerde in 15 gecombineerde 
datasets. Bovendien zijn de gegevens van de zeven studies gegroepeerd in 
vijf leeftijdsgroepen volgens FDA Guidance 1998, waaruit vervolgens vier 
gecombineerde datasets werden gemaakt bestaande uit de volwassengroep en 
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een van de vier pediatrische leeftijdsgroepen. In elk van deze 19 gecombineerde 
datasets, werd de allometrische exponent voor de klaring van propofol geschat 
met behulp van populatie farmacokinetisch modellering (NONMEM 7.2).
De resultaten van deze studie laten een grote variatie zien in de waarde van de 
exponent voor allometrische schaling met waarden variërend van 0,2 tot 2,01 
wanneer gecombineerde datasets van twee pediatrische populaties worden 
bestudeerd. De laagste waarde van de exponent van 0,2 werd vastgesteld bij 
de combinatie van gegevens in baby’s met zuigelingen tot 2 jaar, terwijl de 
hoogste waarde van de exponent van 2,01 werd gevonden bij de combinatie 
van gegevens in pasgeborenen met zuigelingen tot 2 jaar. Deze bevindingen 
laten zien dat er niet een enkele unieke waarde van de allometrische exponent 
is waarmee de variatie in de klaring over het menselijk leeftijdsbereik kan 
worden beschreven. Dit betekent dat de in kinderen op grote schaal toegepaste 
¾ allometrische functie niet kan worden gebruikt voor het voorspellen van 
de klaring bij (premature) pasgeborenen, zuigelingen en jonge kinderen tot 
2-4 jaar. Omdat er aanwijzingen zijn dat de resultaten zoals gevonden voor 
propofol in dit hoofdstuk, ook gelden voor andere geneesmiddelen, wordt 
geconcludeerd dat bij de schaling van de klaring tussen twee pediatrische 
populaties, de waarde van de allometrische exponent moet worden geschat 
om rekening te houden met verschillen in rijpingssnelheid tussen verschillende 
leeftijdsgroepen. Echter, er werd ook gevonden dat met toenemende leeftijd 
de waarde van de allometrische exponent zich steeds meer in de richting van 
de waarde van 0,75 beweegt (hoofdstuk 3, figuur 3B tot 3E). Het lijkt er daarom 
op dat de ¾ allometrische scaling functie van waarde kan zijn bij oudere 
kinderen (> 4 jaar) en volwassenen.
Een nieuw beschrijvend model voor de schaling van de 
klaring van propofol
Het onderzoek in hoofdstuk 4 heeft betrekking op de vergelijking van vier 
verschillende, op allometrie gebaseerde vergelijkingen, voor de beschrijving 
van de veranderingen in de klaring van propofol in de volledige dataset van 
hoofdstuk 3 met gegevens over het volledige leeftijdsbereik van prematuren tot 
volwassenen. De vier verschillende modellen waren: model I – ¾ allometrische 





schaling-model; model II - gemengd allometrisch schalingsmodel van twee 
subgroepen; model III - lichaamsgewicht-gescheiden allometrisch schalings 
model van twee subgroepen en model IV - lichaamsgewicht-afhankelijk 
exponent model. We vonden dat de beschrijving van de data van het 
allometrisch schalingsmodel met een vaste waarde van de exponent van 0,75 
(de ¾ allometrische model; model I) weliswaar een goede beschrijving gaf van 
de variatie in de klaring bij volwassenen, adolescenten, kinderen en peuters, 
maar dat de klaring werd onderschat in jonge kinderen tussen de 1 en 2 jaar 
en werd overschat in prematuren en a terme pasgeborenen. De resultaten van 
het gemengd model met twee subgroepen (model II) en het lichaamsgewicht-
gescheiden model van twee subgroepen(model III) toonden aan dat een 
waarde van de allometrische exponent anders dan 0,75 meer geschikt is 
voor pasgeborenen en zuigelingen. Met een waarde van de allometrische 
exponent die groter is dan 1 voor de subpopulatie die voornamelijk bestaat 
uit pasgeborenen en zuigelingen, geven beide modellen een sterk verbeterde 
beschrijving van de klaring bij deze jongste patiënten met het laagste 
lichaamsgewicht. Dit is in overeenstemming met de waarnemingen voor 
morfine, waar bij kinderen jonger dan 3 jaar, een waarde van de allometrische 
exponent van 1,44 werd gevonden voor de beschrijving van de verandering 
in de klaring. Mahmood meldde ook dat bij kinderen jonger dan 1 jaar de 
voorspelling van de klaring van een scala van verbindingen verbetert wanneer 
een waarde van de allometrische exponent van 1 wordt gebruikt in vergelijking 
met 0.75.
Hoewel de voorspelling van de klaring door de leeftijd heen aanzienlijk verbetert, 
door het gebruik van twee verschillende allometrische exponenten voor twee 
verschillende leeftijdsgroepen in de populatie (modellen II en III), kennen ook 
deze modellen beperkingen. Een belangrijke beperking heeft betrekking op 
de schatting van de klaring in individuen met een leeftijd in het grensgebied 
van de twee subpopulaties. In deze individuen levert de extrapolatie op basis 
van de twee modellen, twee verschillende waarden van de klaring op. Daarom 
is in dit hoofdstuk, een nieuwe benadering voor de beschrijving van de 
verschillen in klaring over de gehele levensduur voorgesteld, die is gebaseerd 
op een allometrische vergelijking met een exponent die varieert met het 
lichaamsgewicht (model IV). Dit zgn. ”lichaamsgewicht afhankelijke exponent 
(BDE) model” bevat een continue sigmoïdale functie om de verandering in 
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de waarde van de allometrische exponent van lichaamsgewicht beschrijven. 
Er wordt aangetoond dat deze functie de beste beschrijving geeft van de 
veranderingen in de klaring van propofol over de gehele leeftijdsbereik van de 
mens. Voor de klaring van propofol werd gevonden dat met een toenemend 
lichaamsgewicht, de waarde van de allometrische exponent op een sigmoïdale 
wijze afneemt van 1,34-0,55, waarbij de helft van de daling werd bereikt bij een 
lichaamsgewicht van 3,78 kg. Ook werd aangetoond dat de BDE functie een 
flexibele functie is is waarmee heel verschillende vormen van de relatie tussen 
klaring en lichaamsgewicht kunnen worden beschreven.
Het toepassen van het nieuwe BDE-model op morfine 
klaring
In hoofdstuk 5 werd het lichaamsgewicht-afhankelijke exponent model 
(BDE model) toegepast om leeftijdsafhankelijke veranderingen in morfine 
klaring over het gehele pediatrische leeftijdsgebied te karakteriseren. 
Daartoe werden morfine en morfine-3-glucuronide (M3G) concentraties 
in 358 prematuren, pasgeborenen, zuigelingen, kinderen en volwassenen, 
en morfine concentraties in 117 adolescenten geanalyseerd met NONMEM 
7.2. Op basis van deze gegevens, werden twee modellen ontwikkeld: i) 
een model op basis van uitsluitend morfine concentraties (model 1) en ii) 
een model op basis van zowel morfine en M3G concentraties (model 2). In 
model 1 werd de verandering in de morfine klaring zeer goed beschreven 
met een op lichaamsgewicht gebaseerde exponentiële functie waarbij de 
waarde van de allometrische exponent op een sigmoïdale wijze afneemt met 
lichaamsgewicht (BDE-model) van 1,47 tot 0,88. Hierbij wordt de helft van de 
daling in de waarde van de exponent bereikt bij een gewicht van 4,01 kg. In 
model 2 werd gevonden dat de waarde van de exponent voor de vorming 
en eliminatieklaring van M3G afneemt van 1,56 tot 0,89 en van 1,06 tot 0,61, 
waarbij de helft van de afname werd bereikt bij een lichaamsgewicht van 
3,89 en 4,87 kg, respectievelijk. Met het BDE model was er geen noodzaak om 
extra covariaten gebruiken om de waargenomen variabiliteit in de klaring te 
beschrijven. Deze studie resultaten bevestigen niet alleen de reeds bekende 
modelresultaten in kinderen jonger dan 3 jaar waarin een exponent van 
1,44 werd vastgesteld, maar vormen ook een basis voor extrapolatie naar 





oudere leeftijd. Bovendien blijkt dat toepassing van een allometrische functie 
waarin de exponent kan variëren met lichaamsgewicht leidt tot een optimale 
beschrijving van de uiteenlopende rijping van de glucuronidering klaring 
van morfine in alle leeftijdsgroepen zonder dat extra leeftijdsgebaseerde 
covariaten (PNA <> 10 dagen) nodig zijn.
Toepassing van het nieuwe BDE-model op 
paracetamolklaring
In hoofdstuk 6 hebben we het BDE-model toegepast voor het beschrijven 
van variatie in de klaring van paracetamol over het gehele pediatrische 
leeftijdsbereik. Plasma concentraties in 220 patiënten uit acht eerder 
gepubliceerde studies over de farmacokinetiek van paracetamol werden 
opgenomen in de analyse, met inbegrip van (premature) pasgeborenen, 
zuigelingen, (jonge) kinderen en volwassenen. Populatie farmacokinetische 
modellering werd uitgevoerd met behulp van NONMEM 7.2. In de covariaat 
analyse voor de klaring werden lineaire functies, power functies en een power-
functie met een lichaamsgewicht-afhankelijke exponent (BDE model) getest. 
Er werd aangetoond dat het BDE model de leeftijd gerelateerde veranderingen 
in de klaring van paracetamol in het menselijke leeftijdsbereik goed beschrijft 
en dat het niet nodig is om aanvullende leeftijd variabelen als covariaat mee te 
nemen. Voor klaring werd gevonden dat met toenemend lichaamsgewicht de 
waarde van de allometrische exponent op een sigmoïdale wijze afneemt van 
1,2-0,75, waarbij de helft van de daling werd bereikt bij een lichaamsgewicht 
van 12,2 kg. Op basis van het uiteindelijke model werden simulaties uitgevoerd 
voor het opstellen van geoptimaliseerde doseringsrichtlijnen voor paracetamol 
over het gehele pediatrische leeftijdsbereik. In dit verband werd met behulp 
van het model een intraveneuze paracetamol dosis berekend voor kinderen 
van alle leeftijden waarbij naar ongeveer gelijke paracetamol blootstelling 
werd gestreefd. Dit is met name van belang omdat er nog geen informatie is 
over de intraveneuze dosering paracetamol bij premature neonaten (Europa) 
of bij kinderen jonger dan 2 jaar (VS).




In dit proefschrift stellen we het lichaamsgewicht afhankelijke exponent (BDE) 
model voor als nieuwe benadering voor het beschrijven van veranderingen 
in geneesmiddelklaring over het gehele pediatrische leeftijdsbereik. Dit geeft 
een alternatieve benadering voor de schatting van de klaring met betere 
statistische eigenschappen. Het model heeft als voordeel dat betere ramingen 
van de klaring van geneesmiddelen kunnen worden verkregen, waardoor de 
voorspelling van de juiste individuele dosering bij kinderen, in het bijzonder 
bij pasgeborenen, kan worden geoptimaliseerd. Bovendien kan het model een 
basis zijn voor fysiologisch gebaseerde farmacokinetische modellen, met name 
daar waar in vitro of andere data ontbreken. Hiermee kunnen mogelijk in de 
toekomst ontwikkelingsveranderingen in klaring van nieuwe geneesmiddelen 
worden voorspeld. Deze voorspellingen vormen de wetenschappelijke basis 
voor geoptimaliseerde trial designs voor studies in kinderen.
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Background and Objectives: The wide variability in pharmacokinetics of busulfan 
in children is one factor influencing outcomes such as toxicity and event free 
survival. A meta-analysis was conducted to describe the pharmacokinetics 
of busulfan in patients from 0.1 to 26 years of age, to elucidate patient 
characteristics that explain the variability in exposure between patients and to 
optimize dosing accordingly.
Patients and Methods: Data were collected from 245 consecutive patients 
(from 3 to 100 kg) who underwent HSCT in four participating centers. The 
inter-patient, inter-occasion and residual variability in the pharmacokinetics of 
busulfan were estimated with a population analysis with the software program 
NONMEM VI (Globomaxx LLC, Hanover, MD, USA). Covariates were selected on 
the basis of their known or theoretical relationships with busulfan PK and were 
plotted independently against the individual PK-parameters and the weighted 
residuals of the model without covariates to visualize relations. Potential 
covariates were formally tested in the model.
Results: In a two-compartment model, body weight was the most predictive 
covariate for clearance, volume of distribution and inter-compartmental 
clearance and explained 65%, 75% and 40% of the observed variability, 
respectively. The relation between body weight and clearance was characterized 
best using an allometric equation with a scaling exponent that changed with 
body weight from 1.2 in neonates to 0.55 in young adults. This implies that 
an increase in body weight in neonates results in a larger increase in busulfan 
clearance than an increase in body weight in older children or adults. Clearance 
on the first day was 12% higher than that of subsequent days (p < 0.001). Inter-
occasion variability on clearance was 15% between the four days. Based on the 
final PK-model, an individualized dosing nomogram was developed.
Conclusions: The model-based individual dosing nomogram is expected to 
result in predictive busulfan exposures in patients ranging between 3 and 
65 kg and thereby to a safer and more effective conditioning regimen for 
hematopoietic stem cell transplantation in children.
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Children may differ from adults in drug pharmacokinetics (PK), in response to 
treatment (efficacy) and their susceptibility to side effects (safety). Variability 
in pharmacokinetics is one factor which alters drug exposure and this in turn 
might explain differences in the (un)wanted responses (Pharmacodynamics, 
PD) between children. Characterization of variability in PK between 
neonates, infants, children and adolescents is therefore important especially 
for drugs with a small therapeutic window such as busulfan. Busulfan is a 
chemotherapeutic drug which is standard of care in preparative chemotherapy 
in patients undergoing hematopoietic stem cell transplantation (HSCT) for a 
variety of malignant and non-malignant diseases [1]. Since the 1970s, total 
body irradiation (TBI) based conditioning regimens have been used [2]. 
Unfortunately, TBI is complicated by cataracts, endocrine disorders (including 
stunted growth), delayed intellectual development and secondary tumors. As 
an alternative to TBI, in the 1980s, chemotherapy-based conditioning (high-
dose oral busulfan in combination with cyclophosphamide) was introduced 
[3, 4]. The therapeutic potential of oral busulfan was limited by the large 
PK-variability [5-8]. This PK-variability has major implications for outcomes 
of treatment; a low total exposure (expressed as the total area under the 
concentration curve using all administrations from day 0 to day 4, AUCday0-4) 
to busulfan is associated with an increased risk of graft failure and relapse [9, 
10],9;10 whereas a high AUC
day0-4
 is associated with an increased risk of toxicity like 
veno-occlusive disease (VOD) and graft versus host disease [9, 10]. To reduce 
the variability in exposure and to improve safety of the regimen, intravenous 
(IV) busulfan was introduced in 2000 [11]. Although this excludes differences in 
absorption, wide inter-individual variability in busulfan pharmacokinetics is still 
observed with the IV formulation, particularly in children [12-17]. Therapeutic 
drug monitoring to guide IV busulfan dosing was therefore introduced [1, 14], 
which resulted in further improved of the event free survival in children [18]. 
It may be anticipated that patient-outcomes after HSCT may further benefit 
from an optimal starting dose for each individual, especially for centers where 
TDM is not available. Previous studies used body surface area (BSA) or body 
weight-based functions to characterize the variable PK of busulfan in children 
[17, 19, 20]. In addition some of the variability was suggested to be explained 
by the underlying disease of the patient [21-23]. However, most of these results 
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originated from relatively small studies. We describe a pharmacokinetic meta-
analysis of 245 patients, in whom a large number of covariates related to the 
PK of busulfan, such as body weight, underlying diseaseand liver function 
tests, were measured. The meta-analysis was conducted with the objective of 
describing the pharmacokinetics of busulfan in patients from 0.1 to 26 years 
of age and to elucidate patient characteristics that explain the variability in 
exposure between patients. The resulting PK-model was used to derive an 
individualized dosing algorithm aiming for an optimal exposure of busulfan in 
each patient.
I.2. Methods
Setting and study population
In this prospective meta-analysis, patients were enrolled in the research 
protocol after the patient and/or their parents (the latter in patients under 
12 years of age) provided written informed consent. The study was approved 
by the local ethics committees. Data were collected from all 245 consecutive 
patients who underwent HSCT between August 2000 to September 2009 in four 
centers and of whom concentration measurements after intravenous busulfan 
administration were available. The four centers were: the University Medical 
Center Utrecht and the Leiden University Medical Center in the Netherlands, 
the Universitätsklinikum at Münster, Germany, and the Children’s Hospital at 
Westmead, Sydney, Australia. Part of the data (135 of the 245 patients) has 
been described in previous publications [17, 21, 24, 25]. The characteristics of 
the settings, busulfan administration and analysis and samples schemes are 
shown in table 1. Busulfan was administered during 3 to 4 consecutive days. In 
98% of patients blood samples were collected on day 1 and in 68% of patients, 
blood samples were also collected on day 2-4.
26664_Chenguang Wang.indd   184 23-09-13   10:37




Table 1: Participating centers.
 
142
Setting and study population 
In this prospective meta-analysis, patients were enrolled in the research protocol after the 
patient and/or their parents (the latter in patients under 12 years of age) provided written 
informed consent. The study was approved by the local ethics committees. Data were 
collected from all 245 consecutive patients who underwent HSCT between August 2000 to 
September 2009 in four centers and of whom concentration measurements after intravenous 
busulfan administration were available. The four centers were: the University Medical Center 
Utrecht and the Leiden University Medical Center in the Netherlands, the Universitätsklinikum 
at Münster, Germany, and the Children's Hospital at Westmead, Sydney, Australia. Part of 
the data (135 of the 245 patients) has been described in previous publications [17, 21, 24, 
25]. The characteristics of the settings, busulfan administration and analysis and samples 
schemes are shown in table 1. Busulfan was administered during 3 to 4 consecutive days. In 
98% of patients blood samples were collected on day 1 and in 68% of patients, blood 
samples were also collected on day 2-4. 
Table 1: Participating centers. 
 
 a. The methods Leiden, Utrecht (HPLC and LC-MS) and Münster were successfully cross validated. 
HPLC = high pressure liquid chromatography, LCMS = liquid chromatography-mass spectrometry, GC = gas 
chromatography, CV = Coefficient of Variation (%), LOQ = limit of quantification, TDM = therapeutic drug monitoring 
 
Transplantation details and other patient characteristics are shown in table 2. All patients 
received IV busulfan-based myeloablative conditioning according to the applicable 
(inter)national protocols. All patients were cared for in high-efficiency, particle-free, air-filtered, 
positive-pressure isolation rooms. Gut decontamination and infection prophylaxis was given 
according to the institutional protocol. Patients received anti-emetic drugs and prophylactic 
anticonvulsive therapy (clobazam, clonazepam, diazepam and in 10 cases phenytoin) during 
busulfan treatment.  
Pharmacokinetic analysis 
Model building and evaluation  
Leiden Münster Sydney Utrecht 
Busulfan preparation/formulation Busilvex® Busilvex® Busulfex® Busilvex®
Pierre Fabre Medicament, France Pierre Fabre Medicament, France Orphan, Australia Pierre Fabre Medicament, France
Busulfan dosing algorithm (day1) until 2003: 3.2 mg / kg  in 2 doses 120 mg / m2 in 1 dose until 2008:
<4 years: 4mg / kg in 4 doses 120mg / m2 in 2 doses 130 mg / m2 in 1 dose <1 years: 80 mg / m2 in 1 dose
≥4 years: 3.2 mg / kg in 4doses 3.2 mg / kg in 4 doses  ≥1years: 120 mg / m2 in 1 dose
 from 2003 from 2008:
<1 years: 80 mg / m2 in 1 dose <0.5 years: 80 mg / m2 in 1 dose
≥1years: 120 mg / m2 in 1 dose 0.5-1years: 120 mg / m2 in 1 dose
≥1years: 130 mg / m2 in 1 dose
Infusion duration day 1 (h) median (range) 3 (2-3) 4 2(1-3.75) 3(2.75-3.25)
Dose adjustments based on TDM yes no yes yes
Sample scheme predose, pre-dose, during infusion, 4-8 samples following the dose 0.08, 1, 2 and 4 hours after inf.
1, 2, 4 hours after inf. 1, 1.5, 2, 3, 6 and 7.5 hours after inf. between 0.08 to 7 hours after inf.
Method of determinationa HPLC LC-MS GC HPLC/LC-MS
LOQ 50 µg/L 5 µg/L 30 µg/L 50 µg/L 
Precision within/between runs (% variation) 3.5%,0.8% <11%,<11% <9%,<10% 2.3%, 0.2%
a. The methods Leiden, Utrecht (HPLC and LC-MS) and Münster were successfully cross validated.
HPLC = high pressure liquid chromatography, LCMS = liquid chromatography-mass spectrometry, GC = 
gas chr matography, CV = Coefficient of Variation (%), LOQ = limit f quantification, TDM = therapeutic 
drug monitoring
Transplantation details and other patient characteristics are shown in table 2. 
All patients received IV busulfan-base  myeloablative conditioning according 
to the applicable (inter)na ional protocols. All patients were cared fo  in 
high- fficiency, particle-free, air-filtered, positive-pressu e isolation rooms. 
Gut econtaminatio  and infection prophylaxis was given ccording to the 
institutional protocol. Patients received anti-emetic drugs and prophylactic 
anticonvulsive therapy (clobazam, clonazepam, diazepam and in 10 cases 
phenytoin) during busulfan treatment.
Pharmacokinetic analysis
Model building and evaluation 
The nonlinear mixed-effects modeling software NONMEM VI using ADVAN 
subroutines with first-order conditional estimation (FOCE) with η-ε interaction 
(Globomaxx LLC, Hanover, MD, USA) was used. Log-transformed busulfan 
concentrations were used for analysis. Twenty-nine of a total of 1775 busulfan 
concentrations were below the limit of quantification (LOQ). The values of these 
samples were set at ½ the LOQ [26]. Mixed effects models consist of a structural 
model (e.g. a one or two-compartment model) describing the relationship 
between dose and concentrations, and a stochastic model describing the random 
variability in the PK-parameters of the structural model. Random variability 
consisted of inter-individual in PK-parameters, inter-occasion variability (inter-
occasion variability, IOV) in PK-parameters and intra-individual variability. Inter-
individual and inter-occasion variability were modeled assuming a log-normal 
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distribution (eq. 1, appendix 1) [27]. Intra-individual variability was modeled 
using an additive error (eq. 2, appendix 1) which is equivalent to a proportional 
error model in the untransformed scale. Discrimination between different 
models was made by comparison of the objective function (-2 log likelihood). 
A value of p < 0.005, df = 1, representing a decrease in objective function of 
7.8 on a χ2 distribution, was considered statistically significant. In addition, 
goodness-of-fit plots (individual predicted versus observed concentrations, 
population predicted versus observed concentrations, conditional weighted 
residuals versus time and conditional weighted residuals versus population PK-
parameters) were used for diagnostic purposes. Furthermore, the confidence 
interval of the parameter estimates, the correlation matrix and visual inspection 
of the distribution of the model parameters, were used to evaluate the model.
In order to determine whether the model was over-parameterized, the 
condition number of the final PK-model was calculated. The condition number 
should not exceed the critical value of 1000 [28]. 29 Finally, η- and ∈-shrinkage 
as defined by Karlsson et al. [29]30 was calculated for all model parameters for 
which inter-individual variability was estimated. A shrinkage-value below 20% 
was considered acceptable.
Covariate analysis
The covariates depicted in table 1 and 2 were selected on the basis of their known 
or theoretical relationships with busulfan PK. As described before, BSA and body 
weight are associated with busulfan PK [17, 19, 20]. Many drugs may interact with 
busulfan [30-32]. Therefore, all concomitant medications used by more than 10% 
of patients were included as a covariate. Underlying disease and clinical chemical 
parameters like liver function have been reported to influence busulfan clearance 
[13, 21-23, 33], while also blood counts may relate to variability in busulfan-PK.
All covariates were plotted independently against the individual PK-parameters 
(post hoc values) and the weighted residuals of the model without covariates 
to visualize relations. Potential covariates were formally tested in the model 
as follows. For continuous covariates such as body weight, age or BSA, the 
influence of the covariate on each PK-parameter was tested using a linear (eq. 
4, appendix 1) or allometric function (eq. 5, appendix 1). In addition, other 
allometric functions were explored for the PK parameters of which the plot 
26664_Chenguang Wang.indd   186 23-09-13   10:37




of inter-individual variability of the PK-parameter versus the covariate showed 
that neither a linear nor an allometric function results in adequate description 
of the data. I.e., the plot of inter-individual variability of Cl versus body weight 
showed that an allometric function over-predicted patients < 10 kg and > 40 kg 
and under-predicted patients between 10 and 40 kg. In this respect, it has been 
reported in studies using small cohorts of children that the scaling exponent of 
the allometric function for clearance is larger in neonates and young children 
(i.e. a scaling exponent> 1) in comparison with older children (i.e. a scaling 
exponent < 1) [34-36]. Wang et al. have used an allometric function with a 
scaling exponent that varied with body weight between 1.35 in neonates to 
0.57 in adults, when studying propofol clearance [35]. Therefore, beside a linear 
or standard allometric function, as a third approach, an allometric function was 
tested with a scaling exponent that varied with bodyweight, age or BSA (eq. 
6, appendix 1). For categorical covariates, typical values of the PK-parameters 
were compared between categories (eq. 7, appendix 1).
Statistical evaluation of the incorporated covariate relationships was performed 
by forward inclusion and backward deletion [37]. A p-value < 0.005 was applied 
to evaluate the covariates in the forward inclusion (decrease of objective 
function of at least 7.8 points), while the backward deletion procedure used 
a stricter criterion (objective function > 10.83, p < 0.001). When two or more 
covariates were found to significantly improve the model, the covariate causing 
the largest reduction in objective function was left in the model. Additional 
covariates had to reduce this objective function further to be retained in the 
model. Moreover, to accept a covariate, a reduction in inter-individual variability 
of the PK parameter involved was required. In addition, individual and population 
PK-parameters were plotted against the most predictive covariate to evaluate 
whether the individual PK-parameters were equally distributed around the 
population parameters [38]. The choice of the model was further evaluated 
as discussed under model building and evaluation, whereby the results of the 
internal validation procedure were also considered.
Internal validation
The robustness of the population pharmacokinetic model was assessed by the 
bootstrap re-sampling method throughout the model-building process and on 
the final PK-model, using 1000 replicate datasets per bootstrap [39]. The mean 
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value, 95%-confidence intervals and covariance of all parameters obtained 
with the bootstrap replicates were compared with the estimates obtained from 
the original data set.
Derivation of model-based dosing regimen
The parameters of the final PK-model were used as a basis to determine an 
individualized dosing regimen in patients from 3-65 kg. The new dosing 
regimen aimed to reach a target exposure (defined as AUC
day0-4
) of 90 mg*h/L 
(≈5400 µM*min/day) in myeloablative regimens and an AUC
day0-3
 of 60 mg*h/L 
for non-myeloablative conditioning regimens, based on the current literature 
of optimal exposures of busulfan in children [12, 15, 22, 24, 40, 41]. For each 
of the 245 patients, AUC 
day0-4
 values were simulated in each patient upon 
four consecutive once daily IV doses, using ONLYSIM-option as implemented 
in NONMEM. All PK-parameters were fixed to the final PK-parameters and all 
covariate relations were included. The amounts were integrated into a dummy 
AUC-compartment. For each patient, an individual dose was derived for each 
of the two target-AUCs, which was plotted versus bodyweight resulting in two 
model-based dosing nomograms.
I.3. Results
Busulfan PK-data on 245 patients were obtained from the four participating 
centers. Patient characteristics such as body weight, underlying disease and 
concomitant medications were rather evenly distributed between centers and 
within the total dataset (table 2).
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Table 2: patient characteristics.  
 
Bu = busulfan, MDS = myelodysplastic syndrome, immunedef. = immune deficiencies, HLH = hemophagocytic 
lymphohistiocytosis, ALL = acute lymphocytic leukemia, AML = acute myeloid leukemia, JMML = juvenile 
myelomonocytic leukemia, CML = chronic myeloid leukemia, Cy = cyclophosphamide, Mel = melphalan, Flu = 
fludarabine, P450 = cytochrome P450 enzymes, BSA = body surface area. 
1) Inborn errors were inborn errors of metabolism and hemoglobinopathies. 
2) In general the dose of melphalan was 140 mg/m2 once daily, etoposide 1200 mg/m2 once daily, 
cyclophosphamide: 60 mg/kg once daily for 4 days, fludarabine 40 mg/m2 for 4 days.  
3) Patients with unrelated donors received serotherapy, either anti-thymoglobulin (ATG)-rabbit (Genzyme/Fresenius) 
or alemtuzumab (Genzyme). 
4) These covariates were measured at day 1 or just before the day of the first busulfan administration. These 
covariates were also explored in relation to their age-related reference-values. 
5) Covariate selection of concomitant medications used in these patients, based on the route of metabolism of the 
drugs (selections were made of medications which were used by more than 10% of patients). 
6) Drugs cleared primarily via renal clearance were antibiotics, trimethoprim, antivirals, fluconazole, alizapride, 
metoclopromide, diuretics. 
7) Drugs cleared primarily via P450 metabolism were phenytoin, antimycotics, proton-pump inhibitors, 
benzodiazepines, opiates. 
8) Drugs cleared primarily via phase 2 metabolism were acetaminophen (if needed medication of acetaminophen 
was not included), metronidazole, co-trimoxazole, corticosteroids, metoclopramide, ondansetron, antihistaminics, 
diuretics, ursodeoxycholic acid.  
 
Leiden Münster Sydney Utrecht Total
Nr. of patients n 102 18 55 70 245
Age (years) median (range) 3.58 (0.2-17) 3.88 (0.8-17) 4.25 (0.2-18) 2.5 (0.1-26) 3.33 (0.1-26)
Body weight (kg) median (range) 15.4 (4-73) 16.5 (9.5-74) 16.7 (3.1-109) 14.8 (3.7-107) 15.3 (3.1-109)
BSA (m2) median (range) 0.65 (0.3-1.8) 0.70 (0.42-2.0) 0.69 (0.2-2.3) 0.61 (0.2 - 2.4) 0.65 (0.2-2.4)
Gender male 66% 56% 56% 50% 58%
Number of samples n (mean per patient) 472 (5) 205 (11) 466 (8) 632 (9) 1775 (7)
Frequency of Bu adm n (4dd, 2dd, 1dd) (39,-,63) (-,18,-) (4,-,51) (-.-,70) (43,18,184)
Underlying disease malignancy / MDS 52 13 24 25 114
bone marrow failure syndrome 7 1 7 6 21
inborn errors (1) 13 4 7 20 44
immunedef. + HLH 29 0 17 19 65
Chemotherapeutic Bu + Cy 41 8 8 37 94
regimen (2) Bu + Cy + Mel 44 8 0 8 60
Bu + Flu 7 0 11 12 30
Bu + Mel 1 1 6 0 8
Bu + Cy + Eto 5 1 3 8 17
Bu + Cy +Flu 4 0 19 4 27
Bu+ Mel+Flu 0 0 8 1 9
Timing chemotherapy Chemo before or during Bu 10 0 36 21 67
Chemo after Bu 92 18 19 49 178
Serotherapy (3) No serotherapy 39% 50% 60% 20% 40%
Nr of transplant 1 102 18 55 67 242
>1 3 3
Type of transpants CB,BM,PBSC (N) (13,73,17) (-,-,19) (20,18,16) (28,33,8) (61,124,60)
GGT (u/L) (4) median (range) 14 (6-870) 21 (4-275) 21 (7-1990) 18.5 (4-1990)
ALAT (u/L)  (4) median (range) 23 (6-253) 11 (4-41) 32 (11-840) 26 (11-550) 26 (4-840)
ASAT (u/L) (4) median (range) 37 (9-145) 14 (6-366) 35 (16-166) 29 (12-350) 32.5 (6-366)
Hemoglobuline (mmol/L) (4) median (range) 6.3 (4.4-8.5) 5.6 (3.7-8.6) 5.9 (3.9-8.6) 5.8 (4.1-9.6) 6.1 (3.7-9.6)
Leukocytes (*10E9/L) (4) median (range) 5.4 (0.3-45) 3.3 (0.4-81) 3.1 (0.2-16.4) 2.9 (0.1-16.6) 3.9 (0.1-81)
Thrombocytes (*10E9/L) (4) median (range) 121 (1-688) 141 (13-615) 192 (12-629) 109 (7-661) 127 (1-688)
Erythrocytes (*10E12/L) (4) median (range) 3.5 (2.5-5.4) 3.5 (2.2-4.6) 3.1 (1.9-5.2) 3.5 (1.9-5.4)
Albumine (g/L) (4) median (range) 40 (29-510) 39 37 (24-47) 31 (13-45) 37 (13-51)
Concomitant medications median nr. (range) 2 (0-8) 8 (6-11) 5 (1-9) 6 (0-13) 5 (0-13)
Glucocorticoids (5) yes 39% 78% 15% 36% 36%
Antibiotics (5) yes 40% 100% 22% 99% 57%
Trimethoprim/cotrimoxazol  (5) yes 0% 89% 5% 0% 8%
Antivirals (5) yes 2% 17% 11% 60% 22%
Omeprazol/pantoprazol (5) yes 2% 28% 5% 24% 11%
Antimycotics (5) yes 2% 19% 25% 32% 17%
Fluconazol (5) yes 5% 39% 73% 89% 47%
Alizapride  yes 12% 0% 0% 4% 6%
Ondansetron (5) yes 58% 72% 100% 97% 80%
Opiates (5) yes 11% 0% 13% 0% 7%
Antihistaminics (5) yes 10% 22% 11% 34% 18%
Diuretics (5) yes 8% 61% 5% 19% 14%
Ursodeoxychol acid (5) yes 0% 6% 75% 0% 17%
Benzodiazepines  (5) yes 21% 78% 73% 96% 58%
> 1 Drug cleared via renal clearance (6) yes 54% 100% 80% 99% 76%
> 1 Drug cleared via P450 metabolism (7) yes 33% 100% 76% 99% 67%
> 1 Drug cleared via phase 2 metabolism (8) yes 79% 100% 100% 99% 91%
Bu = busulfan, MDS = myelodysplastic syndrome, immunedef. = immune deficiencies, HLH = 
hemophagocytic lymphohistiocytosis, ALL = acute lymphocytic leukemia, AML = acute myeloid leukemia, 
JMML = juvenile myelomonocytic leukemia, CML = chronic myeloid leukemia, Cy = cyclophosphamide, 
Mel = melphalan, Flu = fludarabine, P450 = cytochrome P450 enzymes, BSA = body surface area.
1) Inborn errors were inborn errors of metabolism and hemoglobinopathies.
2) I  eneral the dose of melph lan was 140 mg/m2 once daily, etoposide 1200 mg/m2 once daily, 
yclophosphamide: 60 mg/kg once dail  for 4 d ys, fludarabine 40 mg/m2 for 4 days.
3) ti ts with unrelated donors r ceived s rotherapy, either anti-thymoglobulin (ATG)-rabbit 
(Genzyme/Fresenius) or alemtuzumab (Genzyme).
4) These covariates were measured at day 1 or just before the day of the first busulfan administration. 
These covariates were also explored in relation to their age-related reference-values.
5) Covariate selection of concomitant medications used in these patients, based on the route of 
metabolism of the drugs (selectio s were made of medications which were used by more than 10% 
of patients).
6) r s cleared primarily via ren l clearanc  w re a tibiotics, trimethopri , antivirals, fluconazole, 
alizapride, metoclopromide, diuretics.
7) Drugs cleared primarily via P450 metabolism were phenytoin, antimycotics, proton-pump inhibitors, 
benzodiazepines, opiates.
8) Drugs cleared primarily via phase 2 metabolism were acetaminophen (if needed medication of 
acetaminophen was not included), metronidazole, co-trimoxazole, corticosteroids, metoclopramide, 
ondansetron, antihistaminics, diuretics, ursodeoxycholic acid.
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Busulfan concentrations could adequately be described using a two-
compartment model parameterized in terms of clearance (CL), inter-
compartmental clearance (Q), volume of distribution of central compartment 
(V1) and peripheral compartment (V2, estimated as a factor times V1). The 
two-compartment model was superior over a one-compartment model for 
statistical reasons (decrease in objective function of 132 points (p < 0.001)) 
and improved goodness of fit plots. Inter-occasion variability on clearance in 
the structural model resulted in a large reduction of objective function of -309 
(p<0.001). The addition of inter-occasion variability on V1 did not result in a 
significant improvement of the model (objective function -5.9). In the final PK-
model, clearance at day 2-4 was estimated as a fraction of clearance at day 1 (eq 
3, appendix 1) and was 12% lower in comparison with day 1 (objective function 
-45, p<0.001).
Figure 1a (left panel) shows that the two-compartment PK-model without 
covariates could adequately describe the observed concentrations. This model 
showed poor predictive performance, however, as shown by the population 
predicted versus observed concentrations (figure 1a, right panel). Particularly 
in the extremities of the body weight range (3-7 kg and >30 kg) concentrations 
were over- and under-predicted, respectively.
The covariate analysis identified body weight, BSA and age as most important 
covariates related to volume of distribution and clearance. The introduction of 
body weight as a covariate for V1 using a linear function (eq.4, appendix 1) 
resulted in a decrease in objective function of -442 (p<0.001). An allometric 
function for V1 (eq. 5, appendix 1) with a single scaling exponent of 0.89 was 
superior over a linear function (objective function -26 points, p<0.001) and 
resulted in an equal distribution of the individual V1 parameter estimates of all 
body weights around the population V1 parameter estimates. As a result, the 
inter-individual variability on V1 decreased from 76% to 20% in comparison 
with the PK-model without covariates. For clearance, inclusion of body weight 
using a linear equation (eq. 4, appendix 1) further improved the model 
(objective function -457, p<0.001). An allometric function for clearance (eq. 5, 
appendix 1) with a single scaling exponent of 0.91 was superior over a linear 
function (objective function -11 compared to a linear function, p<0.001), but 
the population predicted values of both models were biased compared to 
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the individual predicted PK-parameters. A linear or allometric function over-
predicted patients < 10 kg and > 40 kg and under-predicted patients between 
10 and 40 kg. An allometric equation with a scaling exponent, that changed with 
body weight from 1.2 in neonates to 0.55 in young adults (eq. 6, appendix 1) 
described the relation between bodyweight and clearance significantly better 
compared to the allometric equation with a single scaling exponent (decrease 
in objective function of 35, p<0.001). The population predicted values of this 
model described individual predicted PK-parameters without bias. This model 
resulted in an adequate distribution of the individual Cl parameter estimates 
over the entire body weight-range and resulted in a decrease in inter-individual 
variability on Cl from 99% to 27% in comparison with the PK-model without 
covariates. Body weight was linearly related to Q (objective function -26 , 
p<0.001) and resulted in a decrease in inter-individual variability from 148 to 
88% in comparison with the PK-model without covariates.
Figure1: Individual predicted concentrations vs observed concentrations (leftpanels) and 
population predicted concentrations vs observed concentrations (right panels) of the 
pharmacokinetic model without covariates (a) and the final pharmacokinetic-model (b). 
Data of four body weight categories (kg) are shown separately. Ln = lognormal.
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The inclusion of body weight on the PK-parameters resulted in a more significant 
reduction of the objective function in comparison with age on all parameters 
(objective function +108), while the model using BSA showed similar results 
in comparison with body weight-model given the criteria as defined under 
Methods.
The systematic covariate analysis did not identify any other covariates. No 
differences in the diagnostic-plots were observed between the participating 
centers (appendix 2), frequency of busulfan administration, concomitant 
medications or any of the other covariates.
For the final PK-model, the individual and population predicted versus observed 
concentrations per body weight-category are depicted in figure 1b. The right 
panel demonstrates that the predictive performance of the model is similar in 
all four bodyweight groups. The individual and population PK-parameters (Cl 
and V1) of the final PK-model versus body weight are shown in figure 2. The 
figure shows an equal distribution of the individual PK-parameter estimates of 
all body weights around the population PK-parameter estimates. All parameter 
estimates of the final PK-model and the results of the statistical evaluation 
(bootstrap validation, shrinkage and condition number) are presented in table 
3. These statistical evaluation tools were within the limits, given the criteria 
as defined under Methods, except for shrinkage on Q and inter-occasion 
variability which were both >20%.
Based on the final PK-model, the model-based dosing nomogram was derived 
as depicted in figure 3. With this nomogram, a dose for each individual between 
3-65 kg can be obtained, aiming for a myeloablative (AUCday0-4 of 90 mg*h/L) or 
non-myeloablative conditioning regimen (AUC
day0-3 
of 60 mg*h/L). Table 4 shows 
the model-based nomogram in mg/kg of patients between 3 and 65 kg and the 
deviations of their simulated AUC’s in comparison with the target-AUC
day0-4
 of 
90 mg*h/L. Deviations in the expected AUCs upon the currently approved dose 
in the summary of product characteristics by EMA [30] and a BSA based dosing 
regimen of 130 mg/m2are also shown in table 4. Both regimens are used in 
pediatric clinical practice by different institutes. The first dosing algorithm was 
based on a population-pharmacokinetic study of 24 children by Nguyen et al. 
in 2004 [20], aiming at a target AUC of 78mg*h/L (59-98mg*h/L in combination 
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with cyclophosphamide), which was prospectively validated in 55 children by 
Vassal et al. in 2008 [42]. The BSA-based dosing regimen was used in children 
by Nath et al. and Gordon et al. [22, 43] This dosing regimen was derived from a 
studies using oral busulfan using 130-150mg/m2 per day in children [5, 44] and 
from a study of IV busuflan in adults [45].
Figure 2: Individual predicted pharmacokinetic parameters (post hoc, pre- sented as dots) 
and population predicted pharmacokinetic parameters (black line) of volume of distribution 
of the central compartment (a) and clearance (b) vs body weight of the final pharmacokinetic 
model. The data are presented on log-scale and on normal scale (insert). CL = clearance; V1 = 
volume of dis- tribution of the central compartment.
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Table 3: Population PK-parameter estimates, shrinkage and PK-parameter estimates 
obtained after bootstrap of the final PK-model.
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Table 3: Population PK-parameter estimates, shrinkage and PK-parameter estimates 
obtained after bootstrap of the final PK-model. 
 
Cl15.3kg= clearance for a typical individual of 15.3kg V115.3kg = volume of distribution of the central compartment for a 
typical individual of 15.3kg, V215.3kg = volume of distribution of the peripheral compartment for a typical individual of 
15.3kg, Q15.3kg = inter-compartmental clearance for a typical individual of 15.3kg, 15.3 kg was the mean value of the 
body weights in the dataset. In the allometric function, L1 represents the intercept and M is the exponent, which 
allows the scaling exponent to change with body weight. L2 represents the single scaling exponent . BW= body 
weight (kg) CV= coefficient of variation (%), inter-individual variability was calculated as the square root of the 
exponential variance -1). 
a. Clearance was described, according to the following equations:  
�� � ����.��� � ���15.3�
������
 
b. V1 was described as volume of distribution of the first compartment, according to the following equations:  
�1 � �1��.��� � �����.��
��
    
c. Q was described as inter-compartmental clearance, according to the following equations: 






Dataset Shrinkage  
Parameter  Estimate CV % Median 5-95 percentile
Structural model  
Cl15.3kg (L/h)a 3.47 3.0 3.44 3.24-3.72
V115.3kg (L)b 11.1 1.6 11.1 10.8-11.4
V2 expressed as factor (times V1) 6.92 6 6.89 1.56-13.5
Q15.3kg  (L/h)c 0.495 12.2 0.509 0.29-0.67
L1 in: 1.56 10 1.55 1.31-1.88
M in: -0.226 15 -0.224  -0.29--0.17
L2 in: 0.890 2.0 0.889 0.86-0.92
Clday2-4 expressed as reduction factor of day1 0.12 14 0.12 0.08-0.15
Random variability
Inter-individual variability on Cl (%) 27% 17 16% 27% 23%-31%
Inter-individual variability on V1 (%) 20% 21 19% 20% 17%-24%
Inter-individual variability on Q (%) 88% 24 50% 87% 64%-119%
Corr. IIV ClxV1 0.52 21 0.53 0.39-0.66
Inter-occasion variability Cl (%) 15% 21 42% 15% 12%-18%
Proportional residual error (%)
14% 12 18% 14% 12%-15%
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 = volume of distribution of the central 
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with body weight. L2 represents the single scaling exponent. BW= body weight (kg) CV= coefficient of 
variation (%), inter-individual variability was calculated as the square root of the exponential variance -1).
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Parameter  Estim t CV % Median 5-95 percentile
Structural model  
Cl15.3kg (L/h)a 3.47 3.0 3.44 3.24-3.72
V115.3kg (L)b 11.1 1.6 11.1 0.8- 1.4
V2 expressed as factor (times V1) 6.92 6 6.89 1.56-13.5
Q15.3kg  (L/h)c 0.495 12.2 0.509 0.29-0.67
L1 in: 1.56 10 1.55 1.31-1.88
M in: -0.226 15 -0.224  -0.29--0.17
L2 in: 0.890 2.0 0.889 0.86-0.92
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Inter-occasion variability Cl (%) 15 21 42 15 12 -18
Proportional residual error (%)
14% 12 18% 14% 12%-15%
Objective function -3671 -3702











26664_Chenguang Wang.indd   194 23-09-13   10:37




Table 4: The model-based individualized dosing nomogram of busulfan, expressed in mg/kg 
for 20 patients with body weight ranging between 3 and 65 kg (aiming at a target-AUC
day0-4 
of 90 mg*h/La in combination with fludarabine ). The deviations of their corresponding 
AUC
day0-4
-values in relation with this target-AUC
day0-4 
are shown (left column). For comparison, 
the dosing nomogram of the currently approved dose in the EMA-summary of product 
characteristics (SPC) (43) and deviations in their corresponding AUC
day0-4
 values of the target-
AUC
day0-4 
of 90mg*h/La are shown (middle column). Doses in mg/kg derived from a BSA based 
dosing regimen of 130mg/m2 1dd and their concurrent deviations of the target-AUC
day0-4 
of 
90mg*h/La, are also shown (right column).
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Table 4: The model-based individualized dosing nomogram of busulfan, expressed in 
mg/kg for 20 patients with body weight ranging between 3 and 65 kg (aiming at a 
t rg t-AUCday0-4 of 90 mg*h/La in combination with flud rabine ). The deviations of their 
corresponding AUCday0-4-values in relation with this target-AUCday0-4 are shown (left 
column). For comparison, the dosing nomogram of the currently approved dose in the 
EMA-summary of product characteristics (SPC) (43) and deviations in their 
corresponding AUCday0-4 valu s of the targ t-AUCday0-4 of 90mg*h/La are shown (middle 
column). Doses in mg/kg derived from a BSA based dosing regimen of 130mg/m2 1dd 
and their concurrent deviations of the target-AUCday0-4 of 90mg*h/La, are also shown 
(right column).  
 
a. A total exposure of 90 mg*h/L to 21.6 mM*min total, or 5400 μM*min/day 
b. Doses in mg/kg of the BSA based dosing regimen were extracted from a BSA-for-body weight plot of all patients. 
  
Body weight 
kg Dose (mg/kg) ± % deviation of target AUC Dose (mg/kg) ± % deviation of target AUC Dose (mg/kg) ± % deviation of target AUC
3 3.8 0% 4.0 5% 8.7 128%
5 4.7 0% 4.0 -15% 7.0 49%
7 5.1 0% 4.0 -22% 6.5 28%
8 5.2 0% 4.0 -23% 6.2 19%
9 5.2 0% 4.8 -8% 6.2 19%
11 5.2 0% 4.8 -9% 7.0 33%
13 5.2 0% 4.8 -8% 5.5 6%
15 5.1 0% 4.8 -6% 5.2 2%
16 5.1 0% 4.4 -13% 5.4 7%
20 4.9 0% 4.4 -9% 5.2 7%
23 4.7 0% 3.8 -19% 4.9 4%
25 4.6 0% 3.8 -17% 4.9 8%
30 4.3 0% 3.8 -12% 4.3 0%
35 4.1 0% 3.2 -22% 3.9 -4%
40 3.9 0% 3.2 -18% 3.9 0%
45 3.7 0% 3.2 -14% 3.9 6%
50 3.5 0% 3.2 -10% 3.8 8%
55 3.4 0% 3.2 -6% 3.5 5%
60 3.3 0% 3.2 -2% 3.7 12%
65 3.1 0% 3.2 2% 3.4 8%
4days, 1dd, mg/kg
Model-based individualized dosing nomogram Approved dose  in SPC
4 days, 1dd, mg/kg
target AUCday0-4 90mg*h/La
Myeloablative dose 4 days, 1dd, mg/kg
Dose based on 130 mg/m2b
a. A total exposure of 90 mg*h/L to 21.6 mM*min total, or 5400 μM*min/day
b. s s in mg/kg of the BSA based dosing regimen were extracted fr m a BSA-for-body weight plot 
of all patients.
I.4. Discussion
This international pharmacokinetic meta-analysis of 245 patients was 
conducted to characterize the pharmacokinetics of busulfan from 1month to 
26 years of age. Body weight was the most predictive covariate for clearance 
(Cl), volume of distribution (V1) and inter-compartmental clearance (Q) and 
explained 65%, 75% and 40% of the observed inter-individual variability, 
respectively. The relation between body weight and clearance was clearly non-
linear and was described using an allometric function with a scaling exponent 
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that varied between 1.2 in neonates and 0.55 in young adults. This precise 
relation could be identified as a result of the large range in body weights 
and extensive number of patients and resulted in an individualized dosing 
nomogram for patients between 3-65 kg.
The PK-model was built based on a large dataset obtained from a multi-center 
setting. The dataset contained multiple treatment regimens, a wide range of 
age, bodyweights, underlying diseases and a large number of other covariates. 
The model adequately described the data and only 13% residual variability 
remained in the final PK-model. Statistical evaluation tools (CV of parameter 
estimates, bootstrap) show that this is a robust model. No differences were 
seen between the participating centers, even though the centers had different 
settings. This indicates that the results of the model may be extrapolated to other 
pediatric HSCT centers elsewhere, if patient characteristics are comparable to 
the characteristics in this dataset (like similar concomitant medications). The 
quality of the structural model (figure 1b, left panel) indicates that this PK-
model can reliably predict exposures in new patients, ranging from 3-65 kg.
Body weight, rather than age, was the most predictive covariate that explained 
the variability in exposure between patients from 3-100 kg. Because BSA 
is a composite parameter taking account both length and body weight, 
and the BSA model did not result in improvement of the description of the 
data in comparison with body weight as the only parameter, the final body 
weight model was preferred over the BSA model. The non-linear relation 
between body weight and clearance reflects that an increase in body weight 
in neonates results in a larger increase in busulfan clearance than an increase 
in bodyweight in older children or adults. The maturation of activity and 
expression of glutathione S-transferese have been studied in enterocytes and 
after oral administration of busulfan [13, 46, 47]. Assuming that the expression 
and activity of liver and enterocyte enzymes show similar developmental 
patterns, the non-linear relation of body weight and clearance could be 
related to changes in maturation rate of glutathione S-transferase as described 
in these articles. The effect might also relate to differences in liver volume, 
blood flow and biliary functions in young infants as compared to adults [48, 
49]. This relation between body weight and clearance could not be estimated 
using an allometric function with a single scaling exponent, an approach that 
26664_Chenguang Wang.indd   196 23-09-13   10:37




is commonly applied - also in busulfan PK studies [17, 19, 20]. In this dataset, 
the allometric function with a single scaling exponent of 0.89 on body weight 
overestimated the clearance of busulfan up to 1.5 times in patients < 10 kg and 
> 40 kg, and underestimated the clearance up to 1.25 times in patients between 
10-40 kg. In this meta-analyis we characterized the clearance of busulfan using 
an allometric function with a scaling exponent that varied with body weight 
from 1.2 in neonates to 0.55 in young adults. These values are very similar to a 
recent study of busulfan in children which showed a single scaling exponents 
1.25 in children <9 kg and 0.76 >9kg [50]. In studies using other compounds 
varying (single) scaling exponents are published of 1.3-1.5 in neonates to 0.56 
in adults [34-36], such despite the fact that different routes of metabolism are 
concerned. Literature data suggest that scaling of PK-parameters between 
children could be performed using an allometric scaling function with a fixed 
exponent of 0.75 or 1 for bodyweight and subsequently estimating a function 
that describes maturation processes as a function of age [51]. However, 
postnatal age and body weight are highly correlated. Therefore, in the current 
analysis, one single function based on bodyweight was identified, which 
would adequately describe the pharmacokinetics of busulfan from neonates to 
young adults. It would be of interest to test this function for other drugs when 
studying the effects of maturation in the whole pediatric age range including 
neonates.
After inclusion of body weight in the model, the disease-group (e.g. immune 
deficiencies) was not a significant covariate while also the inter-individual 
variability was similar between the four groups. In our cohort, the patients 
treated for malignancies or bone marrow failures were older and heavier in 
comparison with immune deficiencies, or inborn errors of metabolism. While 
in other studies, the disease group (i.e. diseases like immune deficiencies or 
lysosomal storage disease) has been reported a covariate for busulfan PK [13, 
21-23, 33] we suggest that body weight may be an effect modifier in the relation 
between busulfan-PK [21-23]. As Glutathione S-transferases play an essential 
protective role against reactive oxygen species [52], many drugs could interact 
with busulfan. However, no significant interactions were identified in this large 
dataset, but drugs like metronidazole and phenytoin which have shown to 
influence busulfan PK in previous studies [30-32], could not be studied in full 
extent in this dataset due to use in <10% of patients. Moreover, neither clinical 
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chemistry data nor blood counts showed any biomarkers which could predict 
variability between patients. This analysis shows that the nature of the body 
weight-dependent pharmacokinetics of busulfan, including the smallest and 
heaviest patients, should be adequately characterized first. Only thereafter, 
other less influential covariate relationships like disease can be studied, to 
overcome confounding by maturation.
In this study, 15% day-to-day variability of busulfan clearance between the four 
days of administration was shown, which is only slightly higher than 5-10% 
shown in adults [19, 49]. In addition we showed that busulfan clearance was 
12% lower at day 2-4 compared to day 1. This finding is consistent with results 
of a study in children with thalassemia in which a decrease of 11% in clearance 
between the first and subsequent doses was found [41]. Other studies did 
not report a significant decrease in busulfan AUC on following days [15, 16]. 
Yeh et al. reported that the concurrent use of fludarabine might decrease the 
busulfan clearance from day 1 to day 4 [53]. However, in the current study, the 
difference in clearance between consecutive days was not significantly altered 
in fludarabine as compared to non-fludarabine users. While the decrease in 
clearance deserves further study, it should be accounted for in the design of 
new dosing algorithms and when performing TDM.
Based on the final PK-model, a body weight dependent-dosing nomogram 
was defined (figure 3). The nomogram leads to a smaller range in predicted 
AUC’s between patients of different body weights than the currently approved 
dose in the EMA-summary of product characteristics [30] or BSA-based dosing 
nomogram of 130mg/m2 as shown in table 4. The currently approved dose leads 
to deviations in exposures, especially in children near the edges of each dosing 
category. A limitation of our meta-analysis is however, that only 12 patients 
>65 kg were included and therefore dose recommendations for patients >65 
kg could not be provided based on these analyses.
Table 4 also demonstrates that a dose of 130 mg/m2 [22, 43] results in overdosing 
up to 220% in patients < 0.5 m2 and should therefore not be used. Even though 
the model-based nomogram takes into account variation from differences in 
bodyweight, the remaining unexplained inter-occasion variability in apparent 
clearance in the final PK-model is 15% and the unexplained inter-individual 
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variability 27%. Validation studies are needed to establish the predictive 
performance of the model and dosing regimen. Based on these considerations, 
we advocate that combined with the new dosing nomogram, TDM remains 
needed.
Figure 3: Model-based individualized dosing nomogram of busulfan related to the body 
weight of the patient, aiming for a myeloablative (AUC
day0-4 
of 90 mg*h/La in combination 
with fludarabine) (grey line) and a non-myeloablative conditioning regimen (AUC
day0-3 
of 60 
mg*h/L) (dotted black line).
The model-based dosing nomogram described in this article targets a narrow 
AUC
day0-4
 of 90 mg*h/L (≈5400 µM*min/day) in myeloablative and 60 mg*h/L 
in non-myeloablative conditioning regimens, in a platform with a (preferably 
non-alkylating) immunosuppressive agent (e.g. fludarabine) [45, 54, 55]. In 
the literature, different values for optimal AUC’s have been proposed for 
patients with varying underlying diseases, disease severity and differences 
in concomitant medications given during the conditioning regimens [12, 
15, 22, 24, 40, 41]. Comparing busulfan exposures between studies should 
be performed with care, as AUC’s may have been calculated using different 
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sampling schedules and different methods. Most pediatric literature data are 
based on conditioning regimens containing busulfan and cyclophosphamide, 
resulting in a total AUC
day0-4
 of approximately 80 mg*h/L in children [24, 41]. 
We recently showed that busulfan with a target AUC
day0-4
 between 80 and 100 
mg*h/L combined with fludarabine (n=40) was as effective, but less toxic in 
comparison with Busulfan-cyclophosphamide-melphalan (n=45) [56]. Also 
adult data shows that busulfan-fludarabine targeted to an AUC
day0-4
 < 100 
mg*h/L results in optimal outcome [55, 57]. In children, a target AUC
day0-4
 of 
approximately 45-65 mg*h/L has been published using busulfan-fludarabine 
as a non-myeloablative conditioning regimen [40, 58]. Perhaps in the future, 
additional agents may be added to this busulfan-fludarabine combination to 
enhance the anti-leukemia effect (e.g. clofarabine, which was shown in vitro 
to have a synergistic anti-leukemic effect) [59, 60]. These developments and 
optimizations will lead to further individualization of the target exposures to 
busulfan. Using the structural parameters of this PK-model, simulations can be 
performed leading to a dosing nomogram that can target any desired AUC for 
busulfan.
In conclusion, in this population pharmacokinetic model for busulfan in 
patients ranging between 1 month and 26 years of age, body-weight was the 
most predictive covariate for all PK-parameters of busulfan and explained a 
major part of the observed inter-individual variability. The model-derived 
individualized dosing nomogram is expected to result in predictive busulfan 
exposures in patients ranging between 3 and 65 kg when combined with TDM, 
resulting in a safer and more effective HSCT in children.
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     (eq. 1) 
Equation 1 describes the inter-individual variability and day-to day (inter-occasion) variability27 
of the structural parameters within the population, in which lognormal distribution was 
assumed. Pig represents the individual PK-parameter for subject i on occasion g. Ppop is the 
typical value of the population PK-parameter. An occasion (g) was defined as all 
measurements performed in 1 day, κig is the random effect between days. η and κ are 
random variables that follow the normal distribution with a mean value of 0 and variance ω2 
and π2, respectively.  
 
 ijpredij CC loglog       (eq. 2) 
Equation 2 describes the intra-individual variability; the differences between the observed and 
predicted concentrations. This residual error includes among other factors, model 
misspecification and measurement errors. The intra-individual variability was modeled using 
an additive error, equivalent to a proportional error model in the untransformed scale. Cij, is 
the observed concentration for subject i at time j, and Cpredij is the predicted concentration for 
individual i at time j. ε is a random variable that follows the normal distribution with a mean 




 daypopday fractionCLCl   (eq. 3) 
Equation 3 describes the clearance at day2-4, estimated as a fraction of clearance at day1. 
 (eq. 1)
Equation 1 describes the inter-individual variability and day-to day (inter-
occasion) variability27 of the structural parameters within the population, in 
which lognormal distribution was assumed. P
ig
 represents the individual PK-
parameter for subject i on occasion g. P
pop
 is the typical value of the population 
PK-parameter. An occasion (g) was defined as all measurements performed in 
1 day, κ
ig
 is the random effect between days. η and κ are random variables that 





This pharmacokinetic meta-analysis was performed within the framework of the Dutch Top 




Ap endix 1: Equations:  




     (eq. 1) 
Equation 1 describes the inter-individual variability and day-to day (inter-occasion) variability27 
of the structural parameters within the population, in which lognormal distribution was 
assumed. Pig represents the individual PK-parameter for subject i on occasion g. Ppop is the 
typical value of the population PK-parameter. An occasion (g) was defined as all 
measurements performed in 1 day, κig is the random effect between days. η and κ are 
rando  va iables that follow the normal di tribution with a mean value of 0 and variance ω2 
and π2, respectively.  
 
 ijpredij CC loglog       (eq. 2) 
Equation 2 describes the intra-individual variability; the differences between the observed and 
predicted concentrations. This residual error includes among other factors, model 
misspecification and measurement errors. The intra-individual variability was modeled using 
an additive error, equivalent to a proportional error model in the untransformed scale. Cij, is 
the observed concentration for subject i at time j, and Cpredij is the predicted concentration for 
individual i at time j. ε is a random variable that follows the normal distribution with a mean 




 daypopday fractionCLCl   (eq. 3) 
Equation 3 describes the clearance at day2-4, estimated as a fraction of clearance at day1. 
(eq. 2)
Equation 2 describes the intra-individual variability; the differences between 
the observed and predicted concentrations. This residual error includes 
among other factors, model misspecification and measurement errors. The 
intra-individual variability was modeled using an additive error, equivalent 
to a proportional error model in the untransformed scale. C
ij
, is the observed 
concentration for subject i at time j, and C
predij
 is the predicted concentration for
individual i at time j. ε is a random variable that follows the normal distribution 





This pharmacokinetic meta-analysis was performed within the framework of the Dutch Top 
Institute Pharma project number D2-104. The authors have no other conflicts of interest to 
disclo e.  
 
Appendix: 
Appendix 1: Equations:  




     (eq. 1) 
Equation 1 describes the inter-individual variability and day-to day (inter-occasion) variability27 
of the structural parameters within the population, in which lognormal distribution was 
assumed. Pig represents the individual PK-parameter for subject i on occasion g. Ppop is the 
typical value of the population PK-parameter. An ccasion (g) was defined as all 
measurements p rformed in 1 day, κig is the random effect betw en days. η and κ are 
random variables at f llow he norm l distributio with a mean value o  0 and v riance ω2 
and π2, respectively.  
 
 ijpredij CC loglog       (eq. 2) 
Equation 2 describes the intra-ind vidual variability; the differences between the observed and 
predicted concentrations. This residual error includes among other factors, model 
misspecification and measurement errors. The intra-indivi ual variability as modeled using
an ad itiv  error, quivalent to a proportional error model in the untransformed scale. Cij, is 
the ob erved concentration for subject i at time j, a d Cpredij is the predicted concentration for 
individ l i at time j. ε is a ra dom va iable that follows the normal dist ibuti n with a mean 




 daypopday fractionCLCl   (eq. 3) 
Equation 3 describes the cle rance at day2-4, estimated as a fraction of clearance at day1. 
(eq. 3)
Equation 3 describes the clearance at day
2-4
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The nature of the influence of continuous covariates on each PK parameter was 




Clday1 is the typical value of clearance at day 1. Clpop is the typical value of clearance. Fraction 
day2-4 is the clearance at day2-4 expressed as reduction factor of day1. 
Covariate functions:  
The nature of the influence of continuous covariates on each PK parameter was tested using 













PP    (eq. 4) 
In equation 4, Pi is the individual parameter for subject i with Covi. Ppop is the typical value of 
the population PK-parameter. Covi represents the covariate such as body weight, BSA or age 












    (eq. 5) 
In equation 5, Pi is the individual parameter for subject i with Covi. Ppop is the typical value of 
the population PK-parameter. Covi represents the covariate such as body weight, BSA or age 
for subject i and Covmean represents the mean value of the covariate.L1 represents the scaling 
exponent of the allometric function, which is one fixed estimated value in case of an allometric 














   (eq. 6) 
In equation 6, the allometric function with a scalingexponent that varies with body weight, 
BSA or age is shown, in which Pi is the individual parameter for subject i with Covi. Ppop is the 
typical value of the population PK-parameter. Covi represents the covariate such as body 
weight, BSA or age for subject i and Covmean represents the mean value of the covariate. In 
the scaling exponent, L2 represents the intercept and M is the exponent, which allows the 
scaling exponent to change with the covariate body weight, BSA or age. 
Potential categorical variables were modeled using: 
CCov
cpopi PPP     (eq. 7) 
In equation 7, CCov is the categorical covariate, Pi is the individual parameter for subject I, 
Ppop is the typical value of the population PK-parameter in absence of the covariate of interest 
(CCov=0) and Pc is the fractional change in the typical value of the PK-parameter caused by 
the covariate. 
(eq. 4)
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Background and objective: Major changes in Cytochrome P450 (CYP) 3A may be 
expected in the first months of life with later on relatively limited changes. In this 
analysis we studied the maturation of in vivo CYP3A mediated clearance using 
midazolam as model drug, from preterm neonates of 26 weeks gestational 
age (GA) onwards to adults. To investigate the maturation of in vivo CYP3A 
mediated clearance of drugs from prematurely born neonates with gestational 
ages (GAs) of 26 weeks throughout adulthood using midazolam as a model 
drug.
Methods: Pharmacokinetic data after intravenous midazolam were obtained 
from 6 previously reported studies. Subjects were prematurely born neonates 
(n=24; GA 26-33.5 weeks, PNA 3-11 days, and n=24; GA 26-37 weeks GA, PNA 
0-1 days), 23 children after elective major craniofacial surgery (3-23 months), 
18 pediatric intensive care patients (2 days to 17 years), 18 pediatric oncology 
patients (3-16 years) and 20 healthy male adults (20-31 years). Population 
pharmacokinetic modeling with a systematic covariate analysis was performed 
using NONMEM v6.2.
Results: Across the entire lifespan from prematurely born neonates to adults 
bodyweight was a significant covariate for midazolam clearance. The influence 
of body weight was best described using an allometric equation with an 
exponent changing with bodyweight in an exponential manner from 0.84 in 
preterm neonates (0.77kg) to 0.44 in adults (89kg) showing that the most rapid 
maturation occurs during the youngest age range.
Conclusions: An in vivo maturation function for midazolam clearance from 
prematurely born neonates to adults has been developed. This function can be 
used to derive evidence-based doses for children, and to simulate exposure to 
midazolam and possibly other CYP3A substrates across the pediatric age range 
in population pharmacokinetic or physiologically based pharmacokinetic 
(PBPK) models.
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Cytochrome P4503A (CYP3A) is the most abundant CYP enzyme in the human 
liver. [1] It is involved in the metabolism of over half of all metabolized drugs. 
[2] Large inter-individual and intra-individual variation has been shown for 
CYP3A, resulting in inter-individual differences in the clearance of CYP3A 
substrate drugs. An important factor explaining variation in CYP3A activity is 
age. However, the exact ontogenetic pattern of the CYP3A isoforms CYP3A4 
and CYP3A5 in vivo is still unclear. [3-7] This information gap hampers the 
development of individualized dosing guidelines of CYP3A4/5 substrate 
drugs in children. To define the in vivo activity of CYP3A4/5, surrogate probes 
that correlate with actual enzyme activity can be used. [8] The best validated 
CYP3A4/5 probe is midazolam, which has been used extensively in adults and 
children. [9, 10]
For CYP3A4/5 mediated clearance of midazolam in children between one 
month and 17 years of age, critical illness proved a more significant covariate 
than bodyweight. [11] However, particularly in the first days and weeks of life, 
CYP3A4/5 activity may be expected to be low on the basis of in vitro data and 
in vivo reports on reduced clearance of CYP3A substrates in neonates [6, 7, 12-
15]. Therefore, we report here on the maturation of in vivo CYP3A mediated 
clearance of midazolam across the entire human life span, using a dataset 
consisting of 6 midazolam studies in which the pharmacokinetics were studied 
in populations ranging in age from prematurely born neonates to adults. 
The resulting maturation function may be used as a basis for evidence based 
dosing of midazolam and potentially other CYP3A substrates in population 
pharmacokinetic or physiology based pharmacokinetic (PBPK) models.
II.2. Methods
Patients and data
Individual data from six previous studies were included in the analysis. [3, 
6, 16-19] Individuals were prematurely born neonates (two datasets: n=32; 
gestational age (GA) 26-33.5 weeks, postnatal age (PNA) 3-11 days, and n=24; 
GA 26-37 weeks, PNA 0-1 days), 23 children after elective major craniofacial 
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surgery (3-23 months), 18 pediatric intensive care patients (2 days to 17 years), 
18 pediatric oncology patients (3-17 years) and 20 healthy male adults (20-31 
years). Details on the datasets are provided in table 1.
Pharmacokinetic data analysis
Population pharmacokinetic analysis was performed using the first-order 
conditional estimation (FOCE) with η-ε interaction in NONMEM version 
6.2, release 1.1 (GloboMax LLC, Hanover, MD, USA) [20]. S-plus version 6.2.1 
(Insightful software, Seattle, WA) with NM.SP.interface version 05.03.01 (© 
by LAP&P, Leiden, The Netherlands) was used to visualize the data. Model 
development was performed in four steps: (1) choice of the structural model, (2) 
choice of the error model, (3) covariate analysis, and (4) validation of the model. 
Discrimination between different models was done by comparison of the 
objective function. A decrease in the objective function of 3.8, corresponding 
to a value of p < 0.05, was considered statistically significant. Goodness-of-fit 
plots (observed versus individually predicted concentration, observed versus 
population predicted concentration, conditional weighted residuals versus 
time, and conditional weighted residuals versus population predictions) of all 
data and stratified per dataset, were used for diagnostic purposes. In addition, 
the confidence interval of the parameter estimates, the correlation matrix, and 
visual improvement of the individual plots were used to evaluate the model. 
Furthermore, η-shrinkage as defined by Karlsson et al. [21] was calculated for 
all model parameters for which inter-individual variability was estimated, and 
over-parameterization (ill-conditioning) of the model was tested by calculating 
the condition number. [22]
Model development
For the structural model of midazolam, a one, two and three compartment 
model was tested. In the model, the previously reported influence of critical 
illness on CYP3A mediated clearance of midazolam [11] was incorporated, 
implying a reduction in midazolam clearance in critically ill patients (datasets 
of prematurely born neonates and pediatric intensive care patients) compared 
to non-critically ill children and adults (datasets of children after major 
craniofacial surgery, pediatric oncology patients, and adults). The individual 
value (post hoc value) of the parameters of the ith subject was modeled using 
equation 1, where Pi equals the individual or post hoc value of the parameters 
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structural model, (2) choice of the error model, (3) covariate analysis, and (4) validation of the 
model. Discrimination between different models was done by comparison of the objective 
function. A decrease in the objective function of 3.8, corresponding to a value of p < 0.05, was 
considered statistically significant. Goodness-of-fit plots (observed versus individually 
predicted concentration, observed versus population predicted concentration, conditional 
weighted residuals versus time, and conditional weighted residuals versus population 
predictions) of all data and stratified per dataset, were used for diagnostic purposes. In 
addition, the confidence interval of the parameter estimates, the correlation matrix, and visual 
improvement of the individual plots were used to evaluate the model. Furthermore, η-
shrinkage as defined by Karlsson et al.[21] was calculated for all model parameters for which 
inter-individual variability was estimated, and over-parameterization (ill-conditioning) of the 
model was tested by calculating the condition number.[22]  
Model development 
For the structural model of midazolam, a one, two and three compartment model was tested. 
In the model, the previously reported influence of critical illness on CYP3A mediated 
clearance of midazolam [11] was incorporated, implying a reduction in midazolam clearance in 
critically ill patients (datasets of prematurely born neonates and pediatric intensive care 
patients) compared to non-critically ill children and adults (datasets of children after major 
craniofacial surgery, pediatric oncology patients, and adults). The individual value (post hoc 
value) of the parameters of the ith subject was modeled using equation 1, where Pi equals the 
individual or post hoc value of the parameters of the ith subject, and Ppop is the population 
value of the parameter. Random variable (RV) is assumed to be a gaussian random variable 
with mean zero and variance of ω2, assuming log-normal distribution. 
[1] RVpopi ePP   
The intra-individual variability was described with a proportional error model for all data, 
assuming a constant coefficient of variation over the entire concentration range, shown in 
equation 2, where j is the observed midazolam concentration (Y) of the ith individual, Cpred is 
the predicted midazolam concentration and RVij is the random variable for midazolam, with 
mean zero and variance σ2. 
[2] )1(, ijijpredij RVCY   
Covariate analysis 
Individual post hoc parameter estimates were plotted independently against the covariates to 
visualize potential covariate relationships. The following covariates were tested for all 
parameters: bodyweight, postnatal age, gestational age, study population, and mechanical 
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structural model, (2) choice of the error model, (3) covariate analysis, and (4) validation of the 
model. Discrimination between different models was done by comparison of the objective 
function. A decrease in the objective function of 3.8, corresponding to a value of p < 0.05, was 
considered statistically significant. Goodness-of-fit plots (observed versus individually 
predicted concentration, observed versus population predicted concentration, conditional 
weighted residuals versus time, and conditional weighted residuals versus population 
predictions) of all data and stratified per dataset, were used for diagnostic purposes. In 
addition, the confidence interval of the parameter estimates, the correlation matrix, and visual 
improvement of the individual plots were used to evaluate the model. Furthermore, η-
shrinkage as defined by Karlsson et al.[21] was calculated for all model parameters for which 
inter-individual variability was estimated, and over-parameterization (ill-conditioning) of the 
model was tested by calculating the condition number.[22]  
Model development 
For the structural model of midazolam, a one, two and three compartment model was tested. 
In the model, the previously reported influence of critical illness on CYP3A mediated 
clearance of midazolam [11] was incorporated, implying a reduction in midazolam clearance in 
critically ill patients (datasets of prematurely born neonates and pediatric intensive care 
patients) compared to non-critically ill children and adults (datasets of children after major 
craniofacial surgery, pediatric oncology patients, and adults). The individual value (post hoc 
value) of the parameters of the ith subject was modeled using equation 1, where Pi equ ls the 
individual or post hoc value of the parameters of the ith subject, and Ppop is the population 
value of the parameter. Random variable (RV) is assumed to be a gaussian random variable 
with mean zero and variance of ω2, assuming log-normal distribution. 
[1] RVpopi ePP   
The intra-individual variability was described with a proportional error model for all data, 
assuming a constant coefficient of variation over the entire concentration range, shown in 
equation 2, where j is the observed midazolam concentration (Y) of the ith individual, Cpred is 
the predicted midazolam concentration and RVij is the random variable for midazolam, with 
mean zero and variance σ2. 
[2] )1(, ijijpredij RVCY   
Covariate analysis 
Individual post hoc parameter estimates were plotted independently against the covariates to 
visualize potential covariate relationships. The following covariates were tested for all 
parameters: bodyweight, postnatal age, gestational age, study population, and mechanical 
(2)
Covariate analysis
Individual post hoc parameter estimates were plotted independently 
against the covariates to visualize potential covariate relationships. The 
following covariat  wer  tested for all parameters: bodyweight, p stn tal 
age, gestational age, study population, and mechanical v tilation (yes/ o). 
Continuous covariates were separately entered into the model using a linear 
function (equation 3), or an allometric equation (equation 4), where P
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ventilation (yes/no). Continuous covariates were separately entered into the model using a 
linear function (equation 3), or an allometric equation (equation 4), where Pi equals the 
individual or post hoc value of the parameters of the ith subject, Ppop is the population value of 
the parameter, COV is the concerned covariate, K is the exponent which may be estimated or 
fixed to 0.75. 
[3] )/( medianipopi COVCOVPP   
[4] Kmedianipopi COVCOVPP )/(  
Alternatively, an allometric equation with an exponent that changes with bodyweight [23] was 
tested (equation 5) in which BDE represents the body weight dependent exponent. For BDE, 
a sigmoidal function [23] and an exponential function (equation 6) with Coeff as a coefficient, 
BW as body weight and exp1 as an exponent)[24] were tested. 
[5] BDEmedianipop COVCOVP )/(  
[6] 1expBWCoeffBDE   
Categorical covariates (e.g. mechanical ventilation (yes/no) or study population (critically ill / 
healthy)) were tested using ‘IF’ statements, in which the parameter for one subgroup was 
estimated as a multiple of the parameter estimate for the other subgroup, shown in equations 
7 and 8, in which factor is the multiplication factor, and y equals one of the two subgroups. 
[7].             popi PP   
[8] )(,var factorPpopPiyiableIF   
The influence of a covariate was statistically tested for significance by use of the objective 
function. P-values < 0.005 (decrease of objective function of 7.8 points) were applied to 
evaluate the covariates in the forward inclusion, while a more stringent p value of <0.001 
(decrease of objective function of 10.83 points) was used in the backwards deletion step. 
When two or more covariates were found to significantly improve the model, the covariate 
that showed the largest reduction of the objective function was included in the model. 
Additional covariates had to reduce this objective function further to be retained in the model. 





ventilation (yes/no). ontinuous covariates ere separately entered into the odel using a 
linear function (equation 3), or an allo etric equation (equation 4), here i equals the 
individual or post hoc value of the para eters of the ith subject, pop is the population value of 
the para eter,  is the concerned covariate,  is the exponent hich ay be esti ated or 
fixed to 0.75. 
[3] )/( medianipopi  
[4] Kmedianipopi )/(  
lternatively, an allo etric equation ith an exponent that changes ith body eight [23] as 
tested (equation 5) in hich  represents the body eight dependent exponent. or , 
a sig oidal function [23] and an exponential function (equation 6) ith oeff as a coefficient, 
 as body eight and exp1 as an exponent)[24] ere tested. 
[5] BDEmedianipop )/(  
[6] 1expeff  
ategorical covariates (e.g. echanical ventilation (yes/no) or study population (critically ill / 
healthy)) ere tested using ‘I ’ state ents, in hich the para eter for one subgroup as 
esti ated as a ultiple of the para eter esti ate for the other subgroup, sho n in equations 
7 and 8, in hich factor is the ultiplication factor, and y equals one of the t o subgroups. 
[7].             popi  
[8] )(,ar f ct riyi leI  
he influence of a covariate as statistically tested for significance by use of the objective 
function. -values  0.005 (decrease of objective function of 7.8 points) ere applied to 
evaluate the covariates in the for ard inclusion, hile a ore stringent p value of 0.001 
(decrease of objective function of 10.83 points) as used in the back ards deletion step. 
hen t o or ore covariates ere found to significantly i prove the odel, the covariate 
that sho ed the largest reduction of the objective function as included in the odel. 
dditional covariates had to reduce this objective function further to be retained in the odel. 
he choice of the odel as further evaluated as discussed under ‘phar acokinetic data 
 (4)
Alternatively, an allometric equation with an exponent that changes with 
bodyweight [23] was tested (equation 5) in which BDE represents the body 
weight dependent exponent. For BDE, a sigmoidal function [23] and an 
exponential function (equation 6) wi h Co ff as a coefficient, BW as body weight 
and exp1 as an exponent) [24] were tested.






ventilation (yes/no). Continuous covariates were separately entered into the model using a 
linear function (equation 3), or an allometric equation (equation 4), where Pi equals the 
individual or post hoc value of the parameters of the ith subject, Ppop is the population value of 
the parameter, COV is the concerned covariate, K is the exponent which may be estimated or 
fixed to 0.75. 
[3] )/( medianipopi COVCOVPP   
[4] Kmedianipopi COVCOVPP )/(  
Alternatively, an allometric equation with an exponent that changes with bodyweight [23] was 
tested (equation 5) in which BDE represents the body weight dependent exponent. For BDE, 
a sigmoidal function [23] and an exponential function (equation 6) with Coeff as a coefficient, 
BW as body weight and exp1 as an exponent)[24] were tested. 
[5] BDEmedianipop COVCOVP )/(  
[6] 1expBWCoeffBDE   
Categorical covariates (e.g. mechanical ventilation (yes/no) or study population (critically ill / 
healthy)) were tested using ‘IF’ statements, in which the parameter for one subgroup was 
estimated as a multiple of the parameter estimate for the other subgroup, shown in equations 
7 and 8, in which factor is the multiplication factor, and y equals one of the two subgroups. 
[7].             popi PP   
[8] )(,var factorPpopPiyiableIF   
The influence of a covariate was statistically tested for significance by use of the objective 
function. P-values < 0.005 (decrease of objective function of 7.8 points) were applied to 
evaluate the covariates in the forward inclusion, while a more stringent p value of <0.001 
(decrease of objective function of 10.83 points) was used in the backwards deletion step. 
When two or more covariates were found to significantly improve the model, the covariate 
that showed the largest reduction of the objective function was included in the model. 
Additional covariates had to reduce this objective function further to be retained in the model. 
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Categorical covariates (e.g. mechanical ventilation (yes/no) or study population 
(critically ill / healthy)) were tested using ‘IF’ statements, in which the parameter 
for one subgroup was estima ed as a mul iple of the pa ameter e timate for the 
other subgroup, shown in equations 7 and 8, in which factor is the multiplication 




ventilation (yes/no). Continuous covariates were separately entered into the model using a 
linear function (equation 3), or an allometric equation (equation 4), where Pi equals the 
individual or post hoc value of the parameters of the ith subject, Ppop is the population value of 
the parameter, COV is the concerned covariate, K is the exponent which may be estimated or 
fixed to 0.75. 
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Alternatively, an allometric equation with an exponent that changes with bodyweight [23] was 
tested (equation 5) in which BDE represents the body weight dependent exponent. For BDE, 
a sigmoidal function [23] and an exponential function (equation 6) with Coeff as a coefficient, 
BW as body weight and exp1 as an exponent)[24] were tested. 
[5] BDEmedianipop COVCOVP )/(  
[6] 1expBWCoeffBDE   
Categorical covariates (e.g. mechanical ventilation (yes/no) or study population (critically ill / 
healthy)) were tested u ing ‘IF’ statements, i  wh ch th  parameter for one subgroup w s 
estimated as a multiple of the ar m er estim te for the other subgroup, shown in quations 
7 and 8, in which fac or is the multiplica ion factor, and y quals one of the two subgroups. 
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The influence of a covariate was statistically tested for significance by use of the objective 
function. P-values < 0.005 (decrease of objective function of 7.8 points) were applied to 
evaluate the covariates in the forward inclusion, while a more stringent p value of <0.001 
(decrease of objective function of 10.83 points) was used in the backwards deletion step. 
When two or more covariates were found to significantly improve the model, the covariate 
that showed the largest reduction of the objective function was included in the model. 
Additional covariates had to reduce this objective function further to be retained in the model. 
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linear function (equati  3), r an allometric equation (equatio  4), where Pi equals the 
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the parameter, COV is the c ncerned covariate, K is t e exponent whic  may be estim ted r 
fix d to 0.75. 
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Alternatively, an allometric equation with an exponent that changes with bodyweight [23] was 
tested (equatio  5) in whi h BDE represents the body weight dependent expon nt. For BDE, 
a igmoidal function [23] and an expon ntial function (equation 6) with Coeff as a coefficient, 
BW as body weight and exp1 as an exponent)[24] wer  tested. 
[5] BDEmedianipop COVCOVP )/(  
[6] 1expBWCoeffBDE   
Categorical covariates (e.g. mechanical ventilation (yes/no) or study population (critically ill / 
healthy)) were tested using ‘IF’ statements, in which the parameter for one subgroup was 
estimated as a multiple of the parameter estimate for the other subgroup, shown in equations 
7 and 8, in which factor is the multiplication factor, and y equals one of the two subgroups. 
[7].             popi PP   
[8] )(,var factorPpopPiyiableIF   
The influence of a covariate was statistically tested for significance by use of the objective 
function. P-values < 0.005 (decrease of objective function of 7.8 points) were applied to 
evaluate the covariates in the forward inclusion, while a more stringent p value of <0.001 
(decrease of objectiv  fu ction of 10.83 points) was used in the backwards deletion step. 
When two r more covariates were found to significantly improve the mo el, th  covariate 
that showed the largest reduction of the objective function was included in the model. 
Additional covariates had to reduce this j ti  f ti  further to b  retain d in the model. 
The choice f the model was furth r evaluated as dis ussed under ‘pharm cokinetic data 
(8)
The influence of a covariate was statistically tested for significance by use of 
the objective function. P-values < 0.005 (decrease of objective function of 
7.8 points) were applied to evaluate the covariates in the forward inclusion, 
while a more string nt p value of <0.001 (decrease f objective function of 
10.83 points) was used in the back ard  deletion step. When tw  or more 
covariates were found t  significantly improve the model, the covariate that 
showed h  largest reduction of the objective fu tion was included in the 
model. Additional covariates had to reduce this objective function further to 
be retained in the model. The choice of the model was further evaluated as 
discussed under ‘pharmacokinetic data analysis’ and ‘model development’. This 
included also individual and population parameter estimates versus the most 
predictive covariate in the model. [25]
Validation of the model
For the internal validation of the final model, a bootstrap analysis was 
performed in S-plus, version 6.2.1 (Insightful software, Seattle, WA) with NM.SP.
interface version 05.03.01 (© by LAP&P, Leiden, The Netherlands). Two hundred 
datasets were resampled from the combined original datasets, and refitted to 
the model. [26]
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Secondly, Normalized Prediction Distribution Errors (NPDE) were calculated 
[27] using the NPDE package in R. [28] For this method, the dataset used for 
building the model was simulated 1000 times with inclusion of the inter-
individual variability and residual error.
Simulation dosing regimen
Simulations were performed in S-plus, version 6.2.1 (Insightful software, 
Seattle, WA) with NONMEM SP.interface version 05.03.01 (© by LAP&P, Leiden, 
The Netherlands). The parameter estimates of the final Pharmacokinetic 
model were used to simulate midazolam concentrations in critically ill children 
ranging from prematurely born neonates to adolescents varying in body 
weight between 0.75 and 60 kg (0.75, 1, 2, 3, 5, 10, 20, 45, and 60 kg) upon 
a bolus injection and an infusion duration of 24 hrs. Both dosing schedules 
used in clinical practice (traditional dosing schemes) and model based dosing 
schedules were simulated. The traditional dosing scheme for prematurely 
born neonates was an iv bolus of 0.05 mg/kg and an infusion of 0.06 mg/kg/
hr [29-31] while for children and adolescents an iv bolus of 0.1 mg/kg and an 
infusion of 0.1 mg/kg/hr (conscious sedation in critically ill patients [32]) was 
chosen. The model based dosing regimen consisted of a dosing regimen that 
would result in therapeutic midazolam concentrations 0.25-0.37 μg/mL for 
conscious sedation in children in pediatric intensive care (PICU) patients. [32] 
As therapeutic midazolam concentrations for prematurely born neonates are 
unknown, these were set at 0.2 μg/ml being the lowest target concentration 
aimed for in a prematurely born neonate study. [18]
II.3. Results
Patients and data 
1105 midazolam concentrations from 136 individuals of six different datasets, 
[3, 6, 16-19] with a postnatal age varying between 0 days and 31 years of age, 
and a body weight between 0.77 kg and 89 kg were included for analysis. None 
of the patients received CYP3A inhibitors or inducers. A summary of the patient 
and data characteristics of the six studies is shown in table 1.
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Table 1 Overview of datasets. 
 
Model development and covariate analysis 
The pharmacokinetics of midazolam was best described with a two-compartment model with 
a proportional error model. In the model, the lower midazolam clearance due to critical illness 
[13] was incorporated for the datasets with prematurely born neonates [6, 18] and the dataset 
obtained in children admitted to an intensive care [16]. Introducing inter-individual variance for 
CL, Q, V1, and V2, significantly improved model performance with a total decrease in objective 
function (-2LL) of 3276.7 (p < 0.001).  
Parameter deWildt SN  
et al.[6] 
(2001)  









deWildt SN  
et al.[17] 
(2000)  
van Gerven J.M.A. 
et al.[19] 
(1997)  
Patient Population Preterm neonates 



















in Intensive Care 
Sedation for 
invasive procedure Healthy volunteers 





































13 / 24 24 / 24 2 / 23 15 / 18 0 / 18 0 / 20 
Midazolam Dose 
median (range) 
0.1 mg/kg iv 
infusion in 30 
minutes 
60 µg/kg/hr iv 
infusion 
If GA < 33w 
 after t > 24hr 
30 µg/kg/hr 








0.1 (0.03-0.53)  
mg/kg iv bolus dose 
0.1 mg/kg iv 
infusion in 20 
minutes 
Number of Samples 155 63 198 233 82 336 
 
odel development and covariate analysis
The pharmacokinetics of midazolam was best described with a two-
compartment model with a proportional error model. In the model, the lower 
midazolam clearance due to critical illness [13] was incorporated for the datasets 
with prematurely born neonates [6, 18] and the dataset obtained in children 





, significantly improved model performance with a total decrease 










































Figure 1 Posthoc estimates of CYP3A4 mediated clearance of midazolam versus body weight 
(a), and central volume of distribution versus body weight (b) in the final model.  = preterm 
neonates,  = preterm neonates with RDS syndrome,  = children after elective major 
craniofacial surgery,  = pediatric intensive care patients,  = pediatric oncology patients, and 
 = male adults, with a black line as their post-hoc population predicted values, respectively.
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In the covariate analysis, body weight was the most significant covariate for 
CL resulting in a decrease in objective function of 149.7 points (p < 0.001) 
and explained 65.4% of the inter-individual variability for CL (a decrease 
from 202.58% to 70.13%). The relation between bodyweight and CL was best 
described using an allometric function with an exponent that varies with 
bodyweight (body weight dependent exponent (BDE) [23]), as shown in figure 
1 (left). The BDE was defined as Coeff x BWexp1, in which BW represents body 
weight, Coeff proved 0.81 (CV of 8.2%) and exp1– 0.135 (CV of 31.4%) (table 2), 
resulting in a BDE which decreased from 0.84 in a preterm neonate of 0.77kg 
to 0.44 in adult of 89 kg in an exponential manner. The covariate analysis also 
revealed that bodyweight was of significant influence on V
1 
(delta -2LL of -52.8, 
p < 0.001). The nature of this influence was best described using a linear function 
(figure 1, right), because the exponent was found to not differ significantly from 
1 when using an allometric function. For V
2
, in the postoperative craniofacial 
surgery patients [3] a 6-fold higher peripheral volume of distribution compared 
to the five other datasets was found. A stable model could only be achieved 
when estimating this peripheral volume of distribution for the craniofacial 
surgery patients simultaneously with the addition of bodyweight in an 
allometric function to V
2
. This resulted in a significantly improved model (-2LL 
of -184.6, p < 0.001). A separate addition resulted in model termination, with a 
significant decrease in objective function for each covariate. For Q, there was 
no significant influence of age, bodyweight or population. None of the other 
tested covariates were of influence on any of the pharmacokinetic parameters.
The pharmacokinetic parameters of the final model along with their confidence 
intervals, inter-individual variability, and the results of the bootstrap validation 
are shown in table 2. This table also shows that after the covariate analysis, the 
inter-individual variance for Q could be fixed to 0 in the backwards deletion 
step without deterioration of the model while a successful covariance step 
could be achieved.



















































Figure 2 Visual diagnostics of the final model per dataset. Population predicted concentrations 
by the model versus the observed concentrations of midazolam. (a) de Wildt SN et al. [6]: 
preterm neonates; (b) Jacqz-Aigrain E. et al. [18]: preterm neonates with respiratory distress 
syndrome; (c) Peeters, M.Y. et al. [3]: children after elective major craniofacial surgery; (d) 
de Wildt SN et al. [16]: pediatric intensive care patients; (e) de Wildt SN et al. [17]: oncology 
patients; and (f ) van Gerven J.M.A. et al. [19]: Male adults. PRED predicted concentration. The 
solid line indicates the line of unity.
Figure 2a-f illustrates the population predicted concentrations versus observed 
concentrations for each dataset separately. These diagnostic plots (in log-
scale) indicate that overall the concentrations are predicted by the developed 
pharmacokinetic model without bias, as the concentrations are evenly 
distributed around the line of unity, except for the lower concentrations from 
the craniofacial surgery patients (Figure 2c), for which a slight under-prediction 
was observed.
Validation of the final model using NPDE simulations (figure 3) illustrate the 
distribution of the NPDEs, with a mean close to zero (-0.04 for the mean, and 
0.98 for the variances, respectively), and with no observed trends in time or 





 14.3%), which indicates that the individual parameter estimates 
are reliable. [21] The calculated condition number of 195 of the final model was 
well below the critical value for the indication of ill-conditioning of 1000. [22]
26664_Chenguang Wang.indd   218 23-09-13   10:37








Table 2 Population parameter estimates obtained for the final midazolam 
pharmacokinetic model 
 
f : fraction to estimate CL in intensive care patients compared to CL (f=1 healthy patients, f=0.07 intensive care 
patients), BW : body weight, BDE : bodyweight dependent exponent. Coeff : coefficient of the BDE function, g : 
multiple of distribution volume of peripheral compartment for children after elective major craniofacial surgery, CL13kg : 
midazolam clearance for a median individual of the population with a body weight of 13 kg, V1, 13kg: distribution volume 
of central compartment for a median individual of the population with a body weight of 13 kg, V2, 13kg : distribution 
volume of peripheral compartment for a median individual of the population with a body weight of 13 kg.[11] 
Figure 2a-f illustrates the population predicted concentrations versus observed concentrations 
for each dataset separately. These diagnostic plots (in log-scale) indicate that overall the 
concentrations are predicted by the developed pharmacokinetic model without bias, as the 
concentrations are evenly distributed around the line of unity, except for the lower 
concentrations from the craniofacial surgery patients (Figure 2c), for which a slight under-
prediction was observed. 
 Validation of the final model using NPDE simulations (figure 3) illustrate the distribution of the 
NPDEs, with a mean close to zero (-0.04 for the mean, and 0.98 for the variances, respectively), and 
with no observed trends in time or concentration. In the final model, all values of η-shrinkage were 
below 20% (CL: 5.1%; V1::17.7% ; V2 14.3%), which indicates that the individual parameter 
estimates are reliable.[21] The calculated condition number of 195 of the final model was well 
below the critical value for the indication of ill-conditioning of 1000.[22] 
 
Simulations to derive a model based dosing regimen  
Simulations have been performed using the typical value of the parameters with the aim to 
show the exact influence of the covariates on the overall concentration-time relationships for 
Parameter Model fit Bootstrap results Explanation
 Value  (CV%) Value  (CV%)  
CLi = fCL13kg  (BW/13)BDE 
























CYP3A4/5 mediated clearance of midazolam 
BW dependent exponent of allometric exponent function on CL 
CL for a median individual of the population with a BW of 13 kg 
Coefficient of the BDE function 
Exponent of the BDE function 
Q (L/min) 0.69 (18.1) 0.71 (20.4) Inter-compartmental clearance between central and peripheral compartment 
V1i =V1, 13kg  (BW/13) 
V1 ,13kg  (L) 
2.7 (18.3) 2.7 (18.4) 
Distribution volume of central compartment for a median individual of the 
population with a BW of 13 kg 
V2i =gV2, 13kg  (BW/13)exp2 
























Distribution volume of peripheral compartment (V2) 
V2 for a median individual of the population with a BW of 13 kg 
Allometric exponent of V2 in: V2i :V2  (BW/13) 
exp2 ) 
Multiple of V2 for children after elective major craniofacial surgery
[3] ; 
g=6 children after elective major craniofacial surgery, g=1 all other patients 
ω2 CL 0.37 (17.6) 0.35 (16.8) Variance in CL 
ω2 V1 0.58 (32.4) 0.38 (46.3) Variance in V1 
ω2 V2 0.37 (37.5) 0.36 (37.7) Variance in V2 
ω2 (V2 / V1) 0.41 (41.3) 0.56 (41.4) Correlation between the Variance in V2 and V1 
σ2 proportional 0.12 (14.5) 0.12 (11.7) Residual error (proportional error) 
 
f : fraction to estimate CL in intensive care patients compared to CL (f=1 healthy patients, f=0.07 intensive 
care patients), BW : body weight, BDE : bodyweight dependent exponent. Coeff : coefficient of the 
BDE function, g : multiple of distribution volume of peripheral compartment f r children after elective 
major craniofacial surgery, CL
13kg 
: midazolam clearance for a median individual of the population with 




: distribution volume of central compartment for a median individual of 




: dis ribution v lume of peripheral compartment for 
a median individual of the population with a body weight of 13 kg. [11]
Simulations to derive a model based dosing regimen
Simulations have been performed using the typical value of the parameters 
with the aim to show the exact influence of the covariates on the overall 
concentration-time relationships for different typical individuals. Figure 
4 (left panels) illustrates that based on the traditional dosing scheme for 
conscious sedation in prematurely born neonat s and critically ill children 
large differences in midazolam concentrations between individuals can be 
anticipated, particularly in the pediatric subpopulation. This results from the 
fact that the traditional dosing regimen is expressed in mg/kg/h while the 
results of this study show that clearance relates nonlinearly to body weight. 
Upon a model based dosing regimen aiming for predefined midazolam 
concentration ranges over a 24 hour period (table 3) similar midazolam profiles 
are anticipated across the human life span (Figure 4, right panels). This model-
based d sing r gimen that re ulted from the simulations consists for preterm 
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neonates of 0.05 mg/kg bolus and 0.06mg/kg0.85/h for 7 hours followed by 
0.03mg/kg0.85/h for 17 hours (table 3). For children in the Intensive Care (>5 
kg) requiring conscious sedation, the model based dosing regimen consists of 
0.1 mg/kg bolus and 0.1 mg/kg/h for 3 hours followed by 0.05 mg/kg0.65/h for 
21 hours (table 3). In table 3, both traditional and model-based guidelines are 
presented for conscious sedation with midazolam in preterm neonates and 
children in the Intensive Care ranging in bodyweight between 0.75 and 60 kg.







































Figure 2 Internal validation, Normalised Prediction Distribution Errors (NPDE) of the final 
model. The histogram illustrates the distribution of the NPDE’s for midazolam in which the 
solid line represents a normal distribution. In addition, the distribution of NPDE’s in time 
after first dose and against the observed concentrations is illustrated.
II.4. Discussion
We have developed a novel maturation function for midazolam clearance 
based on a dataset consisting of data obtained in six different clinical studies 
performed with midazolam in (prematurely born) neonates, infants, toddlers, 
children, adolescents, and adults. This model provides a quantitative insight in 
the developmental pattern of in vivo CYP3A activity across the pediatric age 
range, including prematurely born neonates. This model may provide guidance 
to dosing of midazolam in children across all age ranges and potentially other 
CYP3A substrates, i.e. by applying this function that describes the increase 
in midazolam clearance over weight, in population pharmacokinetic and 
physiologically based models, as a priori information.
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Table 3 Traditional and model-based dosing schemes for conscious sedation with midazolam 
in preterm neonates and children in the intensive care
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clearance over weight, in population pharmacokinetic and physiologically based models, as a 
priori information. 
Table 3 Traditional and model-based dosing schemes for conscious sedation with 
midazolam in preterm neonates a d children in the intensive care 
 
*Model-based doses aim for reported therapeutic midazolam concentrations of 0.25-0.37 µg/mL [32] for children and 
0.2 µg/mL [29-31] for preterm neonates, and are 0.06mg/kg0.85/h for 7 hours followed by 0.03mg/kg0.85/h for 17 hours for 
preterm neonates and 0.1 mg/kg/h for 3 hours and 0.05 mg/kg0.65/h for 21 hours for intensive care children. $ 
Depicted doses are maintenance doses after a bolus dose of 0.05 mg/kg for preterm neonates and 0.1 mg/kg for 
intensive care children. 
Previously, we have shown in children between 1 month and 17 years of age that critical 
illness was a more important covariate for CYP3A mediated clearance of midazolam than 
bodyweight.[11] As CYP3A is known to mature particularly in the first days and weeks of life, 
we included in the current analysis midazolam clearance values spanning the age range from 
prematurely born neonates to adults. This allowed to describe the change in CYP3A activity 
from birth onwards to adults. The current analysis suggests that the major change in 
midazolam clearance occurs in the first year of age. (figure 1). More specifically, in 
prematurely born neonates between 0.5 and 4 kg, midazolam clearance was estimated to be 
only 2.6% to 21.8% of adult values. These results confirm a very low CYP3A4/5 activity 
following birth [14] as midazolam is only slightly metabolized by CYP3A7.[33] Our finding that 
the largest change in clearance occurs in the first weeks of life is in line with CYP3A4/5 in 
vitro and in vivo phenotyping data. CYP3A4 mRNA levels in human fetal liver microsomes 
(gestational age 11-30 weeks) were reported to be on average 10% of that in adults.[14, 34] At 
the age of one to three months, Lacroix et al. reported an increase in CYP3A4 activity in vitro 
Patient group Weight Infusion duration Traditional dose$ Model-based dose*$
  kg over 24 hrs mg/hr mg/kg/hr mg/hr mg/kg/hr
Preterm Neonates 0.75 0 – 7   hrs 0.045 0.06 0.047 0.063 
  7 – 24 hrs 0.045 0.06 0.023 0.031 
  1 0 – 7   hrs 0.06 0.06 0.06 0.06 
   7 - 24  hrs 0.06 0.06 0.03 0.03 
  2 0 - 7    hrs 0.12 0.06 0.11 0.054 
   7 - 24  hrs 0.12 0.06 0.054 0.027 
  3 0 - 7    hrs 0.18 0.06 0.15 0.051 
   7- 24   hrs 0.18 0.06 0.076 0.025 
Children  5 0 – 3   hrs 0.5 0.1 0.5 0.1 
   3– 24 hrs 0.5 0.1 0.14 0.028 
  10 0 – 3   hrs 1 0.1 1 0.1 
   3- 24  hrs 1 0.1 0.22 0.022 
  20 0 -3    hrs 2 0.1 2 0.1 
   3- 24  hrs 2 0.1 0.35 0.018 
  45 0 - 3    hrs 4.5 0.1 4.5 0.1 
   3- 24   hrs 4.5 0.1 0.59 0.013 
  60 0 – 3   hrs 6 0.1 6 0.1 
   3– 24  hrs 6 0.1 0.72 0.012 
 
*Model-based doses aim for reported therapeutic midazolam concentrations of 0.25-0.37 µg/mL [32] 
for children and 0.2 µg/mL [29-31] for preterm neonates, and are 0.06mg/kg0.85/h for 7 hours followed 
by 0.03mg/kg0.85/h fo  17 hours for pret rm neonates and 0.1 mg/kg/h for 3 hours and 0.05 mg/kg0.65/h 
for 21 hours for intensive care children. $ Depicted doses are maintenance doses after a bolus dose of 
0.05 mg/kg for preterm neonates and 0.1 mg/kg for intensive care children.
r i usly, we have shown in children between 1 month and 17 years of 
ag  that critical illness was a more important covariate f r CYP3A ediated 
clearance of midazolam tha  bodyw ight. [11] As CYP3A is k o n to mature 
particularly in the first days and weeks of life, we included in the current 
analysis midazolam clearance values spanning the age range from prematurely 
born neonates to adults. This allowed to describe the change in CYP3A activity 
from birth onwards to adults. The current analysis suggests that the major 
change in midazolam clearance occurs in the first year of age. (figure 1). More 
specifically, in prematurely born neonates between 0.5 and 4 kg, midazolam 
clearance was estimated to be only 2.6% to 21.8% of adult values. These results 
confirm a very low CYP3A4/5 activity following birth [14] as midazolam is only 
slightly metabolized by CYP3A7. [33] Our finding that the largest change in 
clearance occurs in the first weeks of life is in line with CYP3A4/5 in vitro and in 
vivo phenotyping data. CYP3A4 mRNA levels in human fetal liver microsomes 
(gestational age 11-30 weeks) were reported to be on average 10% of that in 
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adults. [14, 34] At the age of one to three months, Lacroix et al. reported an 
increase in CYP3A4 activity in vitro reaching 30-40% of adult levels [14], which 
approximates our in vivo findings of 25-35% of adult activity.
Data on CYP3A4 activity after the first year of life, as derived from in vitro and 
different in vivo studies are highly discrepant [35-38]. The in vitro finding by 
Stevens et al. reporting CYP3A4 protein content at age 5–15 years to be only 
about 20% of adult levels [15] is not in agreement with the in vivo data on total 
clearance of midazolam. Based on reported average midazolam clearance 
data from the literature, Johnson et al. summarized that CYP3A4/5 mediated 
midazolam clearance expressed in L/hr reaches approximately 18% and 40% of 
the clearance in adults at the age of 1 year, [39] and 5 years, [39] respectively. 
Interestingly, Anderson et al. using average in vivo clearance values from 
literature data estimated midazolam clearance at birth in a term neonate to be 
14% of an adult, reaching 64% of that in adults at one year of age and 90% at 
two years of age. [40] Additionally, using the urinary ratio of dextromethorphan 
and its metabolite 3-hydroxymorpinan, Johnson et al. simulated an increase in 
CYP3A4 activity that reaches 72% of that in adults at the age of 1 year based on 
a phenotyping study by Blake et al. [37] An explanation for the large variation 
reported in CYP3A activity in in vivo and in vitro studies may relate to the sub-
optimal quality of post-mortem tissue used for the in vitro studies, resulting in 
erroneously low CYP3A activity levels. In addition, the studies by Johnson et 
al. [39] and Anderson et al. [40] both used average clearance values instead of 
individual doses and concentrations to model the maturation of midazolam 
clearance. Furthermore, the number of underlying individual data of children 
between 0 and 1 year of age in these pooled studies was very low. which 
could have resulted in erroneous estimations for this age range [40] For our 
analysis we had access to all raw data on demographics, doses, concentrations, 
and covariates of 136 individuals varying in age between prematurely born 
neonates and adults. We therefore suggest that our analysis was less prone 
to the mentioned drawbacks, and increases the validity of the value of the 
estimated maturation function for in vivo CYP3A4/5 activity. However, as the 
estimated CYP3A4/5 abundance by Johnson et al., and Anderson et al. [39, 
40] was related to age, and not to body weight, the exact difference with our 
model based on body weight, is difficult to derive, and should be kept in mind 
when comparing the results.
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The maturation of CYP3A as assessed by the clearance of midazolam was 
found to be highly nonlinear (figure 1), and could be described best by an 
allometric function with a body weight dependent exponent (BDE). This 
conforms with the report of Wang et al. who first reported that an exponent 
changing with bodyweight that is accounted for with an allometric function, 
best described the changes in propofol clearance occurring between neonatal 
to adult age. [23] In their model, the allometric exponent changed in a 
sigmoidal manner (E
max
 model) with bodyweight, and had four parameters to 
be estimated.[23] For propofol clearance, this exponent was found to change 
from 1.43 for a hypothetical bodyweight of 0 kg, to 0.55 for 10 kg upwards.23] 
In our model, we used a simplified version of the model of Wang et al. [23] by 
allowing the exponent to change in an exponential manner, thereby reducing 
the degrees of freedom from four to two, which was previously applied for 
busulphan in children. [24] This approach allowed us to adequately estimate 
all pharmacokinetic parameters without overparameterization of the model, 
and to describe the midazolam clearance from prematurely born neonates 
to adults without bias over the entire range of bodyweight. This contrasts 
to an allometric function with an estimated exponent or a fixed exponent 
of 0.75, as this resulted in failure to minimize successfully or in inadequate 
description of clearance throughout the entire weight range of the population, 
without adding more age related information in the model. Using those 
models, especially in the lowest weight range, midazolam clearances were 
overestimated. While the addition of an age-based function to capture 
maturation in the youngest age ranges correcting for this overestimation could 
be considered, we decided to use a bodyweight-dependent exponent model 
instead. With the BDE model, the use of two different functions of covariates 
that are correlated (i.e. age and bodyweight) which may potentially lead to 
inappropriate functions, is prevented. [41] Interestingly, using the BDE model 
in which the exponent was found to vary between 0.84 in neonates to 0.44 in 
adults, midazolam clearance, was well estimated across the entire age range. 
The fact that maturation of CYP3A activity appears less steep than reported 
for propofol (highest exponent of 0.91 versus 1.44, respectively) may reflect 
differences in pathways involved in metabolism of midazolam and propofol, 
being CYP3A oxidation and glucuronidation, respectively. [23] As such it seems 
that pathway-specific functions need to be developed across the age range 
for different common metabolic and elimination pathways that can be used to 
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predict changes in drug metabolism and elimination in children. Particularly, 
in view of the growing interest in pediatric PBPK models, [42] it is important 
to quantify the maturational in vivo behavior of all metabolic enzyme systems 
that are clinically relevant.
In this analysis, the results of the current function for CYP3A mediated clearance 
of midazolam have been used to derive a model based dosing scheme for 
conscious sedation in prematurely born neonates and children in the Intensive 
Care. Table 3 shows that instead of empiric dosing in mg/kg/h, it is proposed 
to dose the maintenance dose in a nonlinear manner. In accordance with the 
exponent that was found for changes in clearance within the pediatric range, 
an exponent of 0.85 is proposed for prematurely born neonates while an 
exponent of 0.65 is used for older children. In order to prevent dosing errors, 
a table is provided to guide dosing according to these non-linear functions. 
Figure 4 shows that upon this nonlinear dosing scheme, similar concentrations 
can be expected across a wide range in bodyweight, while in mg/kg/h dosing 
schedule large variations may be expected due to the nonlinear nature of 
clearance across bodyweight. The target midazolam concentration chosen 
from literature [18, 32] may, however, be arbitrary, as it is conceivable that some 
children may require higher concentrations than others. Therefore the dosing 
table (table 3) is only a guide for dose adjustments between children, while the 
absolute value (e.g. 0.06 in 0.06 mg/ kg0.85/hr for prematurely born neonates) 
may be adjusted at the discretion of the attending physician. A previous 
study of our group has shown that it is indeed feasible to apply a nonlinear 
dosing scheme in the context of a clinical trial. [43] In that study, morphine 
was dosed according to a function with an exponent of 1.44, implying that 
neonates require less and older children require more than what is currently 
administered based on mg/kg/h dosing schedule.
No dosing implications have been derived on the basis of the results of this 
study for non-critically ill patients. We have reported previously that absolute 
midazolam clearance in critically ill patients is much lower (figure 1 left) 
compared to relatively healthy children [11]. We hypothesized this phenomenon 
to be due to critical illness related inflammation response causing CYP3A4 
gene repression. [44] Due to the absence of midazolam data in non-critically ill 
neonates it was not possible to quantify the maturational behavior of CYP3A 
26664_Chenguang Wang.indd   224 23-09-13   10:37




in healthy neonates, using midazolam clearance as surrogate. However, as 
healthy neonates and children most often receive bolus doses of midazolam 
for a diagnostic or therapeutic intervention, changes in volume of distribution 
as a result of age may be more important than changes in clearance for this 
age group. While volume of distribution was found to scale linearly with 
bodyweight, there are no clear reasons to change the current practice of 
dosing a bolus in mg/kg across the pediatric age range when midazolam is 
given for procedural sedation. For V2, a 6-fold higher peripheral volume of 
distribution was found in the postoperative craniofacial surgery patients [3] 
compared to the five other datasets. As blood loss during craniofacial surgery 
may increase up to average values of 24% of the total volume of blood, [45] 
blood transfusion is often required to maintain the blood cell-, thrombocyte-, 
and plasma levels at normal values. This may have eventually have led to an 
increase of peripheral volume of distribution of midazolam in these patients, 
compared to the other patients.
As we described in this study, the maturation of hepatic CYP3A activity using 
midazolam as an in vivo probe, the impact of ontogeny on intestinal CYP3A 
activity is still unknown. It has become clear over the years that CYP3A 
activity in the intestine is of considerable importance, thereby necessity the 
investigation of the maturation of CYP3A mediated first pass-elimination of 
midazolam in children across different ages. Another limitation is that external 
validation of a pharmacokinetic model using independent data, and ultimately 
prospective clinical evaluation, which are important steps following internal 
validation of model still needs to be performed. [46] An important issue in 
the validation process of pediatric modeling, is the lack of sufficient data to 
perform the external validation, and the ethical constraints for performing 
prospective clinical evaluation of a drug in children. However, although only 
17% of published pediatric pharmacokinetic and pharmacodynamic models 
are validated, [47] we believe that all models should be at least fully internally 
validated. [46]
In addition, extrapolation of the maturation model for the CYP3A substrate 
midazolam, will test the ability of the model to predict the system specific 
properties of other drugs that share, at least partly, the similar pharmacokinetic 
pathway. [48] Another CYP3A substrate from the literature that has been 
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studied quite adequately during the first months of life is cisapride. [49] Using 
the maturation model for midazolam to describe cisapride pharmacokinetics 














































































Figure 4 Simulated midazolam concentrations versus time in preterm neonates (a, b) and 
children (c, d) in intensive care with traditional dosing regimen (a, c) and model-based dosing 
regimen (b, d) aiming for reported therapeutic midazolam concentrations (horizontal grey 
lines). (a, b): midazolam concentrations in preterm neonates (0.75, 1, 2, 3 kg body weight) 
after traditional dosing regimen [bolus dose of 0.05 mg/kg followed by 0.06 mg/kg/h for 24 
hours (a)], and after model-based dosing regimen as shown in table 3 (b). (c, d): midazolam 
concentrations in critically ill children (5, 10, 20, 45, and 60 kg body weight) after traditional 
dosing regimen [0.1 mg/kg bolus dose followed by 0.1 mg/kg/h for 24 hours (c)], and after 
model-based dosing regimen as shown in table 3 (d).
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In conclusion, an in vivo maturation function for CYP3A mediated clearance 
of midazolam from prematurely born neonates to adults has been developed. 
This maturation function can be used to derive evidence-based doses for 
prematurely born neonates, infants and children, and to simulate exposure to 
midazolam and possibly other CYP3A substrates across the pediatric age range 
in population pharmacokinetic or physiologically based pharmacokinetic 
(PBPK) models.
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